U.S. patent application number 12/965564 was filed with the patent office on 2011-04-07 for antibodies that bind interleukin-4 receptor.
Invention is credited to Paul J. Carter, Hongxing Zhou.
Application Number | 20110081361 12/965564 |
Document ID | / |
Family ID | 34590230 |
Filed Date | 2011-04-07 |
United States Patent
Application |
20110081361 |
Kind Code |
A1 |
Carter; Paul J. ; et
al. |
April 7, 2011 |
ANTIBODIES THAT BIND INTERLEUKIN-4 RECEPTOR
Abstract
The present invention relates to antibodies that bind to the
IL-4 receptor, fragments, muteins, and derivatives of such
antibodies, nucleic acids encoding such antibodies, fragments,
muteins and derivatives, and methods of making and using such
antibodies, fragments, muteins, derivatives and nucleic acids.
Methods for treating medical conditions induced by interleukin-4
involve administering an IL-4 receptor binding antibody, or an IL-4
receptor binding fragment, mutein, or derivative of an IL-4
receptor binding antibody, to a patient afflicted with such a
condition. Particular antibodies provided herein include human
monoclonal antibodies. Certain of the antibodies inhibit both
IL-4-induced and IL-13-induced biological activities.
Inventors: |
Carter; Paul J.; (Mercer
Island, WA) ; Zhou; Hongxing; (Bellevue, WA) |
Family ID: |
34590230 |
Appl. No.: |
12/965564 |
Filed: |
December 10, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
12535648 |
Aug 4, 2009 |
7872113 |
|
|
12965564 |
|
|
|
|
10578410 |
Mar 5, 2007 |
7638606 |
|
|
PCT/US04/37242 |
Nov 4, 2004 |
|
|
|
12535648 |
|
|
|
|
60518166 |
Nov 7, 2003 |
|
|
|
Current U.S.
Class: |
424/172.1 ;
435/366; 435/375 |
Current CPC
Class: |
A61P 7/06 20180101; C07K
2317/565 20130101; A61P 11/16 20180101; C07K 16/2866 20130101; C07K
2317/76 20130101; A61P 13/12 20180101; A61P 37/02 20180101; A61P
13/08 20180101; A61P 1/00 20180101; C07K 2317/567 20130101; A61P
1/14 20180101; A61P 37/08 20180101; A61P 21/04 20180101; A61P 43/00
20180101; A61P 17/00 20180101; A61P 31/04 20180101; C07K 2317/56
20130101; A61P 37/00 20180101; A61P 29/00 20180101; A61P 35/00
20180101; A61K 2039/505 20130101; A61P 17/04 20180101; A61P 11/00
20180101; A61P 31/06 20180101; A61P 1/04 20180101; A61P 19/02
20180101; A61P 7/00 20180101; A61P 11/06 20180101; A61P 31/10
20180101; A61P 17/02 20180101 |
Class at
Publication: |
424/172.1 ;
435/375; 435/366 |
International
Class: |
A61K 39/395 20060101
A61K039/395; C12N 5/071 20100101 C12N005/071; A61P 29/00 20060101
A61P029/00; A61P 37/02 20060101 A61P037/02; A61P 35/00 20060101
A61P035/00; A61P 11/06 20060101 A61P011/06; A61P 19/02 20060101
A61P019/02; A61P 17/00 20060101 A61P017/00; A61P 11/00 20060101
A61P011/00; A61P 1/00 20060101 A61P001/00; A61P 37/08 20060101
A61P037/08; A61P 7/00 20060101 A61P007/00; A61P 13/12 20060101
A61P013/12 |
Claims
1. A method of inhibiting an IL-4 receptor comprising contacting a
cell expressing an IL-4 receptor with an isolated antibody, or an
antigen binding fragment of said isolated antibody, under
conditions that allow said isolated antibody or said fragment to
bind to said IL-4 receptor, wherein said isolated antibody or said
fragment comprises either a. the light chain variable domain of SEQ
ID NO:6, or b. the heavy chain variable domain of SEQ ID NO:42, or
c. said light chain variable domain of a) and said heavy chain
variable domain of b), and the binding of said isolated antibody or
said fragment to said IL-4 receptor inhibits signal transduction
through said IL-4 receptor.
2. The method of claim 1 wherein said cell is a human cell.
3. The method of claim 2 wherein said human cell is in a human.
4. A method of treating a condition in a subject comprising
administering to said subject an isolated antibody, or an antigen
binding fragment of said isolated antibody, in an amount effective
for treating said condition, wherein said isolated antibody or said
fragment comprises either a. the light chain variable domain of SEQ
ID NO:6, or b. the heavy chain variable domain of SEQ ID NO:42, or
c. said light chain variable domain of a) and said heavy chain
variable domain of b).
5. The method of claim 4 wherein said condition is an
immunological, inflammatory or cancerous condition.
6. The method of claim 4 wherein said condition is asthma, septic
arthritis, dermatitis herpetiformis, chronic idiopathic urticaria,
ulcerative colitis, scleroderma, hypertrophic scarring, Whipple's
Disease, benign prostate hyperplasia, a lung disorder in which IL-4
receptor plays a role, condition in which IL-4 receptor-mediated
epithelial barrier disruption plays a role, a disorder of the
digestive system in which IL-4 receptor plays a role, an allergic
reaction to a medication, Kawasaki disease, sickle cell disease,
Churg-Strauss syndrome, Grave's disease, pre-eclampsia, Sjogren's
syndrome, autoimmune lymphoproliferative syndrome, autoimmune
hemolytic anemia, Barrett's esophagus, autoimmune uveitis,
tuberculosis, cyctic fibrosis, allergic bronchopulmonary mycosis,
chronic obstructive pulmonary disease, bleomycin-induced
pneumopathy and fibrosis, radiation-induced pulmonary fibrosis,
pulmonary alveolar proteinosis, adult respiratory distress
syndrome, sarcoidosis, hyper IgE syndrome, idiopathic
hypereosinophil syndrome, an autoimmune blistering disease,
pemphigus vulgaris, bullous pemphigoid, myasthenia gravis, chronic
fatigue syndrome, or nephrosis.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is a divisional of U.S. application Ser.
No. 12/535,648, filed Aug. 4, 2009, now allowed, which is a
divisional of U.S. application Ser. No. 10,578,410, filed Mar. 5,
2007, now U.S. Pat. No. 7,638,606, which is a 371 National Stage
Entry of PCT/US04/37242, filed Nov. 4, 2004, which claims the
benefit of U.S. provisional application No. 60/518,166, filed Nov.
7, 2003. The above-identified applications are incorporated herein
by reference.
REFERENCE TO THE SEQUENCE LISTING
[0002] The present application is being filed along with a Sequence
Listing in electronic format via EFS-Web. The Sequence Listing is
provided as a text file entitled 3492USPCD2st25.txt, created Dec.
9, 2010, which is 122,404 bytes in size. The information in the
electronic format of the Sequence Listing is incorporated herein by
reference in its entirety.
BACKGROUND OF THE INVENTION
[0003] Interleukin-4 (IL-4), previously known as B cell stimulating
factor, or BSF-1, was originally characterized by its ability to
stimulate the proliferation of B cells in response to low
concentrations of antibodies directed to surface immunoglobulin.
IL-4 has been shown to possess a far broader spectrum of biological
activities, including growth co-stimulation of T cells, mast cells,
granulocytes, megakaryocytes, and erythrocytes. In addition, IL-4
stimulates the proliferation of several IL-2- and IL-3-dependent
cell lines, induces the expression of class II major
histocompatibility complex molecules on resting B cells, and
enhances the secretion of IgE and IgG1 isotypes by stimulated B
cells. IL-4 is associated with a TH2-type immune response, being
one of the cytokines secreted by TH2 cells.
[0004] Murine and human IL-4 have been identified and
characterized, including cloning of IL-4 cDNAs and determination of
the nucleotide and encoded amino acid sequences. See Yokota et al.,
1986, Proc. Natl. Acad. Sci. USA 83:5894; Noma et al., 1986, Nature
319:640; Grabstein et al., 1986, J. Exp. Med. 163:1405; and U.S.
Pat. No. 5,017,691.
[0005] IL-4 binds to particular cell surface receptors, which
results in transduction of a biological signal to cells such as
various immune effector cells. IL-4 receptors are described, and
DNA and amino acid sequence information presented, in Mosley et
al., 1989, Cell 59:335-48, (murine IL-4R); Idzerda et al., 1990, J.
Exp. Med. 171:861-73, (human IL-4R); and U.S. Pat. No. 5,599,905.
The IL-4 receptor described in these publications is sometimes
referred to as IL-4R alpha.
[0006] Other proteins have been reported to be associated with
IL-4R alpha on some cell types, and to be components of
multi-subunit IL-4 receptor complexes. One such subunit is IL-2R
gamma, also known as IL-2R gamma c. See the discussion of IL-4R
complexes in Sato et al., 1994, Current Opinion in Cell Biology,
6:174-79. IL-4R alpha also has been reported to be a component of
certain multi-subunit IL-13 receptor complexes. See Zurawski et
al., 1995, J. Biol. Chem. 270:13869; de Vries, 1998, J. Allergy
Clin. Immunol. 102:165; and Callard et al., 1996, Immunology Today,
17:108.
[0007] IL-4 has been implicated in a number of disorders, examples
of which are allergy and asthma.
SUMMARY OF THE INVENTION
[0008] The present invention provides methods and compositions
relating to novel IL-4R antagonists, in particular antibodies and
antibody derivatives, that bind IL-4R alpha. In one aspect, the
present invention provides an antibody, wherein the light chain
variable domain comprises a sequence of amino acids that differs
from SEQ ID NO:4 only by: at least one amino acid substitution
selected from the group consisting of S28T, S30N, S30G, S31N, S32D,
S32N, A52T, S54Y, T57P, T57S, G93D, S94H, S94R, P96A, P97G, and
T99M, and, optionally, one or more amino acid substitutions
selected from the group consisting of E1D, L4M, S7T, G9A, K40R,
F50Y, S68F, S77T, V86I, K105R, V106L, and E107D, and/or the heavy
chain variable domain comprises a sequence of amino acids that
differs from SEQ ID NO:16 only by: at least one amino acid
substitution selected from the group consisting of N58S, Y101W,
F102Y, D103T, D103N, D103P, Y104H, Y104N, Y104W, and Y104R, and,
optionally, one or more amino acid substitutions selected from the
group consisting of Q6E, H13Q, G24A, R86S, and M90T, wherein said
antibody binds to IL-4 receptor alpha. In one embodiment, the light
chain CDR1 comprises a sequence selected from the group consisting
of residues 24-35 of SEQ ID NO:6, residues 24-35 of SEQ ID NO:8,
residues 24-35 of SEQ ID NO:10, residues 24-35 of SEQ ID NO:12; and
residues 24-35 of SEQ ID NO:14, the light chain CDR2 comprises a
sequence selected from the group consisting of residues 51-57 of
SEQ ID NO:4, residues 51-57 of SEQ ID NO:6, residues 51-57 of SEQ
ID NO:10, and residues 51-57 of SEQ ID NO:12, the light chain CDR3
comprises a sequence selected from the group consisting of residues
90-99 of SEQ ID NO:4, residues 90-99 of SEQ ID NO:6, residues 90-99
of SEQ ID NO:8, and residues 90-99 of SEQ ID NO:14, the heavy chain
CDR1 comprises the sequence residues 31-35 of SEQ ID NO:16, the
heavy chain CDR2 comprises a sequence selected from the group
consisting of residues 50-65 of SEQ ID NO:16, and residues 50-65 of
SEQ ID NO:18, and/or the heavy chain CDR3 comprises a sequence
selected from the group consisting of residues 98-104 of SEQ ID
NO:16, residues 98-104 of SEQ ID NO:18, residues 98-104 of SEQ ID
NO:20, residues 98-104 of SE ID NO:22, residues 98-104 of SEQ ID
NO:24, residues 98-104 of SEQ ID NO:26, residues 98-104 of SEQ ID
NO:30, and residues 98-104 of SEQ ID NO:34. In another embodiment,
the light chain FR1 comprises a sequence selected from the group
consisting of residues 1-23 of SEQ ID NO:4, residues 1-23 of SEQ ID
NO:10, residues 1-23 of SEQ ID NO:12, and residues 1-23 of SEQ ID
NO:14, the light chain FR2 comprises a sequence selected from the
group consisting of residues 36-50 of SEQ ID NO:4, and residues
36-50 of SEQ ID NO:14, the light chain FR3 comprises a sequence
selected from the group consisting of residues 58-89 of SEQ ID
NO:4, residues 58-89 of SEQ ID NO:10, and residues 58-89 of SEQ ID
NO:12, the light chain FR4 comprises a sequence selected from the
group consisting of residues 100-109 of SEQ ID NO:4, residues
100-109 of SEQ ID NO:8, and residues 100-109 of SEQ ID NO:12, the
heavy chain FR1 comprises a sequence selected from the group
consisting of residues 1-30 of SEQ ID NO:16, and residues 1-30 of
SEQ ID NO:42, the heavy chain FR2 comprises the sequence of
residues 1-30 of SEQ ID NO:16, the heavy chain FR3 comprises a
sequence selected from the group consisting of residues 66-97 of
SEQ ID NO:16, residues 66-97 of SEQ ID NO:18, and residues 66-97 of
SEQ ID NO:42, and/or the heavy chain FR4 comprises the sequence of
residues 105-115 of SEQ ID NO:16.
[0009] In another aspect, the present invention provides an
antibody comprising: a light chain variable domain comprising a
sequence that is at least 80% identical to a sequence selected from
the group consisting of SEQ ID NO:4, 6, 8, 10, 12, and 14, with the
proviso that said light chain variable domain does not comprise the
sequence of SEQ ID NO:4, and/or a heavy chain variable domain
comprising a sequence that is at least 80% identical to a sequence
selected from the group consisting of SEQ ID NO:16, 18, 20, 22, 24,
26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58,
60, and 62, with the proviso that said heavy chain variable domain
does not comprise the sequence of SEQ ID NO:16, wherein said
antibody binds to IL-4 receptor alpha. In one embodiment, said
light chain variable domain comprises a sequence that is at least
85% identical to a sequence selected from the group consisting of
SEQ ID NO:4, 6, 8, 10, 12, and 14, and/or said heavy chain variable
domain comprises a sequence that is at least 85% identical to a
sequence selected from the group consisting of SEQ ID NO:16, 18,
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52,
54, 56, 58, 60, and 62. In another embodiment, said light chain
variable domain comprises a sequence that is at least 90% identical
to a sequence selected from the group consisting of SEQ ID NO:4, 6,
8, 10, 12, and 14, and/or said heavy chain variable domain
comprises a sequence that is at least 90% identical to a sequence
selected from the group consisting of SEQ ID NO:16, 18, 20, 22, 24,
26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58,
60, and 62. In another embodiment, said light chain variable domain
comprises a sequence that is at least 95% identical to a sequence
selected from the group consisting of SEQ ID NO:4, 6, 8, 10, 12,
and 14, and/or said heavy chain variable domain comprises a
sequence that is at least 95% identical to a sequence selected from
the group consisting of SEQ ID NO:16, 18, 20, 22, 24, 26, 28, 30,
32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62.
In another embodiment, said light chain variable domain comprises a
sequence that is selected from the group consisting of SEQ ID NO:6,
8, 10, 12, and 14, and/or said heavy chain variable domain
comprises a sequence that is selected from the group consisting of
SEQ ID NO:16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42,
44, 46, 48, 50, 52, 54, 56, 58, 60, and 62.
[0010] In another aspect, the present invention provides an
antibody wherein the light chain variable domain comprises a
sequence of at least 15 contiguous amino acids of a sequence
selected from the group consisting of: SEQ ID NO:4, 6, 8, 10, 12,
and 14, with the proviso that said light chain variable domain does
not comprise the sequence of SEQ ID NO:4, and/or wherein the heavy
chain variable domain comprises a sequence of at least 15
contiguous amino acids of a sequence selected from the group
consisting of SEQ ID NO:16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,
38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62, with the
proviso that said heavy chain variable domain does not comprise the
sequence of SEQ ID NO:16, wherein said antibody binds to IL-4
receptor alpha. In one embodiment, the light chain variable domain
comprises a sequence of at least 20 contiguous amino acids of a
sequence selected from the group consisting of: SEQ ID NO:4, 6, 8,
10, 12, and 14, and/or the heavy chain variable domain comprises a
sequence of at least 20 contiguous amino acids of a sequence
selected from the group consisting of SEQ ID NO:16, 18, 20, 22, 24,
26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58,
60, and 62. In another embodiment, the light chain variable domain
comprises a sequence of at least 25 contiguous amino acids of a
sequence selected from the group consisting of: SEQ ID NO:4, 6, 8,
10, 12, and 14, and/or the heavy chain variable domain comprises a
sequence of at least 25 contiguous amino acids of a sequence
selected from the group consisting of: SEQ ID NO:16, 18, 20, 22,
24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56,
58, 60, and 62. In another embodiment, the light chain variable
domain comprises a sequence of at least 35 contiguous amino acids
of a sequence selected from the group consisting of: SEQ ID NO:4,
6, 8, 10, 12, and 14, and/or the heavy chain variable domain
comprises a sequence of at least 35 contiguous amino acids of a
sequence selected from the group consisting of: SEQ ID NO:16, 18,
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52,
54, 56, 58, 60, and 62. In another embodiment, the light chain
variable domain comprises a sequence of at least 50 contiguous
amino acids of a sequence selected from the group consisting of:
SEQ ID NO:4, 6, 8, 10, 12, and 14, and/or the heavy chain variable
domain comprises a sequence of at least 50 contiguous amino acids
of a sequence selected from the group consisting of: SEQ ID NO:16,
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,
52, 54, 56, 58, 60, and 62. In another embodiment, the light chain
variable domain comprises a sequence of at least 75 contiguous
amino acids of a sequence selected from the group consisting of:
SEQ ID NO:4, 6, 8, 10, 12, and 14, and/or the heavy chain variable
domain comprises a sequence of at least 75 contiguous amino acids
of a sequence selected from the group consisting of: SEQ ID NO:16,
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,
52, 54, 56, 58, 60, and 62. In another embodiment, the light chain
variable domain comprises a sequence of at least 100 contiguous
amino acids of a sequence selected from the group consisting of:
SEQ ID NO:4, 6, 8, 10, 12, and 14, and/or the heavy chain variable
domain comprises a sequence of at least 100 contiguous amino acids
of a sequence selected from the group consisting of: SEQ ID NO:16,
18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,
52, 54, 56, 58, 60, and 62.
[0011] In another aspect, the present invention provides an
antibody comprising: a light chain variable domain comprising an
amino acid sequence that is encoded by a nucleotide sequence that
is at least 80% identical to a nucleotide sequence selected from
the group consisting of SEQ ID NO:3, 5, 7, 9, 11, and 13, and/or a
heavy chain variable domain comprising an amino acid sequence that
is encoded by a nucleotide sequence that is at least 80% identical
to a nucleotide sequence selected from the group consisting of SEQ
ID NO:15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43,
45, 47, 49, 51, 53, 55, 57, 59, and 61, with the proviso that said
antibody does not comprise both the light chain variable domain
sequence of SEQ ID NO:4 and the heavy chain variable domain
sequence of SEQ ID NO:16, and wherein said antibody binds to IL-4
receptor alpha. In another embodiment, said light chain variable
domain comprises an amino acid sequence that is encoded by a
nucleotide sequence that is at least 85% identical to a nucleotide
sequence selected from the group consisting of SEQ ID NO:3, 5, 7,
9, 11, and 13, and/or said heavy chain variable domain comprises an
amino acid sequence that is encoded by a nucleotide sequence that
is at least 85% identical to a nucleotide sequence selected from
the group consisting of SEQ ID NO:15, 17, 19, 21, 23, 25, 27, 29,
31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61.
In another embodiment, said light chain variable domain comprises
an amino acid sequence that is encoded by a nucleotide sequence
that is at least 90% identical to a nucleotide sequence selected
from the group consisting of SEQ ID NO:3, 5, 7, 9, 11, and 13,
and/or said heavy chain variable domain comprises an amino acid
sequence that is encoded by a nucleotide sequence that is at least
90% identical to a nucleotide sequence selected from the group
consisting of SEQ ID NO:15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35,
37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61. In another
embodiment, said light chain variable domain comprises an amino
acid sequence that is encoded by a nucleotide sequence that is at
least 95% identical to a nucleotide sequence selected from the
group consisting of SEQ ID NO:3, 5, 7, 9, 11, and 13, and/or said
heavy chain variable domain comprises an amino acid sequence that
is encoded by a nucleotide sequence that is at least 95% identical
to a nucleotide sequence selected from the group consisting of SEQ
ID NO:15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43,
45, 47, 49, 51, 53, 55, 57, 59, and 61. In another embodiment, said
light chain variable domain comprises an amino acid sequence that
is encoded by a nucleotide sequence that is at least 98% identical
to a nucleotide sequence selected from the group consisting of SEQ
ID NO:3, 5, 7, 9, 11, and 13, and/or said heavy chain variable
domain comprises an amino acid sequence that is encoded by a
nucleotide sequence that is at least 98% identical to a nucleotide
sequence selected from the group consisting of SEQ ID NO:15, 17,
19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51,
53, 55, 57, 59, and 61. In another embodiment, said light chain
variable domain comprises an amino acid sequence that is encoded by
a nucleotide sequence selected from the group consisting of SEQ ID
NO:5, 7, 9, 11, and 13, and/or said heavy chain variable domain
comprises an amino acid sequence that is encoded by a nucleotide
sequence selected from the group consisting of SEQ ID NO:16, 18,
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52,
54, 56, 58, 60, and 62.
[0012] In another aspect, the present invention provides an
antibody comprising: a light chain variable domain comprising an
amino acid sequence that is encoded by a nucleotide sequence that
hybridizes under moderately stringent conditions to the complement
of a nucleotide sequence selected from the group consisting of SEQ
ID NO:3, 5, 7, 9, 11, and 13, and/or a heavy chain variable domain
comprising an amino acid sequence that is encoded by a nucleotide
sequence that hybridizes under moderately stringent conditions to
the complement of a nucleotide sequence selected from the group
consisting of SEQ ID NO:15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35,
37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and 61, with the
proviso that said antibody does not comprise both the light chain
variable domain sequence of SEQ ID NO:4 and the heavy chain
variable domain sequence of SEQ ID NO:16, and wherein said antibody
binds to IL-4 receptor alpha. In one embodiment, said light chain
variable domain comprises an amino acid sequence that is encoded by
a nucleotide sequence that hybridizes under stringent conditions to
the complement of a nucleotide sequence selected from the group
consisting of SEQ ID NO:3, 5, 7, 9, 11, and 13, and/or said heavy
chain variable domain comprises an amino acid sequence that is
encoded by a nucleotide sequence that hybridizes under stringent
conditions to the complement of a nucleotide sequence selected from
the group consisting of SEQ ID NO:15, 17, 19, 21, 23, 25, 27, 29,
31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, and
61.
[0013] In another aspect, the present invention provides an
isolated antibody, wherein the light chain variable region of said
antibody comprises an amino acid sequence selected from the group
consisting of SEQ ID NO:6, 8, 10, 12, and 14, and said antibody
binds to IL-4 receptor alpha.
[0014] In another aspect, the present invention provides an
isolated antibody, wherein the heavy chain variable region of said
antibody comprises an amino acid sequence selected from the group
consisting of SEQ ID NO:16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36,
38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, and 62, and said
antibody binds to IL-4 receptor alpha.
[0015] In another aspect, the present invention provides an
antibody selected from the group consisting of L2H1, L3H1, L4H1,
L5H1, L1H2, L1H3, L1H4, L1H5, L1H6, L1H7, L1H8, L1H9, L1H10, L1H11,
L2H4, L2H12, L2H13, L2H14, L6H1, L2H2, L2H3, L2H6, L2H7, L2H8,
L2H9, L2H10, and L2H11.
[0016] In another aspect, the present invention provides a human,
humanized, or chimeric antibody.
[0017] In another aspect, the present invention provides a
monoclonal antibody.
[0018] In another aspect, the present invention provides an
antibody selected from the group consisting of an IgD, IgE, IgM,
IgG1, IgG2, IgG3, IgG4, and IgG4 having at least one mutation in a
hinge region that alleviates a tendency to form intra-H chain
disulfide bond antibody.
[0019] In another aspect, the present invention provides an
isolated polypeptide comprising an IL-4 receptor binding portion of
an antibody of the invention. In one embodiment, said polypeptide
comprises a Fab, F(ab').sub.2, scFv, diabody, triabody, or
tetrabody.
[0020] In another aspect, the present invention provides an
isolated nucleic acid comprising a nucleotide sequence encoding the
light chain of an antibody of the invention, the heavy chain of an
antibody of the invention, or a polypeptide of the invention.
[0021] In another aspect, the present invention provides a vector
comprising an isolated nucleic acid of the invention. In another
embodiment, said vector is an expression vector.
[0022] In another aspect, the present invention provides an
isolated cell comprising a nucleic acid of the invention. In one
embodiment, said cell is a hybridoma. In another embodiment, said
cell is a transgenic cell.
[0023] In another aspect, the present invention provides a cell
comprising an antibody of the invention. In one embodiment, said
cell is a hybridoma. In another embodiment, said cell is a
transgenic cell.
[0024] In another aspect, the present invention provides a cell
comprising a polypeptide of the invention. In one embodiment, said
cell is a transgenic cell.
[0025] In another aspect, the present invention provides a method
of making an antibody of the invention comprising incubating a cell
comprising a nucleic acid encoding the light chain of said antibody
and a nucleic acid encoding the heavy chain of said antibody under
conditions that allow said cell to express said light chain and
said heavy chain and that allow said light chain and said heavy
chain to assemble into said antibody, and isolating said antibody
from said cell. In one embodiment, said cell is a hybridoma. In
another embodiment, said cell is a transgenic cell.
[0026] In another aspect, the present invention provides a method
of inhibiting an IL-4 receptor comprising contacting a cell
expressing IL-4 receptor alpha with an antibody of the invention or
a polypeptide of the invention under conditions that allow said
antibody or said polypeptide to bind to said IL-4 receptor alpha.
In one embodiment, said cell is a human cell. In another
embodiment, said human cell is in a human.
[0027] In another aspect, the present invention provides a method
of treating a condition in a subject comprising administering to
said subject an amount of an antibody of the invention or of a
polypeptide of the invention effective for treating said condition.
In one embodiment, said condition is an inflammatory or cancerous
condition. In another embodiment, said inflammatory or cancerous
condition is an immunological condition. In another embodiment,
said condition is asthma, septic arthritis, dermatitis
herpetiformis, chronic idiopathic urticaria, ulcerative colitis,
scleroderma, hypertrophic scarring, Whipple's Disease, benign
prostate hyperplasia, a lung disorder in which IL-4 receptor plays
a role, condition in which IL-4 receptor-mediated epithelial
barrier disruption plays a role, a disorder of the digestive system
in which IL-4 receptor plays a role, an allergic reaction to a
medication, Kawasaki disease, sickle cell disease, Churg-Strauss
syndrome, Grave's disease, pre-eclampsia, Sjogren's syndrome,
autoimmune lymphoproliferative syndrome, autoimmune hemolytic
anemia, Barrett's esophagus, autoimmune uveitis, tuberculosis,
cyctic fibrosis, allergic bronchopulmonary mycosis, chronic
obstructive pulmonary disease, bleomycin-induced pneumopathy and
fibrosis, radiation-induced pulmonary fibrosis, pulmonary alveolar
proteinosis, adult respiratory distress syndrome, sarcoidosis,
hyper IgE syndrome, idiopathic hypereosinophil syndrome, an
autoimmune blistering disease, pemphigus vulgaris, bullous
pemphigoid, myasthenia gravis, chronic fatigue syndrome, or
nephrosis.
[0028] In another aspect, the present invention provides a
pharmaceutical composition comprising an antibody of the invention
or a polypeptide of the invention and an excipient, diluent, or
buffer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0029] FIGS. 1A-C present the nucleotide sequence of the coding
region of a human IL-4 receptor alpha cDNA. The amino acid sequence
encoded by the cDNA is presented as well. The cDNA clone was
isolated from a cDNA library derived from a human T cell line T22.
The encoded protein comprises (from N- to C-terminus) an N-terminal
signal peptide, followed by an extracellular domain, a
transmembrane region (underlined), and a cytoplasmic domain, as
discussed further in PCT publication WO 01/92340 A3. The nucleotide
sequence and amino acid sequences of FIGS. 1A to 1C also are
presented in SEQ ID NO:1 and 2, respectively.
[0030] FIGS. 2A-2D present polynucleotide sequences encoding the
light chain variable regions of L1 (SEQ ID NO:3), L2 (SEQ ID NO:5),
L3, (SEQ ID NO:7), L4 (SEQ ID NO:9), L5 (SEQ ID NO:11), and L6 (SEQ
ID NO:13), and polynucleotide sequences encoding the heavy chain
variable regions of H1 (SEQ ID NO:15), H2 (SEQ ID NO:17), H3 (SEQ
ID NO:19), H4 (SEQ ID NO:21), H5 (SEQ ID NO:23), H6 (SEQ ID NO:25),
H7 (SEQ ID NO:27), H8 (SEQ ID NO:29), H9 (SEQ ID NO:31), H10 (SEQ
ID NO:33), H11 (SEQ ID NO:35), H12 (SEQ ID NO:37), H13 (SEQ ID
NO:39), H14 (SEQ ID NO:41), H15 (SEQ ID NO:43), H16 (SEQ ID NO:45),
H17 (SEQ ID NO:47), H18 (SEQ ID NO:49), H19 (SEQ ID NO:51), H20
(SEQ ID NO:53), H21 (SEQ ID NO:55), H22 (SEQ ID NO:57), H23 (SEQ ID
NO:59), and H24 (SEQ ID NO:61). The sequences are shown using
one-letter nucleotide abbreviations. Sequences corresponding to
CDR1, CDR2, and CDR3 regions are shown in bold type for each
sequence and underlined in L1 and H1. Sequences corresponding to
FR1, FR2, FR3, and FR4 are shown in plain type.
[0031] FIG. 3 presents the amino acid sequences of the light chain
variable regions of L1 (SEQ ID NO:4), L2 (SEQ ID NO:6), L3, (SEQ ID
NO:8), L4 (SEQ ID NO:10), L5 (SEQ ID NO:12), and L6 (SEQ ID NO:14),
and amino acid sequences of the heavy chain variable regions of H1
(SEQ ID NO:16), H2 (SEQ ID NO:18), H3 (SEQ ID NO:20), H4 (SEQ ID
NO:22), H5 (SEQ ID NO:24), H6 (SEQ ID NO:26), H7 (SEQ ID NO:28), H8
(SEQ ID NO:30), H9 (SEQ ID NO:32), H10 (SEQ ID NO:34), H11 (SEQ ID
NO:36), H12 (SEQ ID NO:38), H13 (SEQ ID NO:40), H14 (SEQ ID NO:42),
H15 (SEQ ID NO:44), H16 (SEQ ID NO:46), H17 (SEQ ID NO:48), H18
(SEQ ID NO:50), H19 (SEQ ID NO:52), H20 (SEQ ID NO:54), H21 (SEQ ID
NO:56), H22 (SEQ ID NO:58), H23 (SEQ ID NO:60), and H24 (SEQ ID
NO:62). The sequences of the L1 and H1 variable regions are shown
using one-letter amino acid abbreviations. Other light chain and
heavy chain variable sequences are indicated by dashes at residues
where they are identical to L1 or H1 and with the appropriate
one-letter amino acid abbreviation where they differ from L1 or H1.
Sequences corresponding to CDR1, CDR2, and CDR3 regions are shown
in bold type for each sequence and underlined in L1 and H1.
Sequences corresponding to FR1, FR2, FR3, and FR4 are shown in
plain type.
DETAILED DESCRIPTION OF THE INVENTION
[0032] The present invention provides compositions and methods
relating to anti-IL-4 receptor (IL-4R) antibodies, including
methods for treating certain conditions mediated by IL-4R, and for
inhibiting biological activities of interleukin-4 (IL-4) and
interleukin-13 (IL-13) in vivo. Compositions of the invention
include, for example, anti-IL-4R antibodies, polypeptides,
polynucleotides, cells comprising or expressing antibodies,
polypeptides or polynucleotides of the invention, and
pharmaceutical compositions, examples of which are provided
below.
[0033] Polynucleotide and polypeptide sequences are indicated using
standard one- or three-letter abbreviations. Unless otherwise
indicated, polypeptide sequences have their amino termini at the
left and their carboxy termini at the right and single-stranded
nucleic acid sequences, and the top strand of double-stranded
nucleic acid sequences, have their 5' termini at the left and their
3' termini at the right. A particular polypeptide or polynucleotide
sequence also can be described by explaining how it differs from a
reference sequence. For example, the phrase "a polypeptide sequence
that differs from SEQ ID NO:4 at 528T" describes a polypeptide
sequence that is identical to SEQ ID NO:4 except that the serine
residue at position 28 of SEQ ID NO:4 is replaced by a threonine
residue.
[0034] Polynucleotide and polypeptide sequences of particular light
and heavy chain variable regions are shown in FIGS. 2 and 3,
respectively, where they are labeled, for example, L1 ("light chain
variable region 1"), H1 ("heavy chain variable region 1"), etc.
Antibodies comprising a light chain and heavy chain from FIG. 3 are
indicated by combining the name of the light chain and the name of
the heavy chain variable regions. For example, "L4H7," indicates an
antibody comprising the light chain variable sequence of L4 and the
heavy chain variable sequence of H7.
[0035] "Light chain variable domain (or region)," "heavy chain
variable domain (or region)," "CDR1, 2, and 3" and "FR1, 2, 3, and
4" are defined according to the scheme of Kabat et al. in Sequences
of Proteins of Immunological Interest, 5.sup.th Ed., US Dept. of
Health and Human Services, PHS, NIH, NIH Publication no. 91-3242,
1991.
[0036] The "percent identity" of two polynucleotide or two
polypeptide sequences is determined by comparing the sequences
using the GAP computer program (a part of the GCG Wisconsin
Package, version 10.3 (Accelrys, San Diego, Calif.)) using its
default parameters.
[0037] A biological molecule (e.g., a polypeptide, antibody, or
nucleic acid) is "isolated" or "substantially purified" if it is
sufficiently free of other biological molecules, cell debris, and
other substances to be used in standard laboratory protocols (e.g.,
a binding or hybridization assay). Methods of substantially
purifying polypeptides, antibodies, and nucleic acids are
well-known in the art.
[0038] The terms "peptide," "polypeptide" and "protein" are used
interchangeably throughout and refer to a molecule comprising two
or more amino acid residues joined to each other by peptide
bonds.
[0039] The terms "polynucleotide," "oligonucleotide" and "nucleic
acid" are used interchangeably throughout and include DNA molecules
(e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of
the DNA or RNA generated using nucleotide analogs (e.g., peptide
nucleic acids and non-naturally occurring nucleotide analogs), and
hybrids thereof. The nucleic acid molecule can be single-stranded
or double-stranded. In one embodiment, the nucleic acid molecules
of the invention comprise a contiguous open reading frame encoding
an antibody, or a fragment, derivative, mutein, or variant thereof,
of the invention.
[0040] Two single-stranded nucleic acid molecules are "the
complement" of each other if their sequences can be aligned in an
anti-parallel orientation such that every nucleotide in one
sequence is opposite its complementary nucleotide in the other
sequence, without the introduction of gaps, and without unpaired
nucleotides at the 5' or the 3' end of either sequence. A nucleic
acid molecule that is "complementary" to a given nucleotide
sequence is one that is sufficiently complementary to the given
nucleotide sequence that it can hybridize under moderately
stringent conditions to the given nucleotide sequence. Thus, a
nucleic acid can be complementary to another nucleic acid without
being its complement.
[0041] A "vector" is a nucleic acid that can be used to introduce
another nucleic acid linked to it into a cell. One type of vector
is a "plasmid," which refers to a linear or circular double
stranded DNA molecule into which additional nucleic acid segments
can be ligated. Another type of vector is a viral vector (e.g.,
replication defective retroviruses, adenoviruses and
adeno-associated viruses), wherein additional DNA segments can be
introduced into the viral genome. Certain vectors are capable of
autonomous replication in a host cell into which they are
introduced (e.g., bacterial vectors comprising a bacterial origin
of replication and episomal mammalian vectors). Other vectors
(e.g., non-episomal mammalian vectors) are integrated into the
genome of a host cell upon introduction into the host cell, and
thereby are replicated along with the host genome. An "expression
vector" is a type of vector that can direct the expression of a
chosen polynucleotide.
[0042] A nucleotide sequence is "operably linked" to a regulatory
sequence if the regulatory sequence affects the expression (e.g.,
the level, timing, or location of expression) of the nucleotide
sequence. A "regulatory sequence" is a nucleic acid that affects
the expression (e.g., the level, timing, or location of expression)
of a nucleic acid. The regulatory sequence can, for example, exert
its effects directly on the regulated nucleic acid, or through the
action of one or more polypeptides (e.g., polypeptides that bind to
the regulatory sequence and/or the nucleic acid). Examples of
regulatory sequences include promoters, enhancers and other
expression control elements (e.g., polyadenylation signals).
Further examples of regulatory sequences are described in, for
example, Goeddel, 1990, Gene Expression Technology: Methods in
Enzymology 185, Academic Press, San Diego, Calif. and Baron et al.,
1995, Nucleic Acids Res. 23:3605-06.
[0043] A "host cell" is a cell that can be used to express a
nucleic acid, e.g., a nucleic acid of the invention. A host cell
can be a prokaryote, for example, E. coli, or it can be a
eukaryote, for example, a single-celled eukaryote (e.g., a yeast or
other fungus), a plant cell (e.g., a tobacco or tomato plant cell),
an animal cell (e.g., a human cell, a monkey cell, a hamster cell,
a rat cell, a mouse cell, or an insect cell) or a hybridoma.
Examples of host cells include the COS-7 line of monkey kidney
cells (ATCC CRL 1651) (see Gluzman et al., 1981, Cell 23:175), L
cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary
(CHO) cells or their derivatives such as Veggie CHO and related
cell lines which grow in serum-free media (see Rasmussen et al.,
1998, Cytotechnology 28:31) or CHO strain DX-B11, which is
deficient in DHFR (see Urlaub et al., 1980, Proc. Natl. Acad. Sci.
USA 77:4216-20), HeLa cells, BHK (ATCC CRL 10) cell lines, the
CV1/EBNA cell line derived from the African green monkey kidney
cell line CV1 (ATCC CCL 70) (see McMahan et al., 1991, EMBO J.
10:2821), human embryonic kidney cells such as 293, 293 EBNA or MSR
293, human epidermal A431 cells, human Colo205 cells, other
transformed primate cell lines, normal diploid cells, cell strains
derived from in vitro culture of primary tissue, primary explants,
HL-60, U937, HaK or Jurkat cells. Typically, a host cell is a
cultured cell that can be transformed or transfected with a
polypeptide-encoding nucleic acid, which can then be expressed in
the host cell. The phrase "recombinant host cell" can be used to
denote a host cell that has been transformed or transfected with a
nucleic acid to be expressed. A host cell also can be a cell that
comprises the nucleic acid but does not express it at a desired
level unless a regulatory sequence is introduced into the host cell
such that it becomes operably linked with the nucleic acid. It is
understood that the term host cell refers not only to the
particular subject cell but to the progeny or potential progeny of
such a cell. Because certain modifications may occur in succeeding
generations due to either mutation or environmental influences,
such progeny may not, in fact, be identical to the parent cell, but
are still included within the scope of the term as used herein.
[0044] A "chimeric antibody" is an antibody in which a portion of
the heavy and/or light chain is identical with, homologous to, or
derived from an antibody from a particular species or belonging to
a particular antibody class or subclass, while the remainder of the
chain(s) is/are identical with, homologous to, or derived from an
antibody (-ies) from another species or belonging to another
antibody class or subclass. Also included are fragments of such
antibodies, that exhibit the desired biological activity (i.e., the
ability to specifically bind IL-4 receptor). See, U.S. Pat. No.
4,816,567 and Morrison, 1985, Science 229:1202-07.
[0045] A "CDR grafted antibody" is an antibody comprising one or
more CDRs derived from an antibody of a particular species or
isotype and the framework of another antibody of the same or
different species or isotype.
[0046] A "multi-specific antibody" is an antibody that recognizes
more than one epitope on one or more antigens. A subclass of this
type of antibody is a "bi-specific antibody" which recognizes two
distinct epitopes on the same or different antigens.
[0047] A "variant" of a polypeptide (e.g., an antibody) comprises
an amino acid sequence wherein one or more amino acid residues are
inserted into, deleted from and/or substituted into the amino acid
sequence relative to another polypeptide sequence. Variants of the
invention include fusion proteins.
[0048] A "derivative" of a polypeptide is a polypeptide (e.g., an
antibody) that has been chemically modified in some manner distinct
from insertion, deletion, or substitution variants, e.g., via
conjugation to another chemical moiety. Unless otherwise indicated,
the term "antibody" includes, in addition to antibodies comprising
two full-length heavy chains and two full-length light chains,
derivatives, variants, fragments, and muteins thereof, examples of
which are described below.
[0049] A molecule (e.g., an antibody) "specifically binds IL-4
receptor" if it bind to IL-4 receptor, or a fragment thereof, with
at least 10 times higher affinity than the molecule binds to a
polypeptide unrelated to IL-4 receptor.
[0050] An "antigen binding domain" or "antigen binding region" is
the portion of an antibody molecule which contains the amino acid
residues (or other moieties) that interact with an antigen and
confer on the antibody its specificity and affinity for the
antigen.
[0051] An "epitope" is the portion of a molecule that is bound by
an antibody. An epitope can comprise non-contiguous portions of the
molecule (e.g., in a polypeptide, amino acid residues that are not
contiguous to one another in the polypeptide's sequence but that,
together in the context of the molecule, are bound by an
antibody).
Indications
[0052] In one aspect, the present invention provides methods of
treating, preventing, curing, relieving, or ameliorating a disease,
disorder, condition, or illness. Among the conditions to be treated
in accordance with the present invention are asthma,
septic/reactive arthritis, dermatitis herpetiformis, chronic
idiopathic urticaria, scleroderma, hypertrophic scarring, Whipple's
Disease, benign prostate hyperplasia, lung disorders in which IL-4
plays a role, conditions in which IL-4-induced epithelial barrier
disruption plays a role, disorders of the digestive system in which
IL-4 plays a role, including inflammatory bowel disease and other
inflammatory conditions in the gastrointestinal tract, allergic
reactions to medication, Kawasaki disease, sickle cell disease
(including sickle cell crisis), Churg-Strauss syndrome, Grave's
disease, pre-eclampsia, Sjogren's syndrome, autoimmune
lymphoproliferative syndrome, autoimmune hemolytic anemia,
Barrett's esophagus, autoimmune uveitis, tuberculosis, and
nephrosis, as described in more detail below. IL-4R antagonists
also find use as adjuvants to allergy immunotherapy and as vaccine
adjuvants.
[0053] Examples of antibodies suitable for treating these
conditions are described below, and include, e.g., antibodies that
bind IL-4R and inhibit the binding of IL-4 thereto. Particularly
useful antibodies also inhibit the binding of IL-13 to IL-13
receptor (IL-13R). Particular embodiments of the invention include
novel antibodies and antibody derivatives, fragments, muteins and
variants, polypeptides, nucleic acid molecules, cells, methods of
making the preceding, methods of inhibiting IL-4R.alpha., and
methods of treating a subject, examples of which are described
below.
[0054] In one aspect, the present invention provides methods
comprising administering an anti-IL-4R.alpha. antibody to a
subject. In one embodiment, the subject is afflicted with, or at
risk for developing, a condition (including, e.g., an illness,
infection, injury, disease, or disorder) that is caused, induced,
mediated, potentiated, exacerbated, or otherwise affected, directly
or indirectly, by the activity of IL-4R.alpha.. Such conditions
include, for example, conditions caused, induced, mediated,
potentiated, exacerbated, or otherwise affected, directly or
indirectly, by IL-4 and/or IL-13. Other factors or cytokines also
may play a role in such conditions.
[0055] The biological activities of IL-4 are mediated through
binding to specific cell surface receptors, referred to as
interleukin-4 receptors (IL-4R). IL-4-induced conditions include
those arising from biological responses that result from the
binding of IL-4 to a native IL-4 receptor on a cell, or which may
be inhibited or suppressed by preventing IL-4 from binding to an
IL-4 receptor. Conditions that may be treated include, but are not
limited to, medical disorders characterized by abnormal expression
of IL-4 or of one or more components of an IL-4R or IL-13R
(including, for example, overexpression, misexpression in a
particular tissue or cell type, or misexpression at a particular
developmental stage), or by an abnormal host response to IL-4
production. Further examples are conditions in which IL-4-induced
antibody production, or proliferation or influx of a particular
cell type, plays a role. IL-4-induced disorders include those in
which IL-4 induces upregulation of IL-4 receptors or enhanced
production of another protein that plays a role in a disease (e.g.,
another cytokine).
[0056] A method for treating a mammal, including a human subject,
who has such a medical disorder comprises administering an
anti-IL-4R antibody, or derivative thereof, to the mammal or
otherwise contacting an IL-4R of the mammal with the antibody or
derivative, e.g., in an ex vivo procedure. Conditions that may be
treated in accordance with the present invention are described, for
example, in U.S. Ser. No. 09/847,816, filed May 1, 2001, the
relevant disclosure of which is incorporated by reference herein.
Such conditions include, but are not limited to, asthma,
septic/reactive arthritis, dermatitis herpetiformis, urticaria
(especially chronic idiopathic urticaria), ulcers, gastric
inflammation, mucosal inflammation, ulcerative colitis, Crohn's
Disease, inflammatory bowel disease, other disorders of the
digestive system in which IL-4 plays a role (e.g., IL-4-induced
inflammation of part of the gastrointestinal tract), conditions in
which IL-4-induced barrier disruption plays a role (e.g.,
conditions characterized by decreased epithelial barrier function
in the lung or gastrointestinal tract), scleroderma, hypertrophic
scarring, Whipple's Disease, benign prostate hyperplasia,
IL-4-induced pulmonary conditions (including those listed below),
allergic reactions to medication, Kawasaki disease, sickle cell
disease or crisis, Churg-Strauss syndrome, Grave's disease,
pre-eclampsia, Sjogren's syndrome, autoimmune lymphoproliferative
syndrome, autoimmune hemolytic anemia, Barrett's esophagus,
autoimmune uveitis, tuberculosis, nephrosis, pemphigus vulgaris or
bullous pemphigoid (autoimmune blistering diseases), and myasthenia
gravis (an autoimmune muscular disease).
[0057] Anti-IL-4R antibodies, and derivatives thereof, also find
use as adjuvants to allergy immunotherapy and as vaccine adjuvants.
Accordingly, an anti-IL-4R antibody may be employed as an adjuvant
to allergy immunotherapy treatment. Anti-IL-4R antibody find
further use as vaccine adjuvants, such as adjuvants for cancer
vaccines and infectious disease vaccines. The use of IL-4
adjuvants, especially when directing the immune response toward a
TH1 response would be beneficial in treating or preventing the
disease in question.
[0058] Septic/Reactive Arthritis
[0059] An anti-IL-4R antibody may be employed in treating septic
arthritis, which also is known as reactive arthritis or bacterial
arthritis. Septic arthritis can be triggered by (result from, or
develop subsequent to) infection with such microbes as
Staphylococcus aureus, Chlamydia trachomatis, Yersinia e.g., Y.
enterocolitica, Salmonella, e.g., S. enteritidis, Shigella and
Campylobacter. S. aureus has been reported to be the major human
pathogen in septic arthritis, responsible for the majority of
cases.
[0060] IL-4 and IL-4-dependent Th2 responses play roles in
promoting septic arthritis. Anti-IL-4R antibody can be employed in
accordance with the invention to inhibit IL-4 and also to suppress
the Th2 response in patients having septic arthritis or at risk for
developing septic arthritis.
[0061] IL-4 increases bacterial burden and bacterial persistence in
joints, by inhibiting clearance of the bacteria. Anti-IL-4R
antibody may be employed to assist in the clearance of bacteria
associated with reactive arthritis, thereby reducing clinical
manifestations such as swelling in joints. Anti-IL-4R antibody may
be administered to a human subject afflicted with septic arthritis,
to reduce IL-4-mediated joint inflammation. In one approach, an
antagonist is injected into a joint, e.g., into synovial fluid in
the knee.
[0062] The use of an anti-IL-4R antibody may benefit subjects
having (or at risk for) septic arthritis by suppressing a TH2
response and promoting a TH1 response against the infection. TH2
cytokines may contribute to bacterial persistence in the joint,
whereas a TH1 response plays a role in eliminating the
bacteria.
[0063] The antibody may be administered to subjects infected with
bacteria or other microbes such as those listed above, to prevent
development of septic arthritis. An Antibody may be administered,
for example, after diagnosis with such an infection, but before
development of clinical symptoms of septic arthritis.
[0064] Whipple's Disease
[0065] Tropheryma whippelii is the causative bacterium for
Whipple's Disease, also known as intestinal lipodystrophy and
lipophagia granulomatosis. The disease is characterized by
steatorrhea, frequently generalized lymphadenopathy, arthritis,
fever, and cough. Also reported in Whipple's Disease patients are
an abundance of "foamy" macrophages in the jejunal lamina propria,
and lymph nodes containing periodic acid-schiff positive particles
appearing bacilliform by electron microscopy (Steadman's Medical
Dictionary, 26.sup.th Edition, Williams & Wilkins, Baltimore,
Md., 1995).
[0066] The use of anti-IL-4R antibody may benefit subjects having
(or at risk for developing) Whipple's Disease, by restoring a
normal balance between the TH1 and TH2 components of the patient's
immune response. Increased production of IL-4 (a TH2-type cytokine)
and decreased levels of certain TH1-type cytokines have been
associated with Whipple's Disease. TH2 cytokines may contribute to
bacterial persistence, whereas a TH1 response plays a role in
clearing the causative bacteria. IL-4R antagonists may be
administered to subjects infected with T. whippelii, whether or not
the subject exhibits clinical symptoms of Whipple's Disease.
[0067] Dermatitis Herpetiformis
[0068] Dermatitis herpetiformis, also known as Duhring's disease,
is a chronic skin condition characterized by blistering skin
lesions, cutaneous IgA deposits, and itching. Patients have an
immunobullous skin disorder with an associated gluten sensitive
enteropathy, which is mediated by a Th2 immune response. Anti-IL-4R
antibody is administered in accordance with the present invention,
to inhibit IL-4 and the Th2 response, thus promoting healing of
current lesions and reducing or preventing the formation of
blisters on the extensor body surfaces.
[0069] Hypertrophic Scarring
[0070] In accordance with the present invention, anti-IL-4R
antibody is administered to subjects who have, or are susceptible
to developing, hypertrophic scarring. In one method provided
herein, an anti-IL-4R antibody is administered to a subject with a
burn injury. An immune response to burns and other injury is
believed to play a role in the pathogenesis of hypertrophic
scarring. Increased production of TH2-type cytokines, including
IL-4, and reduced levels of certain TH1-type cytokines have been
reported in burn patients who have hypertrophic scarring. The use
of anti-IL-4R antibodies may benefit subjects having (or at risk
for developing) hypertrophic scarring, by suppressing a TH2-type
immune response.
[0071] Urticaria
[0072] Urticaria, especially chronic forms thereof such as chronic
idiopathic urticaria (CIU), may be treated with an anti-IL-4R
antibody in accordance with the present invention. CIU patients
have higher serum levels of IL-4 than controls, and may have a
predominantly TH2-type cytokine profile. Mast cells and Th2-type T
cells are implicated as primary effector cells in chronic
urticaria. IL-4 stimulates mast cell proliferation. Mast cell
degranulation leads to histamine release, subsequent erythema,
eosinophilia, redness of skin, and itching. Anti-IL-4R antibodies
are administered to inhibit IL-4 and reduce the TH2-type response,
thereby helping to control a subject's urticaria.
[0073] Ulcerative Colitis; Other Disorders of the Gastrointestinal
Tract
[0074] IL-4 is implicated in the pathogenesis of ulcerative
colitis. Th2-type cytokines including IL-4 may predominate in the
colonic mucosa of patients with this disorder. The use of
anti-IL-4R antibodies to suppress the TH2 response may alleviate
this condition.
[0075] In addition to ulcerative colitis, other disorders of the
gastrointestinal tract or digestive system may be treated with
anti-IL-4R antibodies. Examples of such disorders include, but are
not limited to, inflammatory bowel disease (IBD), with ulcerative
colitis and Crohn's Disease being forms of IBD, gastritis, ulcers,
and mucosal inflammation.
[0076] Any gastrointestinal condition in which IL-4 plays a role
may be treated with an anti-IL-4R antibody in accordance with the
present invention. For example, conditions involving IL-4-induced
inflammation of part of the gastrointestinal tract may be treated
with an anti-IL-4R antibody. Particular embodiments are directed to
treatment of chronic inflammatory conditions in the
gastrointestinal tract.
[0077] Other embodiments are directed to conditions in which
IL-4-induced barrier disruption plays a role, e.g., conditions
characterized by decreased epithelial barrier function in at least
a portion of the gastrointestinal tract. Such conditions may, for
example, involve damage to the epithelium that is induced by IL-4,
directly or indirectly.
[0078] The intestinal epithelium forms a relatively impermeable
barrier between the lumen and the submucosa. Disruption of the
epithelial barrier has been associated with conditions such as
inflammatory bowel disease. See the discussion in Youakim, A. and
M. Ahdieh (Am. J. Physiol. 276 (Gastrointest. Liver Physiol.
39):G1279-G1288, 1999), hereby incorporated by reference in its
entirety. A damaged or "leaky" barrier can allow antigens to cross
the barrier, which in turn elicits an immune response that may
cause further damage to gastrointestinal tissue. Such an immune
response may include recruitment of neutrophils or T cells, for
example. An anti-IL-4R antibody may be administered to inhibit
undesirable stimulation of an immune response.
[0079] Lung Disorders
[0080] Methods for treating IL-4-induced pulmonary disorders are
provided herein. Such disorders include, but are not limited to,
lung fibrosis, including chronic fibrotic lung disease, other
conditions characterized by IL-4-induced fibroblast proliferation
or collagen accumulation in the lungs, pulmonary conditions in
which a TH2-type immune response plays a role, conditions
characterized by decreased barrier function in the lung (e.g.,
resulting from IL-4-induced damage to the epithelium), or
conditions in which IL-4 plays a role in an inflammatory response
(e.g., asthma).
[0081] Cystic fibrosis is characterized by the overproduction of
mucus and development of chronic infections. Inhibiting IL-4 and
the Th2 response will reduce mucus production and help control
infections such as allergic bronchopulmonary aspergillosis
(ABPA).
[0082] Allergic bronchopulmonary mycosis occurs primarily in
patients with cystic fibrosis or asthma, where a Th2 immune
response is dominant. Inhibiting IL-4 and the Th2 response will
help clear and control these infections.
[0083] Chronic obstructive pulmonary disease is associated with
mucus hypersecretion and fibrosis. Inhibiting IL-4 and the Th2
response will reduce the production of mucus and the development of
fibrous thereby improving respiratory function and delaying disease
progression.
[0084] Bleomycin-induced pneumopathy and fibrosis, and
radiation-induced pulmonary fibrosis are disorders characterized by
fibrosis of the lung which is manifested by the influx of Th2,
CD4.sup.+ cells and macrophages, which produce IL-4 which in turn
mediates the development of fibrosis. Inhibiting IL-4 and the Th2
response will reduce or prevent the development of these
disorders.
[0085] Pulmonary alveolar proteinosis is characterized by the
disruption of surfactant clearance. IL-4 increases surfactant
product. Use of anti-IL-4R antibody will decrease surfactant
production and decrease the need for whole lung lavage.
[0086] Adult respiratory distress syndrome (ARDS) may be
attributable to a number of factors, one of which is exposure to
toxic chemicals. One patient population susceptible to ARDS is
critically ill patients who go on ventilators. ARDS is a frequent
complication in such patients. Anti-IL-4R antibody treatment may
alleviate ARDS by reducing inflammation and adhesion molecules,
although methods for treating such subjects in accordance with the
present invention are not limited by a particular mechanism of
action. Anti-IL-4R antibody may be used to prevent or treat
ARDS.
[0087] Sarcoidosis is characterized by granulomatus lesions. Use of
anti-IL-4R antibody to treat sarcoidosis, particularly pulmonary
sarcoidosis, is contemplated herein.
[0088] Conditions in which IL-4-induced barrier disruption plays a
role (e.g., conditions characterized by decreased epithelial
barrier function in the lung) may be treated with anti-IL-4R
antibody. Damage to the epithelial barrier in the lungs may be
induced by IL-4 directly or indirectly. The epithelium in the lung
functions as a selective barrier that prevents contents of the lung
lumen from entering the submucosa. A damaged or "leaky" barrier
allows antigens to cross the barrier, which in turn elicits an
immune response that may cause further damage to lung tissue. Such
an immune response may include recruitment of eosinophils or mast
cells, for example. An anti-IL-4R antibody may be administered to
inhibit such undesirable stimulation of an immune response.
[0089] Anti-IL-4R antibodies may be employed to promote healing of
lung epithelium, thus restoring barrier function. Anti-IL-4R
antibody may be employed to promote healing of lung epithelium in
asthmatics, for example. Alternatively, the antagonist is
administered for prophylactic purposes, to prevent IL-4-induced
damage to lung epithelium.
[0090] Tuberculosis
[0091] A TH2-type immune response is implicated in playing a role
in causing tissue damage (e.g., necrosis of lung tissue) in
tuberculosis (TB) patients. Elevated levels of IL-4 are associated
with TB. IL-4 production may be particularly elevated in cavitary
tuberculosis (i.e., in TB patients who have developed pulmonary
cavities, which can be detected/visualized by such techniques as
radiographs of the chest).
[0092] Anti-IL-4R antibodies may benefit TB patients (especially
those with cavitary TB) by suppressing a TH2-type immune response.
Methods for treating such subjects in accordance with the present
invention are not limited by a particular mechanism of action,
however. Anti-IL-4R antibody advantageously are administered in an
amount that restores the desired balance between the TH1 and TH2
components of the immune response, and reduces IL-4-induced tissue
damage in a patient.
Churg-Strauss Syndrome
[0093] Churg-Strauss syndrome, a disease also known as allergic
granulomatous angiitis, is characterized by inflammation of the
blood vessels in persons with a history of asthma or allergy, and
by eosinophilia. Anti-IL-4R antibodies may be administered to
alleviate inflammation in subjects with this syndrome. The use of
anti-IL-4R antibodies to suppress a TH2-type immune response, and
to combat eosinophilia, would benefit the subjects.
[0094] Pre-Eclampsia
[0095] Pre-eclampsia is a toxemia of late pregnancy. The condition
is characterized by a sharp rise in blood pressure, generally
accompanied by edema and albuminuria, during the third term of
pregnancy.
[0096] Elevated TH1-type and TH2-type immune responses may play a
role in the condition. One method provided herein comprises
administering an anti-IL-4R antibody to a pregnant woman who has
developed pre-eclampsia. The anti-IL-4R antibody is administered in
an amount, and for a period of time, sufficient to reduce the level
of IL-4 (or of TH2-type cytokines collectively) to a level that is
considered normal during pregnancy. In general, the anti-IL-4R
antibody is administered repeatedly throughout the duration of the
pregnancy.
[0097] Scleroderma
[0098] Anti-IL-4R antibodies are administered to subjects with
scleroderma in accordance with the invention. The antibodies reduce
IL-4-induced collagen synthesis by fibroblasts in the patients. The
antibodies may be employed in preventing or reducing fibrosis in
skin and lung tissues, as well as other tissues in which fibrosis
occurs in scleroderma patients, suppressing collagen synthesis in
such tissues, and in treating scleroderma-related pulmonary
disease.
[0099] Benign Prostate Hyperplasia
[0100] Benign prostate hyperplasia (BPH), also known as benign
prostate hypertrophy, may be treated with anti-IL-4R antibodies.
While not wishing to be bound by a particular mechanism of action,
administration of an anti-IL-4R antibody may benefit a subject with
BPH by suppressing IL-4-induced inflammation, or by suppressing a
TH2-type immune response.
[0101] Grave's Disease
[0102] Antibodies directed against thyrotropin receptor play an
important role in Grave's Disease, a disorder characterized by
hyperthyroidism. Studies of cytokine production in Grave's Disease
patients show a shift toward a TH2-type cytokine response. Use of
an anti-IL-4R antibody to suppress the TH2-type immune response,
and suppress antibody production, would benefit Grave's Disease
patients.
[0103] Sickle Cell Disease
[0104] Sickle cell disease patients typically experience
intermittent periods of acute exacerbation called crises, with the
crises being categorized as anemic or vaso-occlusive. Anti-IL-4R
antibodies find use in treating or preventing sickle cell crisis,
especially in subjects with elevated IL-4 levels or in whom the
immune response has shifted toward a TH2-type response. Sickle cell
disease (especially sickle cell crisis) has been associated with
increased susceptibility to infectious diseases, including
bacterial infections. Administering anti-IL-4R antibodies to sickle
cell disease patients may help the patient mount an immune response
against infectious diseases.
[0105] Sjogren's Syndrome
[0106] The autoimmune disease known as Sjogren's syndrome or sicca
syndrome typically combines dry eyes and dry mouth with a disorder
of the connective tissues, such as rheumatoid arthritis, lupus,
scleroderma, or polymyositis. The vast majority of patients are
middle age (or older) females. Sjogren's syndrome is an
inflammatory disease of glands (e.g., lacrimal and salivary glands)
and other tissues of the body. The syndrome typically is associated
with autoantibody production.
[0107] Anti-IL-4R antibodies may be administered to reduce the
inflammatory response (such as inflammation of glands, including
lacrimal glands) in such subjects. Anti-IL-4R antibodies may
benefit Sjogren's syndrome patients by suppressing a TH2-type
immune response. Methods for treating subjects in accordance with
the present invention are not limited by a particular mechanism of
action, however.
[0108] Autoimmune Lymphoproliferative Syndrome
[0109] Manifestations of autoimmune lymphoproliferative syndrome
include lymphoproliferation and autoantibody production. Patients
with the syndrome reportedly have an inherited deficiency in
apoptosis. Anti-IL-4R antibodies may benefit subjects with this
syndrome by suppressing a TH2-type immune response. Methods for
treating such subjects in accordance with the present invention are
not limited by a particular mechanism of action, however.
[0110] Autoimmune Hemolytic Anemia
[0111] Excessive IL-4 secretion, and a deficiency in TH1-type
cytokines, are implicated in contributing to the pathogenesis of
autoimmune hemolytic anemia. Anti-IL-4R antibodies are administered
in accordance with the present invention, to benefit the patients
by reducing autoantibody production, and by restoring a more normal
balance between the TH1 and TH2 components of the immune
response.
[0112] Autoimmune Uveitis
[0113] Uveitis involves inflammation of the uvea (generally
considered to include the iris, ciliary body, and choroid,
considered together). Excess IL-4 secretion is implicated as
playing a role in pathogenesis of this sight-threatening
inflammatory eye disease. In accordance with the present invention,
anti-IL-4R antibodies are administered to a subject with, or at
risk for developing, uveitis. In one embodiment, anti-IL-4R
antibodies are administered to an individual who has autoimmune
uveoretinitis.
[0114] Kawasaki Disease
[0115] Also known as the mucocutaneous lymph node syndrome,
Kawasaki disease (KD) mainly afflicts young children. The disease
is characterized by particular changes in the mucus membranes
lining the lips and mouth, and by enlarged, tender lymph glands.
Symptoms typically include fever, conjunctivitis, inflammation of
the lips and mucous membranes of the mouth, swollen glands in the
neck, and a rash covering the hands and feet, leading to hardened,
swollen and peeling skin on hands and feet. In children with
Kawasaki Disease (KD), inflammation of arteries (vasculitis) may
develop. Due to the effect of the disease on the vascular system,
KD reportedly is the main cause of acquired heart disease in
children.
[0116] Anti-IL-4R antibodies may be administered to subjects with
Kawasaki Disease. Excessive IL-4 secretion and a deficiency in
TH1-type cytokines contribute to the pathogenesis of the
disease.
[0117] Barrett's Esophagus
[0118] Barrett's esophagus is a condition characterized by
alteration (subsequent to irritation) of the cells in the
epithelial tissue that lines the lower portion of the esophagus.
Frequent reflux of the stomach contents into the esophagus, over
time, can lead to Barrett esophagus. Patients with Barrett
esophagus are at risk for developing esophageal cancer (e.g.,
adenocarcinoma). While not wishing to be bound by a particular
mechanism of action, administration of an anti-IL-4R antibody may
benefit a subject with Barrett's esophagus by suppressing a
TH2-type immune response. In one embodiment, an anti-IL-4R antibody
is administered to a subject with esophagitis, to inhibit
progression to Barrett's esophagus.
[0119] Nephrosis
[0120] Nephrosis, also known as nephrotic syndrome, is a kidney
disease that is non-inflammatory and non-malignant. In the
condition known as minimal change nephrosis, glomerular damage
(believed to arise from structural changes in glomerular visceral
epithelial cells) results in abnormalities that include
proteinuria. A TH2-type immune response (especially secretion of
the TH2-type cytokines IL-4 and IL-13) are implicated as playing a
role in pathogenesis of minimal change nephrosis.
[0121] Other Indications
[0122] Additional examples of conditions that may be treated in
accordance with the present invention include but are not limited
to the following. Anti-IL-4R antibodies may be employed in treating
or preventing hyper IgE syndrome, idiopathic hypereosinophil
syndrome, allergic reactions to medication, autoimmune blistering
diseases (e.g., pemphigus vulgaris or bullous pemphigoid),
myasthenia gravis (an autoimmune muscular disease), and chronic
fatigue syndrome. Anti-IL-4R antibodies may be employed in treating
GVHD; particular methods for treating GVHD in combination with
other therapeutic agents are described below. Anti-IL-4R antibodies
also find use in treating or preventing hepatotoxicity induced by
drugs such as diclofenac (a non-steroidal anti-inflammatory
drug).
[0123] An anti-IL-4R antibody may be employed as an adjuvant to
allergy immunotherapy treatment. Anti-IL-4R antibodies find further
use as vaccine adjuvants, such as adjuvants for cancer vaccines and
infectious disease vaccines. The use of anti-IL-4R antibodies is
especially advantageous when favoring a TH1-type immune response
would be beneficial in preventing or treating the condition for
which the vaccine is being administered. Anti-IL-4R antibodies may
be employed when reducing an antibody-mediated immune response
and/or promoting a T-cell-mediated immune response is desired.
[0124] Anti-IL-4R Antibodies
[0125] In one aspect, the present invention provides antibodies,
and fragments, derivatives, muteins, and variants thereof, which
bind to IL-4 receptor alpha, e.g., human IL-4 receptor alpha.
[0126] Anti-IL-4R antibodies that may be employed in accordance
with the present invention include antibodies that inhibit a
biological activity of IL-4. Examples of such biological activities
include associating with another receptor component (e.g., IL-2R
gamma or IL-13R alpha), binding (either alone or as part of a
multimeric receptor complex) a signaling molecule (e.g., IL-4 or
IL-13), and transducing a signal in response to binding a signaling
molecule.
[0127] Different anti-IL-4R antibodies may bind to different
domains or epitopes of IL-4R or act by different mechanisms of
action. Examples include but are not limited to antibodies that
interfere with binding of IL-4 to IL-4R or that inhibit signal
transduction. The site of action may be, for example, intracellular
(e.g., by interfering with an intracellular signaling cascade) or
extracellular. An antibody need not completely inhibit an IL-4
induced activity to find use in the present invention; rather,
antibodies that reduce a particular activity of IL-4 are
contemplated for use as well.
[0128] The above-presented discussions of particular mechanisms of
action for anti-IL-4R antibodies in treating particular diseases
are illustrative only, and the methods presented herein are not
bound thereby. The mechanisms of action by which anti-IL-4R
antibodies ameliorate diseases are not limited to those discussed
above.
[0129] An anti-IL-4R antibody may inhibit an IL-4-mediated influx
of cells involved in an immune or inflammatory response. An
antibody may act by, for example, reducing proliferation,
activation, migration, influx, or accumulation of a particular cell
type, or by inhibiting a biological response directly or indirectly
attributable to a particular cell type. Examples of particular cell
types are fibroblasts, mast cells, and eosinophils.
[0130] As discussed above, some conditions may be treated by
suppressing a TH2-type immune response. IL-4R is associated with a
TH2 response, and is one of the cytokines secreted by T-helper
cells of type 2 (TH2 cells). An anti-IL-4R antibody may be
administered to reduce a TH2-type immune response. The IL-4R
antibody may be said to reduce proliferation of TH2 cells, to
suppress a TH2 response, to shift the immune response toward a TH1
response, or to favor a TH1-type response. Antagonists of other
TH2-type cytokine(s), such as IL-5, IL-10, or IL-13, may be
additionally administered to subjects who have a disorder involving
elevated levels of such cytokines. Techniques for measuring the
amount of such cytokines in a subject, e.g., in the subject's
serum, are well known.
[0131] One embodiment of the invention is directed to a method for
inhibiting IL-4-induced damage to epithelium, comprising
administering an anti-IL-4R antibody to a subject who has, or is at
risk of developing, a condition in which IL-4-mediated epithelial
barrier disruption plays a role.
[0132] Particular embodiments of methods provided herein comprise
administering an anti-IL-4R antibody to inhibit IL-4-induced damage
to epithelium in the gastrointestinal tract or lung. Such methods
may be employed to prevent epithelial damage, or to restore
epithelial barrier function (i.e., promote repair or healing of the
epithelium). The ability of an anti-IL-4R antibody to inhibit
IL-4-induced damage to epithelium may be confirmed in any of a
number of suitable assays, such as those described herein.
[0133] Any inflammation associated with (or subsequent to) an
infection also may be treated with an anti-IL-4R antibody. The
antibody may be administered to inhibit any IL-4-induced component
of an inflammatory response resulting from microbial infection in
the gastrointestinal tract, for example.
[0134] Combinations of two or more antibodies or antibody
derivatives, or of an antibody or antibody derivative and one or
more other IL-4, IL-13, IL-4R and/or IL-13R antagonists (as
described, for example, in U.S. Pat. Nos. 5,599,905, 5,840,869,
5,856,296, 5,767,065, 5,717,072, 6,391,581, 5,710,023, Idzerda et
al., 1990, J. Exp. Med. 171:861-73, and Mosley et al., 1989, Cell
59:335-48, incorporated herein by reference in their entireties)
may be employed in methods and compositions of the present
invention.
[0135] Oligonucleotide-directed site-specific mutagenesis
procedures can be employed to provide an altered gene having
particular codons altered according to the substitution, deletion,
or insertion required. Examples of techniques for making such
alterations are described in Walder et al., 1986, Gene 42:133;
Bauer et al. 0.1985, Gene 37:73; Craik, BioTechniques, January
1985, 12-19; Smith et al., 1981, Genetic Engineering: Principles
and Methods, Plenum Press; and U.S. Pat. Nos. 4,518,584 and
4,737,462. These and other methods can be used to make, for
example, derivatives of anti-IL-4R antibodies that have, for
example, increased affinity, avidity, or specificity for IL-4R as
compared to the underivatized antibody.
[0136] Other derivatives of anti-IL-4R antibodies within the scope
of this invention include covalent or aggregative conjugates of
anti-IL-4R antibodies, or fragments thereof, with other proteins or
polypeptides, such as by expression of recombinant fusion proteins
comprising heterologous polypeptides fused to the N-terminus or
C-terminus of an anti-IL-4R antibody polypeptide. For example, the
conjugated peptide may be a heterologous signal (or leader)
polypeptide, e.g., the yeast alpha-factor leader, or a peptide such
as an epitope tag. Anti-IL-4R antibody-containing fusion proteins
can comprise peptides added to facilitate purification or
identification of the anti-IL-4R antibody (e.g., poly-His). An
anti-IL-4R antibody polypeptide also can be linked to the FLAG
peptide Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys (DYKDDDDK) (SEQ ID NO:69)
as described in Hopp et al., Bio/Technology 6:1204, 1988, and U.S.
Pat. No. 5,011,912. The FLAG peptide is highly antigenic and
provides an epitope reversibly bound by a specific monoclonal
antibody (mAb), enabling rapid assay and facile purification of
expressed recombinant protein. Reagents useful for preparing fusion
proteins in which the FLAG peptide is fused to a given polypeptide
are commercially available (Sigma, St. Louis, Mo.).
[0137] Oligomers that contain one or more anti-IL-4R antibody
polypeptides may be employed as IL-4R antagonists. Oligomers may be
in the form of covalently-linked or non-covalently-linked dimers,
trimers, or higher oligomers. Oligomers comprising two or more
anti-IL-4R antibody polypeptides are contemplated for use, with one
example being a homodimer. Other oligomers include heterodimers,
heterotrimers, etc.
[0138] One embodiment is directed to oligomers comprising multiple
anti-IL-4R antibody polypeptides joined via covalent or
non-covalent interactions between peptide moieties fused to the
anti-IL-4R antibody polypeptides. Such peptides may be peptide
linkers (spacers), or peptides that have the property of promoting
oligomerization. Leucine zippers and certain polypeptides derived
from antibodies are among the peptides that can promote
oligomerization of IL-4R polypeptides attached thereto, as
described in more detail below.
[0139] In particular embodiments, the oligomers comprise from two
to four anti-IL-4R antibody polypeptides. The anti-IL-4R antibody
moieties of the oligomer may be in any of the forms described
above, e.g., variants or fragments. Preferably, the oligomers
comprise anti-IL-4R antibody polypeptides that have IL-4R binding
activity.
[0140] In one embodiment, an oligomer is prepared using
polypeptides derived from immunoglobulins. Preparation of fusion
proteins comprising certain heterologous polypeptides fused to
various portions of antibody-derived polypeptides (including the Fc
domain) has been described, e.g., by Ashkenazi et al., 1991, PNAS
USA 88:10535; Byrn et al., 1990, Nature 344:677; and Hollenbaugh et
al., 1992 "Construction of Immunoglobulin Fusion Proteins", in
Current Protocols in Immunology, Suppl. 4, pages
10.19.1-10.19.11.
[0141] One embodiment of the present invention is directed to a
dimer comprising two fusion proteins created by fusing an IL-4R
binding fragment of an anti-IL-4R antibody to the Fc region of an
antibody. The dimer can be made by, for example, inserting a gene
fusion encoding the fusion protein into an appropriate expression
vector, expressing the gene fusion in host cells transformed with
the recombinant expression vector, and allowing the expressed
fusion protein to assemble much like antibody molecules, whereupon
interchain disulfide bonds form between the Fc moieties to yield
the dimer.
[0142] The term "Fc polypeptide" as used herein includes native and
mutein forms of polypeptides derived from the Fc region of an
antibody. Truncated forms of such polypeptides containing the hinge
region that promotes dimerization are also included. Fusion
proteins comprising Fc moieties (and oligomers formed therefrom)
offer the advantage of facile purification by affinity
chromatography over Protein A or Protein G columns.
[0143] One suitable Fc polypeptide, described in PCT application WO
93/10151 (hereby incorporated by reference), is a single chain
polypeptide extending from the N-terminal hinge region to the
native C-terminus of the Fc region of a human IgG1 antibody.
Another useful Fc polypeptide is the Fc mutein described in U.S.
Pat. No. 5,457,035 and in Baum et al., 1994, EMBO J. 13:3992-4001.
The amino acid sequence of this mutein is identical to that of the
native Fc sequence presented in WO 93/10151, except that amino acid
19 has been changed from Leu to Ala, amino acid 20 has been changed
from Leu to Glu, and amino acid 22 has been changed from Gly to
Ala. The mutein exhibits reduced affinity for Fc receptors.
[0144] In other embodiments, the variable portion of the heavy
and/or light chains of an anti-IL-4R antibody may be substituted
for the variable portion of an antibody heavy and/or light
chain.
[0145] Alternatively, the oligomer is a fusion protein comprising
multiple anti-IL-4R antibody polypeptides, with or without peptide
linkers (spacer peptides). Among the suitable peptide linkers are
those described in U.S. Pat. Nos. 4,751,180 and 4,935,233.
[0146] Another method for preparing oligomeric anti-IL-4R antibody
derivatives involves use of a leucine zipper. Leucine zipper
domains are peptides that promote oligomerization of the proteins
in which they are found. Leucine zippers were originally identified
in several DNA-binding proteins (Landschulz et al., 1988, Science
240:1759), and have since been found in a variety of different
proteins. Among the known leucine zippers are naturally occurring
peptides and derivatives thereof that dimerize or trimerize.
Examples of leucine zipper domains suitable for producing soluble
oligomeric proteins are described in PCT application WO 94/10308,
and the leucine zipper derived from lung surfactant protein D (SPD)
described in Hoppe et al., 1994, FEBS Letters 344:191, hereby
incorporated by reference. The use of a modified leucine zipper
that allows for stable trimerization of a heterologous protein
fused thereto is described in Fanslow et al., 1994, Semin. Immunol.
6:267-78. In one approach, recombinant fusion proteins comprising
an anti-IL-4R antibody fragment or derivative fused to a leucine
zipper peptide are expressed in suitable host cells, and the
soluble oligomeric anti-IL-4R antibody fragments or derivatives
that form are recovered from the culture supernatant.
[0147] Anti-IL-4R antibody polypeptides and fusion proteins
described herein may be prepared by any of a number of conventional
techniques. For example, anti-IL-4R antibody polypeptides may be
purified from cells that naturally express them, or they may be
produced in recombinant expression systems, using any technique
known in the art.
[0148] Any expression system known in the art can be used to make
the recombinant polypeptides of the invention. In general, host
cells are transformed with a recombinant expression vector that
comprises DNA encoding a desired anti-IL-4R antibody polypeptide.
Among the host cells that may be employed are prokaryotes, yeast or
higher eukaryotic cells. Prokaryotes include gram negative or gram
positive organisms, for example E. coli or bacilli. Higher
eukaryotic cells include insect cells and established cell lines of
mammalian origin. Examples of suitable mammalian host cell lines
include the COS-7 line of monkey kidney cells (ATCC CRL 1651)
(Gluzman et al., 1981, Cell 23:175), L cells, 293 cells, C127
cells, 3T3 cells (ATCC CCL 163), Chinese hamster ovary (CHO) cells,
HeLa cells, BHK (ATCC CRL 10) cell lines, and the CV1/EBNA cell
line derived from the African green monkey kidney cell line CVI
(ATCC CCL 70) as described by McMahan et al., 1991, EMBO J. 10:
2821. Appropriate cloning and expression vectors for use with
bacterial, fungal, yeast, and mammalian cellular hosts are
described by Pouwels et al. (Cloning Vectors: A Laboratory Manual,
Elsevier, New York, 1985).
[0149] The transformed cells are cultured under conditions that
promote expression of the anti-IL-4R antibody polypeptide, and the
polypeptide is recovered by conventional protein purification
procedures. One such purification procedure includes the use of
affinity chromatography, e.g., over a matrix having all or a
portion (e.g., the extracellular domain) of IL-4R bound thereto.
Polypeptides contemplated for use herein include substantially
homogeneous recombinant mammalian anti-IL-4R antibody polypeptides
substantially free of contaminating endogenous materials.
[0150] In one aspect, the present invention provides antibodies
that interfere with the binding of IL-4 to an IL-4 receptor. Such
antibodies, referred to herein as blocking antibodies, may be
raised against IL-4R, or a fragment, variant or derivative thereof,
and screened in conventional assays for the ability to interfere
with binding of IL-4 to IL-4 receptors. Examples of suitable assays
are assays that test the antibodies for the ability to inhibit
binding of IL-4 to cells expressing IL-4R, or that test antibodies
for the ability to reduce a biological or cellular response that
results from the binding of IL-4 to cell surface IL-4
receptors.
[0151] It has been reported that IL-4R alpha is a component of
certain multi-subunit IL-13 receptor complexes (Zurawski et al.,
1995, J. Biol. Chem. 270: 13869; de Vries, 1998, J. Allergy Clin.
Immunol. 102:165; and Callard et al., 1996, Immunology Today,
17:108, each incorporated by reference herein). Accordingly, in one
embodiment, an antibody is provided that blocks binding of IL-4 and
also of IL-13 to cells. The antibodies inhibit IL-4-induced
biological activity and also inhibit IL-13-induced activity, and
thus may be employed in treating conditions induced by either or
both cytokines. Examples of such conditions include but are not
limited to IgE-mediated conditions, asthma, allergic conditions,
allergic rhinitis, and dermatitis including atopic dermatitis.
[0152] Antibodies that bind to IL-4R alpha may be screened in
various conventional assays to determine whether they interfere
with the binding of IL-13 to IL-4R alpha-containing IL-13 receptor
complexes. Antibodies may be screened, for example, in binding
assays or tested for the ability to inhibit an IL-IL-13-induced
biological activity. An example of a suitable assay is illustrated
in Example 2 below.
[0153] Antibodies specific for IL-4R alpha may be prepared using
any technique known in the art. See, for example, Monoclonal
Antibodies, Hybridomas: A New Dimension in Biological Analyses,
Kennet et al. (eds.), Plenum Press, New York (1980); and
Antibodies: A Laboratory Manual, Harlow and Land (eds.), Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.,
(1988).
[0154] Antigen-binding fragments of antibodies of the invention may
be produced by conventional techniques. Examples of such fragments
include, but are not limited to, Fab and F(ab').sub.2 fragments.
Antibody fragments and derivatives produced by genetic engineering
techniques are also contemplated. Unless otherwise specified, the
terms "antibody" and "monoclonal antibody" as used herein encompass
both whole antibodies and antigen-binding fragments and/or
derivatives thereof.
[0155] Additional embodiments include chimeric antibodies, e.g.,
humanized versions of murine monoclonal antibodies. Such humanized
antibodies may be prepared by known techniques, and offer the
advantage of reduced immunogenicity when the antibodies are
administered to humans. In one embodiment, a humanized monoclonal
antibody comprises the variable domain of a murine antibody (or all
or part of the antigen binding site thereof) and a constant domain
derived from a human antibody. Alternatively, a humanized antibody
fragment may comprise the antigen binding site of a murine
monoclonal antibody and a variable domain fragment (lacking the
antigen-binding site) derived from a human antibody. Procedures for
the production of chimeric and further engineered monoclonal
antibodies include those described in Riechmann et al., 1988,
Nature 332:323, Liu et al., 1987, Proc. Nat. Acad. Sci. USA
84:3439, Larrick et al., 1989, Bio/Technology 7:934, and Winter et
al., 1993, TIPS 14:139. In one embodiment, the chimeric antibody is
a CDR grafted antibody.
[0156] Procedures have been developed for generating human or
partially human antibodies in non-human animals. For example, mice
in which one or more endogenous immunoglobulin genes have been
inactivated by various means have been prepared. Human
immunoglobulin genes have been introduced into the mice to replace
the inactivated mouse genes. Antibodies produced in the animal
incorporate human immunoglobulin polypeptide chains encoded by the
human genetic material introduced into the animal. In one
embodiment, a non-human animal, such as a transgenic mouse, is
immunized with an IL-4R polypeptide, such that antibodies directed
against the IL-4R polypeptide are generated in said animal. One
example of a suitable immunogen is a soluble human IL-4R, such as a
polypeptide comprising the extracellular domain of the protein of
SEQ ID NO:2, or other immunogenic fragment of the protein of SEQ ID
NO:2.
[0157] Examples of techniques for production and use of transgenic
animals for the production of human or partially human antibodies
are described in U.S. Pat. Nos. 5,814,318, 5,569,825, and
5,545,806, which are incorporated by reference herein.
[0158] In another aspect, the present invention provides monoclonal
antibodies that bind to IL-4 receptor. Monoclonal antibodies may be
produced using any technique known in the art, e.g., by
immortalizing spleen cells harvested from the transgenic animal
after completion of the immunization schedule. The spleen cells can
be immortalized using any technique known in the art, e.g., by
fusing them with myeloma cells to produce hybridomas. Myeloma cells
for use in hybridoma-producing fusion procedures preferably are
non-antibody-producing, have high fusion efficiency, and enzyme
deficiencies that render them incapable of growing in certain
selective media which support the growth of only the desired fused
cells (hybridomas). Examples of suitable cell lines for use in
mouse fusions include Sp-20, P3-X63/Ag8, P3-X63-Ag8.653, NS1/1.Ag 4
1, Sp210-Ag14, FO, NSO/U, MPC-11, MPC11--X45-GTG 1.7 and S194/5XX0
Bul; examples of cell lines used in rat fusions include R210.RCY3,
Y3-Ag 1.2.3, IR983F and 4B210. Other cell lines useful for cell
fusions are U-266, GM1500-GRG2, LICR-LON-HMy2 and UC729-6.
[0159] In one embodiment, a hybridoma cell line is produced by
immunizing an animal (e.g., a transgenic animal having human
immunoglobulin sequences) with an IL-4R immunogen; harvesting
spleen cells from the immunized animal; fusing the harvested spleen
cells to a myeloma cell line, thereby generating hybridoma cells;
establishing hybridoma cell lines from the hybridoma cells, and
identifying a hybridoma cell line that produces an antibody that
binds an IL-4R polypeptide. Such hybridoma cell lines, and
anti-IL-4R monoclonal antibodies produced therefrom, are
encompassed by the present invention.
[0160] Monoclonal antibodies secreted by a hybridoma cell line can
be purified using any technique known in the art. Hybridomas or
mAbs may be further screened to identify mAbs with particular
properties, such as the ability to block an IL-4- and/or an
IL-13-induced activity. Example of such screens are provided in
Examples 2, 3, and 4.
[0161] Further examples of procedures for preparing antibodies
directed against human IL-4 (including monoclonal antibodies),
assays by which blocking antibodies are identified, and techniques
for generating humanized or genetically engineered derivatives of
anti-IL-4 antibodies, are described in U.S. Pat. Nos. 5,041,381,
5,863,537, 5,928,904, and 5,676,940, which are hereby incorporated
by reference. Further examples of antibodies that may be employed
as IL-4 antagonists are described in WO 91/09059, also incorporated
by reference herein.
[0162] In another aspect, the present invention provides human
antibodies that bind IL-4R. In one embodiment of the invention,
human antibodies raised against IL-4R alpha and produced by
techniques involving use of transgenic mice, block binding of IL-4
and also IL-13 to cells. Such antibodies are IL-4 antagonists and
additionally function as IL-13 antagonists.
[0163] Antibodies of the invention can comprise any constant region
known in the art. The light chain constant region can be, for
example, a kappa- or lambda-type light chain constant region, e.g.,
a human kappa- or lambda-type light chain constant region. The
heavy chain constant region can be, for example, an alpha-, delta-,
epsilon-, gamma-, or mu-type heavy chain constant regions, e.g., a
human alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain
constant region. In one embodiment, the light or heavy chain
constant region is a fragment, derivative, variant, or mutein of a
naturally occurring constant region.
[0164] Antibodies directed against an IL-4R can be used, for
example, in assays to detect the presence of IL-4R polypeptides,
either in vitro or in vivo. The antibodies also may be employed in
purifying IL-4R proteins by immunoaffinity chromatography. Those
antibodies that additionally can block binding of IL-4 to IL-4R may
be used to inhibit a biological activity that results from such
binding. Blocking antibodies find use in the methods of the present
invention. Such antibodies which function as IL-4 antagonists may
be employed in treating any IL-4-induced condition, including but
not limited to asthma and allergies, e.g., allergic rhinitis,
contact dermatitis, and atopic dermatitis. In one embodiment, a
human anti-IL-4R monoclonal antibody generated by procedures
involving immunization of transgenic mice is employed in treating
such conditions.
[0165] Antibodies may be employed in an in vitro procedure, or
administered in vivo to inhibit an IL-4-induced biological
activity. Disorders caused or exacerbated (directly or indirectly)
by the interaction of IL-4 with cell surface IL-4 receptors,
examples of which are provided above, thus may be treated. In one
embodiment, the present invention provides a therapeutic method
comprising in vivo administration of an IL-4 and/or IL-13 blocking
antibody to a mammal in need thereof in an amount effective for
reducing an IL-4- and/or IL-13-induced biological activity.
[0166] Antibodies of the invention include, but are not limited to,
partially human and fully human monoclonal antibodies that inhibit
a biological activity of IL-4 and also inhibit a biological
activity of IL-13. One embodiment is directed to a human monoclonal
antibody that at least partially blocks binding of IL-4 to a cell,
and at least partially blocks binding of IL-13 to a cell. In one
embodiment, the antibodies are generated by immunizing a transgenic
mouse with an IL-4 receptor immunogen. In another embodiment, the
immunogen is a human IL-4 receptor polypeptide. Hybridoma cell
lines derived from the thus-immunized mice, wherein the hybridoma
secretes a monoclonal antibody that binds IL-4R, also are provided
herein.
[0167] Although human, partially human, or humanized antibodies
will be suitable for many applications, particularly those
involving administration of the antibody to a human subject, other
types of antibodies will be suitable for other applications. The
non-human antibodies of the invention can be, for example, derived
from any antibody-producing animal, such as mouse, rat, rabbit,
goat, donkey, or non-human primate (such as monkey (e.g.,
cynomologous or rhesus monkey) or ape (e.g., chimpanzee)).
Non-human antibodies of the invention can be used, for example, in
in vitro and cell-culture based applications, or any other
application where an immune response to the antibody of the
invention does not occur or is insignificant, can be prevented, is
not a concern, or is desired. In one embodiment, a non-human
antibody of the invention is administered to a non-human subject.
In another embodiment, the non-human antibody does not elicit an
immune response in the non-human subject. In another embodiment,
the non-human antibody is from the same species as the non-human
subject, e.g., a mouse antibody of the invention is administered to
a mouse. An antibody from a particular species can be made by, for
example, immunizing an animal of that species with the desired
immunogen (e.g., a soluble IL-4 receptor polypeptide) or using an
artificial system for generating antibodies of that species (e.g.,
a bacterial or phage display-based system for generating antibodies
of a particular species), or by converting an antibody from one
species into an antibody from another species by replacing, e.g.,
the constant region of the antibody with a constant region from the
other species, or by replacing one or more amino acid residues of
the antibody so that it more closely resembles the sequence of an
antibody from the other species. In one embodiment, the antibody is
a chimeric antibody comprising amino acid sequences derived from
antibodies from two or more different species.
[0168] In another aspect, the present invention provides antibodies
that comprise a light chain variable region selected from the group
consisting of L1-L6 and/or a heavy chain variable region selected
from the group consisting of H1-H24, and fragments, derivatives,
muteins, and variants thereof (see FIGS. 2 and 3). Such an antibody
can be denoted using the nomenclature "LxHy", wherein x corresponds
to the number of the light chain variable region and y corresponds
to the number of the heavy chain variable region as they are
labeled in FIG. 3. For example, L4H17 refers to an antibody with a
light chain variable region comprising the amino acid sequence of
L4 and a heavy chain variable region comprising the amino acid
sequence of H17, as shown in FIG. 3.
[0169] FIGS. 2 and 3 also indicate the location of the CDR and
framework regions of each of these variable domain sequences.
Antibodies of the invention include, for example, L2H1, L3H1, L4H1,
L5H1, L1H2, L1H3, L1H4, L1H5, L1H6, L1H7, L1H8, L1H9, L1H10, L1H11,
L2H4, L2H12, L2H13, L2H14, L6H1, L2H2, L2H3, L2H6, L2H7, L2H8,
L2H9, L2H10, and L2H11. Additional antibody variable sequences,
e.g., human antibody variable sequences, also can be used. See,
e.g., Sblattero et al., 1998, Immunotechnology 3:271-78, de Haard
et al., 1999, J. Biol. Chem. 274:18218-30.
[0170] In one embodiment, the present invention provides an
antibody comprising a light chain-variable domain comprising a
sequence of amino acids that differs from the sequence of L1 only
at one or more residues where any one of the sequences of L2-L6
differs from the sequence of L1 (e.g., said sequence of said
antibody differs from the sequence of L1 at residue(s) 1, 4, 7
etc.). In another embodiment, said sequence of said light
chain-variable domain comprises at least one amino acid residue of
any of the sequence of any one of L2-L6 at a position where it
differs from the sequence of L1 (e.g., said sequence comprises the
residue(s) E1D, L4M, S7T, etc.). In another embodiment, said
sequence differs from the sequence of L1 in at least one CDR (e.g.,
CDR1, CDR2, or CDR3). In another embodiment, said sequence differs
from the sequence of L1 in at least one FR (e.g., FR1, FR2, FR3, or
FR4). In another embodiment, the present invention provides an
antibody comprising a heavy chain-variable domain comprising a
sequence of amino acids that differs from the sequence of H1 only
at one or more residues where any one of the sequences of H2-H24
differs from the sequence of H1 (e.g., said sequence of said
antibody differs from the sequence of H1 at residue(s) 6, 13, 24
etc.). In another embodiment, said sequence of said heavy
chain-variable domain comprises at least one amino acid residue of
any of the sequence of any one of H2-H24 at a position where it
differs from the sequence of H1 (e.g., said sequence comprises the
residue(s) Q6E, H13Q, G24A, etc.). In another embodiment, said
sequence differs from the sequence of H1 in at least one CDR (e.g.,
CDR2 or CDR3). In another embodiment, said sequence differs from
the sequence of H1 in at least one FR (e.g., FR1 or FR3).
[0171] In another embodiment, the present invention provides an
antibody comprising an amino acid sequence selected from the group
consisting of: a light chain complementarity determining region
(CDR) 1 that differs by the insertion, deletion, or substitution of
no more than 3, 2, 1, or 0 amino acid residues from a sequence
selected from the group consisting of: residues 24-35 of SEQ ID
NO:6, wherein the N at residue 8 is not substituted by an S;
residues 24-35 of SEQ ID NO:8, wherein the T at residue 5 is not
substituted by an S and/or the N at residue 7 is not substituted by
an S and/or the D at residue 9 is not substituted by an S; residues
24-35 of SEQ ID NO:10, wherein the D at residue 9 is not
substituted by an S; residues 24-35 of SEQ ID NO:12, wherein the N
at residue 7 is not substituted by S and/or the N at residue 9 is
not substituted by an S; and residues 24-35 of SEQ ID NO:14,
wherein the G at residue 7 is not substituted by an S; a light
chain CDR2 that differs by the insertion, deletion, or substitution
of no more than 3, 2, 1, or 0 amino acid residues from a sequence
selected from the group consisting of: residues 51-57 of SEQ ID
NO:6, wherein the P at residue 7 is not substituted by a T;
residues 51-57 of SEQ ID NO:10, wherein the S at residue 7 is not
substituted by a T; and residues 51-57 of SEQ ID NO:12, wherein the
T at residue 2 is not substituted by an A and/or the Y at residue 4
is not substituted by an S; a light chain CDR3 that differs by the
insertion, deletion, or substitution of no more than 3, 2, 1, or 0
amino acid residues from a sequence selected from the group
consisting of: residues 90-99 of SEQ ID NO:6, wherein the D at
residue 4 is not substituted by a G, the H at residue 5 is not
substituted by an S, the A at residue 7 is not substituted by a P,
and/or the G at residue 8 is not substituted by a P; residues 90-99
of SEQ ID NO:8, wherein the R at residue 5 is not substituted by an
S; and residues 90-99 of SEQ ID NO:14, wherein the M a residue 10
is not substituted by a T; a heavy chain CDR2 that differs by the
insertion, deletion, or substitution of no more than 3 amino acid
residues from the sequence of residues 50-65 of SEQ ID NO:18,
wherein the S at residue 9 is not substituted by an N; and a heavy
chain CDR3 that differs by the insertion, deletion, or substitution
of no more than 3, 2, 1, or 0 amino acid residues from a sequence
selected from the group consisting of: residues 98-104 of SEQ ID
NO:18, wherein the Tat residue 6 is not substituted by a D and/or
the H at residue 7 is not substituted by a Y; residues 98-104 of
SEQ ID NO:20, wherein the W at residue 4 is not substituted by a Y,
the Y at residue 5 is not substituted by an F, the N at residue 6
is not substituted by a D, and/or the N at residue 7 is not
substituted by a Y; residues 98-104 of SEQ ID NO:22, wherein the P
at residue 6 is not substituted by a D and/or the W at residue 7 is
not substituted by a Y; residues 98-104 of SEQ ID NO:24, wherein
the T at residue 6 is not substituted by a D and/or the R at
position 7 is not substituted by a Y; residues 98-104 of SEQ ID
NO:26, wherein the Y at residue 5 is not substituted by an F;
residues 98-104 of SEQ ID NO:30, wherein the W at residue 4 is not
substituted by a Y; and residues 98-104 of SEQ ID NO:34, wherein
the W at residue 4 is not substituted by a Y and/or the Y at
residue 5 is not substituted by an F; wherein said antibody binds
to IL-4 receptor alpha.
[0172] In another embodiment, the antibody inhibits the binding of
IL-4 to an IL-4 receptor. In another embodiment, the antibody
inhibits the binding of IL-13 to an IL-13 receptor. In another
embodiment, the antibody inhibits the binding of IL-4 to an IL-4
receptor and of IL-13 to an IL-13 receptor. In another embodiment,
the antibody specifically binds IL-4 receptor alpha.
[0173] In another embodiment, the antibody comprises two or three
such light chain complementarity determining regions (CDR).
[0174] In another embodiment, the antibody comprises two or three
such heavy chain complementarity determining regions.
[0175] In another embodiment, the antibody further comprises a
framework segment (FR) comprising a sequence selected from the
group consisting of: a light chain framework segment (FR) 1 that
differs by the insertion, deletion, or substitution of no more than
3, 2, 1, or 0 amino acid residues from a sequence selected from the
group consisting of: residues 1-23 of SEQ ID NO:4; residues 1-23 of
SEQ ID NO:10; residues 1-23 of SEQ ID NO:12; and residues 1-23 of
SEQ ID NO:14; a light chain FR2 that differs by the insertion,
deletion, or substitution of no more than 3, 2, 1, or 0 amino acid
residues from a sequence selected from the group consisting of:
residues 36-50 of SEQ ID NO:4; residues 36-50 of SEQ ID NO:6; and
residues 36-50 of SEQ ID NO:14; a light chain FR3 that differs by
the insertion, deletion, or substitution of no more than 3, 2, 1,
or 0 amino acid residues from a sequence selected from the group
consisting of: residues 58-89 of SEQ ID NO:4; residues 58-89 of SEQ
ID NO:10; and residues 58-89 of SEQ ID NO:12; a light chain FR4
that differs by the insertion, deletion, or substitution of no more
than 3, 2, 1, 0 amino acid residues from a sequence selected from
the group consisting of: residues 100-109 of SEQ ID NO:4; residues
100-109 of SEQ ID NO:8; and residues 100-109 of SEQ ID NO:12; a
heavy chain FR1 that differs by the insertion, deletion, or
substitution of no more than 3, 2, 1, or 0 amino acid residues from
a sequence selected from the group consisting of: residues 1-30 of
SEQ ID NO:16; and residues 1-30 of SEQ ID NO:42; heavy chain FR2
that differs by the insertion, deletion, or substitution of no more
than 3, 2, 1, or 0 amino acid residues from the sequence residues
36-49 of SEQ ID NO:16, a heavy chain FR3 that differs by the
insertion, deletion, or substitution of no more than 3, 2, 1, or 0
amino acid residues from a sequence selected from the group
consisting of: residues 66-97 of SEQ ID NO:16; residues 66-97 of
SEQ ID NO:18; and residues 66-97 of SEQ ID NO:42; and a heavy chain
FR4 that differs by the insertion, deletion, or substitution of no
more than 3 amino acid residues from the sequence residues 105-115
of SEQ ID NO:16.
[0176] In another embodiment, the antibody comprises a light chain
variable domain that is at least 80, 85, 90, 95, or 100% identical
to a sequence selected from the group consisting of: SEQ ID NO:6,
8, 10, 12, and 14, with the proviso that the said light chain
variable domain does not comprise the sequence of SEQ ID NO:4.
[0177] In another embodiment, the antibody comprises a heavy chain
variable domain that is at least 80, 85, 90, 95, or 100% identical
to a sequence selected from the group consisting of: SEQ ID NO:18,
20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 46, 48, 50, 52, 54,
56, 58, 60, and 62 with the proviso that said heavy chain variable
domain does not comprise the sequence of SEQ ID NO:16.
[0178] In another embodiment, the present invention provides a
fragment of such an antibody, wherein said fragment binds to IL-4
receptor alpha.
[0179] In one embodiment, particular antibodies of the invention
are selected from the group consisting of L2H1; an antibody that is
cross-reactive L2H1, an antibody that binds to the same epitope as
L2H1; an antibody that competes with L2H1 for binding to a cell
that expresses human IL-4R; an antibody that possesses a biological
activity of L2H1 and an antigen-binding fragment (including one
derived by recombinant means) of L2H1. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H1 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0180] One example of a biological activity of L2H1 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H1;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H1. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0181] Complementarity determining regions (CDRs) of a given
antibody may be identified using the system described by Kabat et
al. in Sequences of Proteins of Immunological Interest, 5.sup.th
Ed., US Dept. of Health and Human Services, PHS, NIH, NIH
Publication no. 91-3242, 1991. Particular embodiments of antibodies
of the present invention comprise, within the variable domain of
their light chain, at least one of the complementarity determining
regions (CDRs), or hypervariable regions, found in the light chain
of L2H1. CDRs of L2H1 are discussed in Example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable domain
of L2H1: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:6. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L2H1. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:16.
[0182] The DNA sequence of the variable domain of the light chain
of L2H1 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H1 is presented as SEQ ID
NO:15, and the encoded amino acid sequence is presented in SEQ ID
NO:16. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain, SEQ ID
NO:6; and antibodies that additionally or alternatively comprise,
in their heavy chain, SEQ ID NO:16.
[0183] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L3H1; an
antibody that is cross-reactive with L3H1; an antibody that binds
to the same epitope as L3H1; an antibody that competes with L3H1
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L3H1; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L3H1 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0184] One example of a biological activity of L3H1 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L3H1,
and possesses IL-13-blocking activity substantially equivalent to
that of L3H1. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0185] IgG4 antibodies derived from L3H1 are provided herein.
Another embodiment is directed to IgM antibodies derived from L3H1.
Procedures for switching (altering) the subclass or isotype of an
antibody are known in the pertinent field. Such procedures may
involve, for example, recombinant DNA technology, whereby DNA
encoding antibody polypeptide chains that confer the desired
subclass is substituted for DNA encoding the corresponding
polypeptide chain of the parent antibody.
[0186] The DNA sequence of the variable domain of the light chain
of L3H1 is presented in SEQ ID NO:7, and the encoded amino acid
sequence is presented in SEQ ID NO:8. The DNA sequence for the
variable domain of the heavy chain of L3H1 is presented as SEQ ID
NO:15, and the encoded amino acid sequence is presented in SEQ ID
NO:16. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:8; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:16.
[0187] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L3H1.
CDRs of L3H1 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:8.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L3H1. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:16.
[0188] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L4H1; an
antibody that is cross-reactive with L4H1; an antibody that binds
to the same epitope as L4H1; an antibody that competes with L4H1
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L4H1; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L4H1 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0189] One example of a biological activity of L4H1 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L4H1;
and possesses IL-13-blocking activity substantially equivalent to
that of L4H1. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0190] The DNA sequence of the variable domain of the light chain
of L4H1 is presented in SEQ ID NO:9, and the encoded amino acid
sequence is presented in SEQ ID NO:10. The DNA sequence for the
variable domain of the heavy chain of L4H1 is presented as SEQ ID
NO:15, and the encoded amino acid sequence is presented in SEQ ID
NO:16. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:10; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:16.
[0191] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L4H1.
CDRs of L4H1 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:10.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L4H1. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 99-104 of SEQ ID NO:16.
[0192] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L5H1; an
antibody that is cross-reactive with L5H1; an antibody that binds
to the same epitope as L5H1; an antibody that competes with L5H1
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L5H1; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L5H1 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0193] One example of a biological activity of L5H1 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L5H1;
and possesses IL-13-blocking activity substantially equivalent to
that of L5H1. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0194] The DNA sequence of the variable domain of the light chain
of L5H1 is presented in SEQ ID NO:11, and the encoded amino acid
sequence is presented in SEQ ID NO:12. The DNA sequence for the
variable domain of the heavy chain of L5H1 is presented as SEQ ID
NO:15, and the encoded amino acid sequence is presented in SEQ ID
NO:16. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:12; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:16.
[0195] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L5H1.
CDRs of L5H1 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:12.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L5H1. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:16.
[0196] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H2; an
antibody that is cross-reactive with L1H2; an antibody that binds
to the same epitope as L1H2; an antibody that competes with L1H2
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H2; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H2 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0197] One example of a biological activity of L1H2 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H2;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H2. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0198] The DNA sequence of the variable domain of the light chain
of L1H2 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H2 is presented as SEQ ID
NO:17, and the encoded amino acid sequence is presented in SEQ ID
NO:18. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:18.
[0199] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H2.
CDRs of L1H2 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H2. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:18.
[0200] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H3; an
antibody that is cross-reactive with L1H3; an antibody that binds
to the same epitope as L1H3; an antibody that competes with L1H3
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H3; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H3 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0201] One example of a biological activity of L1H3 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H3;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H3. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0202] The DNA sequence of the variable domain of the light chain
of L1H3 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H3 is presented as SEQ ID
NO:19, and the encoded amino acid sequence is presented in SEQ ID
NO:20. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:20.
[0203] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H3.
CDRs of L1H3 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H3. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:20.
[0204] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H4; an
antibody that is cross-reactive with L1H4; an antibody that binds
to the same epitope as L1H4; an antibody that competes with L1H4
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H4; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H4 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0205] One example of a biological activity of L1H4 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H4;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H4. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0206] The DNA sequence of the variable domain of the light chain
of L1H4 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H4 is presented as SEQ ID
NO:21, and the encoded amino acid sequence is presented in SEQ ID
NO:22. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:22.
[0207] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H4.
CDRs of L1H4 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H4. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:22.
[0208] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H5; an
antibody that is cross-reactive with L1H5; an antibody that binds
to the same epitope as L1H5; an antibody that competes with L1H5
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H5; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H5 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0209] One example of a biological activity of L1H5 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H5;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H5. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0210] The DNA sequence of the variable domain of the light chain
of L1H5 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H5 is presented as SEQ ID
NO:23, and the encoded amino acid sequence is presented in SEQ ID
NO:24. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:24.
[0211] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H5.
CDRs of L1H5 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H5. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:24.
[0212] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H6; an
antibody that is cross-reactive with L1H6; an antibody that binds
to the same epitope as L1H6; an antibody that competes with L1H6
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H6; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H6 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0213] One example of a biological activity of L1H6 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H6;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H6. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0214] The DNA sequence of the variable domain of the light chain
of L1H6 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H6 is presented as SEQ ID
NO:25, and the encoded amino acid sequence is presented in SEQ ID
NO:26. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:26.
[0215] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H6.
CDRs of L1H6 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H6. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:26.
[0216] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H7; an
antibody that is cross-reactive with L1H7; an antibody that binds
to the same epitope as L1H7; an antibody that competes with L1H7
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H7; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H7 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0217] One example of a biological activity of L1H7 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H7;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H7. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0218] The DNA sequence of the variable domain of the light chain
of L1H7 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H7 is presented as SEQ ID
NO:27, and the encoded amino acid sequence is presented in SEQ ID
NO:28. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:28.
[0219] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H7.
CDRs of L1H7 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H7. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:28.
[0220] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H8; an
antibody that is cross-reactive with L1H8; an antibody that binds
to the same epitope as L1H8; an antibody that competes with L1H8
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H8; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H8 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0221] One example of a biological activity of L1H8 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H8;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H8. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0222] The DNA sequence of the variable domain of the light chain
of L1H8 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H8 is presented as SEQ ID
NO:29, and the encoded amino acid sequence is presented in SEQ ID
NO:30. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:30.
[0223] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H8.
CDRs of L1H8 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H8. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:30.
[0224] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H9; an
antibody that is cross-reactive with L1H9; an antibody that binds
to the same epitope as L1H9; an antibody that competes with L1H9
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H9; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H9 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0225] One example of a biological activity of L1H9 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H9;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H9. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0226] The DNA sequence of the variable domain of the light chain
of L1H9 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H9 is presented as SEQ ID
NO:31, and the encoded amino acid sequence is presented in SEQ ID
NO:32. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:32.
[0227] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L1H9.
CDRs of L1H9 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:4.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L1H9. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:32.
[0228] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H10; an
antibody that is cross-reactive with L1H10; an antibody that binds
to the same epitope as L1H10; an antibody that competes with L1H10
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H10; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H10 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0229] One example of a biological activity of L1H10 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H10;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H10. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0230] The DNA sequence of the variable domain of the light chain
of L1H10 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H10 is presented as SEQ ID
NO:33, and the encoded amino acid sequence is presented in SEQ ID
NO:34. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:34.
[0231] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of
L1H10. CDRs of L1H10 are discussed in example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable
domain: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:4. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L1H10. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:34.
[0232] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L1H11; an
antibody that is cross-reactive with L1H11; an antibody that binds
to the same epitope as L1H11; an antibody that competes with L1H11
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L1H11; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L1H11 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0233] One example of a biological activity of L1H11 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L1H11;
and possesses IL-13-blocking activity substantially equivalent to
that of L1H11. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0234] The DNA sequence of the variable domain of the light chain
of L1H11 is presented in SEQ ID NO:3, and the encoded amino acid
sequence is presented in SEQ ID NO:4. The DNA sequence for the
variable domain of the heavy chain of L1H11 is presented as SEQ ID
NO:35, and the encoded amino acid sequence is presented in SEQ ID
NO:36. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:4; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:36.
[0235] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of
L1H11. CDRs of L1H11 are discussed in example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable
domain: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:4. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L1H11. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:36.
[0236] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H4; an
antibody that is cross-reactive with L2H4; an antibody that binds
to the same epitope as L2H4; an antibody that competes with L2H4
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H4; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H4 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0237] One example of a biological activity of L2H4 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H4;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H4. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0238] The DNA sequence of the variable domain of the light chain
of L2H4 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H4 is presented as SEQ ID
NO:21, and the encoded amino acid sequence is presented in SEQ ID
NO:22. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:22.
[0239] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L2H4.
CDRs of L2H4 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:6.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L2H4. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:22.
[0240] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H12; an
antibody that is cross-reactive with L2H12; an antibody that binds
to the same epitope as L2H12; an antibody that competes with L2H12
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H12; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H12 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0241] One example of a biological activity of L2H12 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H12;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H12. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0242] The DNA sequence of the variable domain of the light chain
of L2H12 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H12 is presented as SEQ ID
NO:37, and the encoded amino acid sequence is presented in SEQ ID
NO:38. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:38.
[0243] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of
L2H12. CDRs of L2H12 are discussed in example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable
domain: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:6. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L2H12. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:38.
[0244] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H13; an
antibody that is cross-reactive with L2H13; an antibody that binds
to the same epitope as L2H13; an antibody that competes with L2H13
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H13; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H13 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0245] One example of a biological activity of L2H13 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H13;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H13. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0246] The DNA sequence of the variable domain of the light chain
of L2H13 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H13 is presented as SEQ ID
NO:39, and the encoded amino acid sequence is presented in SEQ ID
NO:40. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:40.
[0247] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of
L2H13. CDRs of L2H13 are discussed in example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable
domain: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:6. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L2H13. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:40.
[0248] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H14; an
antibody that is cross-reactive with L2H14; an antibody that binds
to the same epitope as L2H14; an antibody that competes with L2H14
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H14; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H14 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0249] One example of a biological activity of L2H14 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H14;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H14. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0250] The DNA sequence of the variable domain of the light chain
of L2H14 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H14 is presented as SEQ ID
NO:41, and the encoded amino acid sequence is presented in SEQ ID
NO:42. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:42.
[0251] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of
L2H14. CDRs of L2H14 are discussed in example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable
domain: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:6. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L2H14. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:42.
[0252] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L6H1; an
antibody that is cross-reactive with L6H1; an antibody that binds
to the same epitope as L6H1; an antibody that competes with L6H1
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L6H1; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L6H1 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention. One example of a biological
activity of L6H1 is the ability to function as both an IL-4
antagonist and an IL-13 antagonist. In one embodiment, an antibody
of the invention possesses IL-4-blocking activity substantially
equivalent to that of L6H1; and possesses IL-13-blocking activity
substantially equivalent to that of L6H1. Such activity may be
measured in any suitable conventional assay (e.g., as measured in
the CD23 expression assay described in Example 2).
[0253] The DNA sequence of the variable domain of the light chain
of L6H1 is presented in SEQ ID NO:13, and the encoded amino acid
sequence is presented in SEQ ID NO:14. The DNA sequence for the
variable domain of the heavy chain of L6H1 is presented as SEQ ID
NO:15, and the encoded amino acid sequence is presented in SEQ ID
NO:16. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:14; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:16.
[0254] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L6H1.
CDRs of L6H1 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:14.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L6H1. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:16.
[0255] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H2; an
antibody that is cross-reactive with L2H2; an antibody that binds
to the same epitope as L2H2; an antibody that competes with L2H2
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H2; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H2 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0256] One example of a biological activity of L2H2 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H2;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H2. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0257] The DNA sequence of the variable domain of the light chain
of L2H2 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H2 is presented as SEQ ID
NO:17, and the encoded amino acid sequence is presented in SEQ ID
NO:18. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:18.
[0258] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L2H2.
CDRs of L2H2 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:6.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L2H2. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:18.
[0259] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H3; an
antibody that is cross-reactive with L2H3; an antibody that binds
to the same epitope as L2H3; an antibody that competes with L2H3
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H3; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H3 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0260] One example of a biological activity of L2H3 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H3;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H3. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0261] The DNA sequence of the variable domain of the light chain
of L2H3 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H3 is presented as SEQ ID
NO:19, and the encoded amino acid sequence is presented in SEQ ID
NO:20. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:20.
[0262] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L2H3.
CDRs of L2H3 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:6.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L2H3. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:20.
[0263] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H6; an
antibody that is cross-reactive with L2H6; an antibody that binds
to the same epitope as L2H6; an antibody that competes with L2H6
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H6; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H6 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0264] One example of a biological activity of L2H6 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H6;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H6. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0265] The DNA sequence of the variable domain of the light chain
of L2H6 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H6 is presented as SEQ ID
NO:25, and the encoded amino acid sequence is presented in SEQ ID
NO:26. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:26.
[0266] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L2H6.
CDRs of L2H6 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:6.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L2H6. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:26.
[0267] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H7; an
antibody that is cross-reactive with L2H7; an antibody that binds
to the same epitope as L2H7; an antibody that competes with L2H7
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H7; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H7 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0268] One example of a biological activity of L2H7 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H7;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H7. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0269] The DNA sequence of the variable domain of the light chain
of L2H7 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H7 is presented as SEQ ID
NO:27, and the encoded amino acid sequence is presented in SEQ ID
NO:28. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:28.
[0270] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L2H7.
CDRs of L2H7 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:6.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L2H7. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:28.
[0271] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H8; an
antibody that is cross-reactive with L2H8; an antibody that binds
to the same epitope as L2H8; an antibody that competes with L2H8
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H8; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H8 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0272] One example of a biological activity of L2H8 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H8;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H8. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0273] The DNA sequence of the variable domain of the light chain
of L2H8 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H8 is presented as SEQ ID
NO:29, and the encoded amino acid sequence is presented in SEQ ID
NO:30. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:30.
[0274] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L2H8.
CDRs of L2H8 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:6.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L2H8. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:30.
[0275] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H9; an
antibody that is cross-reactive with L2H9; an antibody that binds
to the same epitope as L2H9; an antibody that competes with L2H9
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H9; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H9 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0276] One example of a biological activity of L2H9 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H9;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H9. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0277] The DNA sequence of the variable domain of the light chain
of L2H9 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H9 is presented as SEQ ID
NO:31, and the encoded amino acid sequence is presented in SEQ ID
NO:32. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:32.
[0278] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of L2H9.
CDRs of L2H9 are discussed in example 5. Thus, among the antibodies
provided herein are those comprising from one to all three of the
following sequences in the light chain variable domain: amino acid
residues 24-35; residues 51-57; and residues 90-99 of SEQ ID NO:6.
Particular antibodies provided herein comprise, within the variable
domain of their heavy chain, at least one of the CDRs found in the
heavy chain of L2H9. Thus, among the antibodies provided herein are
those comprising from one to all three of the following sequences
in the heavy chain variable domain: residues 31-35; residues 50-65;
and residues 98-104 of SEQ ID NO:32.
[0279] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H10; an
antibody that is cross-reactive with L2H10; an antibody that binds
to the same epitope as L2H10; an antibody that competes with L2H10
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H10; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H10 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0280] One example of a biological activity of L2H10 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H10;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H10. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0281] The DNA sequence of the variable domain of the light chain
of L2H10 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H10 is presented as SEQ ID
NO:33, and the encoded amino acid sequence is presented in SEQ ID
NO:34. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, SEQ ID NO:34.
[0282] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of
L2H10. CDRs of L2H10 are discussed in example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable
domain: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:6. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L2H10. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:34.
[0283] In another embodiment, particular antibodies of the
invention are selected from the group consisting of L2H11; an
antibody that is cross-reactive with L2H11; an antibody that binds
to the same epitope as L2H11; an antibody that competes with L2H11
for binding to a cell that expresses human IL-4R; an antibody that
possesses a biological activity of L2H11; and an antigen-binding
fragment of any of the foregoing antibodies. In one embodiment, the
antibody has a binding affinity for human IL-4R that is
substantially equivalent to the binding affinity of L2H11 for human
IL-4R. Hybridoma cell lines that produce any such antibodies also
are provided by the present invention.
[0284] One example of a biological activity of L2H11 is the ability
to function as both an IL-4 antagonist and an IL-13 antagonist. In
one embodiment, an antibody of the invention possesses
IL-4-blocking activity substantially equivalent to that of L2H11;
and possesses IL-13-blocking activity substantially equivalent to
that of L2H11. Such activity may be measured in any suitable
conventional assay (e.g., as measured in the CD23 expression assay
described in Example 2).
[0285] The DNA sequence of the variable domain of the light chain
of L2H11 is presented in SEQ ID NO:5, and the encoded amino acid
sequence is presented in SEQ ID NO:6. The DNA sequence for the
variable domain of the heavy chain of L2H11 is presented as SEQ ID
NO:35, and the encoded amino acid sequence is presented in SEQ ID
NO:36. Antibodies of the present invention include, but are not
limited to, antibodies that comprise, in their light chain,
residues 1 to 109 of SEQ ID NO:6; and antibodies that additionally
or alternatively comprise, in their heavy chain, residues 1 to 115
of SEQ ID NO:36.
[0286] Particular embodiments of antibodies of the present
invention comprise, within the variable domain of their light
chain, at least one of the complementarity determining regions
(CDRs), or hypervariable regions, found in the light chain of
L2H11. CDRs of L2H11 are discussed in example 5. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the light chain variable
domain: amino acid residues 24-35; residues 51-57; and residues
90-99 of SEQ ID NO:6. Particular antibodies provided herein
comprise, within the variable domain of their heavy chain, at least
one of the CDRs found in the heavy chain of L2H11. Thus, among the
antibodies provided herein are those comprising from one to all
three of the following sequences in the heavy chain variable
domain: residues 31-35; residues 50-65; and residues 98-104 of SEQ
ID NO:36.
Nucleic Acids
[0287] In one aspect, the present invention provides isolated
nucleic acid molecules. The nucleic acids comprise, for example,
polynucleotides that encode an antibody of the invention, or a
fragment, derivative, mutein, or variant thereof, polynucleotides
sufficient for use as hybridization probes, PCR primers or
sequencing primers for identifying, analyzing, mutating or
amplifying a polynucleotide encoding a polypeptide, anti-sense
nucleic acids for inhibiting expression of a polynucleotide, and
complementary sequences of the foregoing. The nucleic acids can be
any length. They can be, for example, 5, 10, 15, 20, 25, 30, 35,
40, 45, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450,
500, 750, 1,000, 1,500, 3,000, 5,000 or more nucleotides in length,
and/or can comprise one or more additional sequences, for example,
regulatory sequences, and/or be part of a larger nucleic acid, for
example, a vector. The nucleic acids can be single-stranded or
double-stranded and can comprise RNA and/or DNA nucleotides, and
artificial variants thereof (e.g., peptide nucleic acids).
[0288] DNA encoding antibody polypeptides (e.g., heavy or light
chain, variable domain only or full length) may be isolated from
B-cells of mice that have been immunized with IL-4R. The DNA may be
isolated by conventional procedures such as polymerase chain
reaction (PCR). Phage display is another example of a known
technique whereby derivatives of antibodies may be prepared. In one
approach, polypeptides that are components of an antibody of
interest are expressed in any suitable recombinant expression
system, and the expressed polypeptides are allowed to assemble to
form antibody molecules.
[0289] FIG. 2 provides nucleic acid sequences encoding the variable
regions of the heavy and light chain variable regions shown in FIG.
3. Due to the degeneracy of the genetic code, each of the
polypeptide sequences in FIG. 3 also is encoded by a large number
of other nucleic acid sequences. The present invention provides
each degenerate nucleotide sequence encoding each antibody of the
invention.
[0290] The invention further provides nucleic acids that hybridize
to other nucleic acids (.e.g., nucleic acids comprising a
nucleotide sequence of FIG. 2) under particular hybridization
conditions. Methods for hybridizing nucleic acids are well-known in
the art. See, e.g., Current Protocols in Molecular Biology, John
Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. As defined herein, a
moderately stringent hybridization condition uses a prewashing
solution containing 5.times. sodium chloride/sodium citrate (SSC),
0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization buffer of about 50%
formamide, 6.times.SSC, and a hybridization temperature of
55.degree. C. (or other similar hybridization solutions, such as
one containing about 50% formamide, with a hybridization
temperature of 42.degree. C.), and washing conditions of 60.degree.
C., in 0.5.times.SSC, 0.1% SDS. A stringent hybridization condition
6.times.SSC at 45.degree. C., followed by one or more washes in
0.1.times.SSC, 0.2% SDS at 68.degree. C. Furthermore, one of skill
in the art can manipulate the hybridization and/or washing
conditions to increase or decrease the stringency of hybridization
such that nucleic acids comprising nucleotide sequences that are at
least 65, 70, 75, 80, 85, 90, 95, 98 or 99% identical to each other
typically remain hybridized to each other. The basic parameters
affecting the choice of hybridization conditions and guidance for
devising suitable conditions are set forth by Sambrook, Fritsch,
and Maniatis (1989, Molecular Cloning: A Laboratory Manual, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters
9 and 11; and Current Protocols in Molecular Biology, 1995, Ausubel
et al., eds., John Wiley & Sons, Inc., sections 2.10 and
6.3-6.4), and can be readily determined by those having ordinary
skill in the art based on, for example, the length and/or base
composition of the DNA.
[0291] Changes can be introduced by mutation into a nucleic acid,
thereby leading to changes in the amino acid sequence of a
polypeptide (e.g., an antibody) that it encodes. Mutations can be
introduced by standard techniques, such as site-directed
mutagenesis and PCR-mediated mutagenesis. Preferably, conservative
amino acid substitutions are made at one or more predicted
non-essential amino acid residues. Alternatively, mutations can be
introduced randomly along all or part of the coding sequence, such
as by saturation mutagenesis, and the resultant mutants can be
screened for biological activity to identify mutants that retain
activity (e.g., binding to IL-4 receptor). Following mutagenesis,
the encoded protein can be expressed recombinantly and the activity
of the protein can be determined. The mutations can be introduced
into a nucleic acid without significantly altering the biological
activity of a peptide that it encodes. For example, one can make
nucleotide substitutions leading to amino acid substitutions at
non-essential amino acid residues. In one embodiment, a nucleotide
sequence provided in FIG. 2, or a desired fragment, variant, or
derivative thereof, is mutated such that it encodes an amino acid
sequence comprising one or more deletions or substitutions of amino
acid residues that are shown in FIG. 3 to be residues where two or
more sequences differ. In another embodiment, the mutagenesis
inserts an amino acid adjacent to one or more amino acid residues
shown in FIG. 3 to be residues where two or more sequences differ.
Alternatively, mutations can be introduced into a nucleic acid that
selectively change the biological activity (e.g., binding of IL-4
receptor, inhibiting IL-4 and/or IL-13, etc.) of a polypeptide that
it encodes. For example, the mutation can quantitatively or
qualitatively change the biological activity. Examples of
quantitative changes include increasing, reducing or eliminating
the activity. Examples of qualitative changes include changing the
antigen specificity of an antibody.
[0292] In another aspect, the present invention provides nucleic
acid molecules that are suitable for use as primers or
hybridization probes for the detection of nucleic acid sequences of
the invention. A nucleic acid molecule of the invention can
comprise only a portion of a nucleic acid sequence encoding a full
length polypeptide of the invention, for example, a fragment that
can be used as a probe or primer or a fragment encoding an active
portion (e.g., an IL-4 receptor binding portion) of a polypeptide
of the invention.
[0293] Probes based on the sequence of a nucleic acid of the
invention can be used to detect the nucleic acid or similar nucleic
acids, for example, transcripts encoding a polypeptide of the
invention. The probe can comprise a label group, e.g., a
radioisotope, a fluorescent compound, an enzyme, or an enzyme
co-factor. Such probes can be used identify a cell that expresses
the polypeptide.
[0294] In another aspect, the present invention provides vectors
comprising a nucleic acid encoding a polypeptide of the invention
or a portion thereof. Examples of vectors include, but are not
limited to, plasmids, viral vectors, non-episomal mammalian vectors
and expression vectors, for example, recombinant expression
vectors.
[0295] The recombinant expression vectors of the invention can
comprise a nucleic acid of the invention in a form suitable for
expression of the nucleic acid in a host cell. The recombinant
expression vectors include one or more regulatory sequences,
selected on the basis of the host cells to be used for expression,
which is operably linked to the nucleic acid sequence to be
expressed. Regulatory sequences include those that direct
constitutive expression of a nucleotide sequence in many types of
host cells (e.g., SV40 early gene enhancer, Rous sarcoma virus
promoter and cytomegalovirus promoter), those that direct
expression of the nucleotide sequence only in certain host cells
(e.g., tissue-specific regulatory sequences, see Voss et al., 1986,
Trends Biochem. Sci. 11:287, Maniatis et al., 1987, Science
236:1237, incorporated by reference herein in their entireties),
and those that direct inducible expression of a nucleotide sequence
in response to particular treatment or condition (e.g., the
metallothionin promoter in mammalian cells and the tet-responsive
and/or streptomycin responsive promoter in both prokaryotic and
eukaryotic systems (see id.). It will be appreciated by those
skilled in the art that the design of the expression vector can
depend on such factors as the choice of the host cell to be
transformed, the level of expression of protein desired, etc. The
expression vectors of the invention can be introduced into host
cells to thereby produce proteins or peptides, including fusion
proteins or peptides, encoded by nucleic acids as described
herein.
[0296] In another aspect, the present invention provides host cells
into which a recombinant expression vector of the invention has
been introduced. A host cell can be any prokaryotic cell (for
example, E. coli) or eukaryotic cell (for example, yeast, insect,
or mammalian cells (e.g., CHO cells)). Vector DNA can be introduced
into prokaryotic or eukaryotic cells via conventional
transformation or transfection techniques. For stable transfection
of mammalian cells, it is known that, depending upon the expression
vector and transfection technique used, only a small fraction of
cells may integrate the foreign DNA into their genome. In order to
identify and select these integrants, a gene that encodes a
selectable marker (e.g., for resistance to antibiotics) is
generally introduced into the host cells along with the gene of
interest. Preferred selectable markers include those which confer
resistance to drugs, such as G418, hygromycin and methotrexate.
Cells stably transfected with the introduced nucleic acid can be
identified by drug selection (e.g., cells that have incorporated
the selectable marker gene will survive, while the other cells
die), among other methods.
Derivatives, Fragments, and Muteins of Antibodies
[0297] Derivatives of antibodies directed against IL-4R may be
prepared, and screened for desired properties, by any of a number
of known techniques. Certain of the techniques involve isolating
DNA encoding a polypeptide chain (or portion thereof) of an
antibody of interest, and manipulating the DNA through recombinant
DNA technology. The DNA may be fused to another DNA of interest, or
altered (e.g., by mutagenesis or other conventional techniques) to
add, delete, or substitute one or more amino acid residues, for
example.
[0298] In one aspect, the present invention provides
antigen-binding fragments of the antibodies of the invention. Such
fragments can consist entirely of antibody-derived sequences or can
comprise additional sequences. Examples of antigen-binding
fragments include Fab and F(ab').sub.2. Other examples are provided
in Lunde et al., 2002, Biochem. Soc. Trans. 30:500-06.
[0299] Single chain antibodies may be formed by linking heavy and
light chain variable domain (Fv region) fragments via an amino acid
bridge (short peptide linker), resulting in a single polypeptide
chain. Such single-chain Fvs (scFvs) have been prepared by fusing
DNA encoding a peptide linker between DNAs encoding the two
variable domain polypeptides (V.sub.L and V.sub.H). The resulting
polypeptides can fold back on themselves to form antigen-binding
monomers, or they can form multimers (e.g., dimers, trimers, or
tetramers), depending on the length of a flexible linker between
the two variable domains (Kortt et al., 1997, Prot. Eng. 10:423;
Kortt et al., 2001, Biomol. Eng. 18:95-108). By combining different
V.sub.L and V.sub.H-comprising polypeptides, one can form
multimeric scFvs that bind to different epitopes (Kriangkum et al.,
2001, Biomol. Eng. 18:31-40). Techniques developed for the
production of single chain antibodies include those described in
U.S. Pat. No. 4,946,778; Bird, 1988, Science 242:423; Huston et
al., 1988, Proc. Natl. Acad. Sci. USA 85:5879; Ward et al., 1989,
Nature 334:544, de Graaf et al., 2002, Methods Mol. Biol.
178:379-87. Single chain antibodies derived from antibodies
provided herein (including but not limited to scFvs comprising the
variable domain combinations L2H1, L3H1, L4H1, L5H1, L1H2, L1H3,
L1H4, L1H5, L1H6, L1H7, L1H8, L1H9, L1H10, L1H11, L2H4, L2H12,
L2H13, L2H14, L6H1, L2H2, L2H3, L2H6, L2H7, L2H8, L2H9, L2H10, and
L2H111) are encompassed by the present invention.
[0300] Techniques are known for deriving an antibody of a different
subclass or isotype from an antibody of interest, i.e., subclass
switching. Thus, IgG antibodies may be derived from an IgM
antibody, for example, and vice versa. Such techniques allow the
preparation of new antibodies that possess the antigen-binding
properties of a given antibody (the parent antibody), but also
exhibit biological properties associated with an antibody isotype
or subclass different from that of the parent antibody. Recombinant
DNA techniques may be employed. Cloned DNA encoding particular
antibody polypeptides may be employed in such procedures, e.g., DNA
encoding the constant domain of an antibody of the desired isotype.
See also Lantto et al., 2002, Methods Mol. Biol. 178:303-16.
[0301] Accordingly, the antibodies of the present invention include
those comprising, for example, the variable domain combinations
L2H1, L3H1, L4H1, L5H1, L1H2, L1H3, L1H4, L1H5, L1H6, L1H7, L1H8,
L1H9, L1H10, L1H11, L2H4, L2H12, L2H13, L2H14, L6H1, L2H2, L2H3,
L2H6, L2H7, L2H8, L2H9, L2H10, and L2H11, having a desired isotype
(for example, IgA, IgG1, IgG2, IgG3, IgG4, IgM, IgE, and IgD) as
well as Fab or F(ab').sub.2 fragments thereof. Moreover, if an IgG4
is desired, it may also be desired to introduce a point mutation
(CPSCP->CPPCP) in the hinge region as described in Bloom et al.,
1997, Protein Science 6:407, incorporated by reference herein) to
alleviate a tendency to form intra-H chain disulfide bonds that can
lead to heterogeneity in the IgG4 antibodies.
[0302] Moreover, techniques for deriving antibodies having
different properties (i.e., varying affinities for the antigen to
which they bind) are also known. One such technique, referred to as
chain shuffling, involves displaying immunoglobulin variable domain
gene repertoires on the surface of filamentous bacteriophage, often
referred to as phage display. Chain shuffling has been used to
prepare high affinity antibodies to the hapten
2-phenyloxazol-5-one, as described by Marks et al., 1992,
BioTechnology, 10:779.
[0303] Molecular evolution of the complementarity determining
regions (CDRs) in the center of the antibody binding site has also
been used to isolate antibodies with increased affinity, for
example, antibodies having increased affinity for c-erbB-2, as
described by Schier et al., 1996, J. Mol. Biol. 263:551.
Accordingly, such techniques are useful in preparing antibodies to
IL-4R.
[0304] In particular embodiments, antibodies of the present
invention have a binding affinity (Ka) for IL-4R of at least
1.times.10.sup.8. In other embodiments, the antibodies exhibit a Ka
of at least 1.times.10.sup.9, at least 1.times.10.sup.10 or at
least 1.times.10.sup.11.
[0305] The present invention further includes multi-specific
antibodies, for example, bispecific antibodies, e.g., two different
epitopes of IL-4R, or an epitope of IL-4R and an epitope of IL-13R,
via two different antigen binding sites or regions. Moreover,
bispecific antibodies as disclosed herein can comprise an antigen
binding site from one of the herein described antibodies and a
second antigen binding region from another of the herein described
antibodies. Alternatively, a bispecific antibody may comprise an
antigen binding site from one of the herein described antibodies
and a second antigen binding site from another IL-4R antibody that
is known in the art (or one that can be prepared by known
methods).
[0306] Numerous methods of preparing bispecific antibodies are
known in the art, and discussed in U.S. patent application Ser. No.
09/839,632, filed Apr. 20, 2001 (incorporated by reference herein).
Such methods include the use of hybrid-hybridomas as described by
Milstein et al., 1983, Nature 305:537, and others (U.S. Pat. No.
4,474,893, U.S. Pat. No. 6,106,833), and chemical coupling of
antibody fragments (Brennan et al., 1985, Science 229:81; Glennie
et al., 1987, J. Immunol. 139:2367; U.S. Pat. No. 6,010,902).
Moreover, bispecific antibodies can be produced via recombinant
means, for example by using leucine zipper moieties (i.e., from the
Fos and Jun proteins, which preferentially form heterodimers;
Kostelny et al., 1992, J. Immunol. 148:1547) or other lock and key
interactive domain structures as described in U.S. Pat. No.
5,582,996. Additional useful techniques include those described in
Kortt et al., 1997, supra; U.S. Pat. No. 5,959,083; and U.S. Pat.
No. 5,807,706.
[0307] In another aspect, the present invention provides a
derivative of an antibody. The derivatized antibody can comprise
any molecule or substance that imparts a desired property to the
antibody, such as increased half-life in a particular use. The
derivatized antibody can comprise, for example, a detectable (or
labeling) moiety (e.g., a radioactive, colorimetric, antigenic or
enzymatic molecule, a detectable bead (such as a magnetic or gold
bead), or a molecule that binds to another molecule (e.g.,
biotin)), a therapeutic or diagnostic moiety (e.g., a radioactive,
cytotoxic, or pharmaceutically active moiety), or a molecule that
increases the suitability of the antibody for a particular use
(e.g., administration to a subject, such as a human subject, or
other in vivo or in vitro uses). Examples of molecules that can be
used to derivatize an antibody are albumin (e.g., human serum
albumin) and polyethylene glycol (PEG). Albumin-linked and
PEGylated derivatives of antibodies can be prepared using
techniques well known in the art. In one embodiment, the antibody
is conjugated or otherwise linked to transthyretin (TTR) or a TTR
variant. The TTR or TTR variant can be chemically modified with,
for example, a chemical selected from the group consisting of
dextran, poly(n-vinyl pyurrolidone), polyethylene glycols,
propropylene glycol homopolymers, polypropylene oxide/ethylene
oxide co-polymers, polyoxyethylated polyols and polyvinyl alcohols.
US Pat. App. No. 20030195154.
Therapeutic Methods and Administration of Antibodies
[0308] Methods provided herein comprise administering an anti-IL-4R
antibody to a subject, thereby reducing an IL-4-induced biological
response that plays a role in a particular condition. In particular
embodiments, methods of the invention involve contacting endogenous
IL-4R with an anti-IL-4R antibody, e.g., in an ex vivo
procedure.
[0309] Treatment encompasses alleviation or prevention of at least
one symptom of a disorder, or reduction of disease severity, and
the like. An antibody need not effect a complete "cure", or
eradicate every symptom or manifestation of a disease, to
constitute a viable therapeutic agent. As is recognized in the
pertinent field, drugs employed as therapeutic agents may reduce
the severity of a given disease state, but need not abolish every
manifestation of the disease to be regarded as useful therapeutic
agents. One embodiment of the invention is directed to a method
comprising administering to a patient an IL-4R antagonist in an
amount and for a time sufficient to induce a sustained improvement
over baseline of an indicator that reflects the severity of the
particular disorder.
[0310] Antibodies that inhibit the binding of both IL-4 and IL-13
to cells are discussed herein. A method for suppressing
IL-4-induced and IL-13-induced activities in humans comprises
administering an effective amount of such an antibody. Conditions
induced by IL-4 or by IL-13, or by both cytokines, thus may be
treated.
[0311] As is understood in the pertinent field, antibodies are
administered to a subject in a manner appropriate to the
indication. Antibodies may be administered by any suitable
technique, including but not limited to parenterally, topically, or
by inhalation. If injected, the antibody can be administered, for
example, via intra-articular, intravenous, intramuscular,
intralesional, intraperitoneal or subcutaneous routes, by bolus
injection, or continuous infusion. Localized administration, e.g.
at a site of disease or injury is contemplated, as are transdermal
delivery and sustained release from implants. Delivery by
inhalation includes, for example, nasal or oral inhalation, use of
a nebulizer, inhalation of the antagonist in aerosol form, and the
like. Other alternatives include eyedrops; oral preparations
including pills, syrups, lozenges or chewing gum; and topical
preparations such as lotions, gels, sprays, and ointments.
[0312] Use of anti-IL-4R antibodies in ex vivo procedures also is
contemplated. For example, a patient's blood or other bodily fluid
may be contacted with an antibody that binds IL-4R ex vivo. The
antibody may be bound to a suitable insoluble matrix or solid
support material.
[0313] Advantageously, antibodies are administered in the form of a
composition comprising at least one anti-IL-4R antibody and one or
more additional components such as a physiologically acceptable
carrier, excipient or diluent. The present invention provides such
compositions comprising an effective amount of an anti-IL-4R
antibody, for use in the methods provided herein.
[0314] The compositions contain anti-IL-4R antibody(-ies) in, for
example, any of the forms described herein. The antibody may be a
whole antibody or an antigen-binding fragment or engineered
derivative thereof, for example.
[0315] Compositions may, for example, comprise an antibody together
with a buffer, antioxidant such as ascorbic acid, low molecular
weight polypeptide (such as those having fewer than 10 amino
acids), protein, amino acid, carbohydrate such as glucose, sucrose
or dextrins, chelating agents such as EDTA, glutathione, and other
stabilizers and excipients. Neutral buffered saline or saline mixed
with conspecific serum albumin are examples of appropriate
diluents. In accordance with appropriate industry standards,
preservatives such as benzyl alcohol may also be added. The
composition may be formulated as a lyophilizate using appropriate
excipient solutions (e.g., sucrose) as diluents. Suitable
components are nontoxic to recipients at the dosages and
concentrations employed. Further examples of components that may be
employed in pharmaceutical formulations are presented in
Remington's Pharmaceutical Sciences, 16.sup.th Ed., Mack Publishing
Company, Easton, Pa., 1980.
[0316] Kits for use by medical practitioners include an anti-IL-4R
antibody and a label or other instructions for use in treating any
of the conditions discussed herein. The kit preferably includes a
sterile preparation of one or more anti-IL-4R antibodies, which may
be in the form of a composition as disclosed above, and may be in
one or more vials.
[0317] Dosages and the frequency of administration may vary
according to such factors as the route of administration, the
particular antibody employed, the nature and severity of the
disease to be treated, whether the condition is acute or chronic,
and the size and general condition of the subject. Appropriate
dosages can be determined by procedures known in the pertinent art,
e.g. in clinical trials that may involve dose escalation
studies.
[0318] An antibody may be administered, for example, once or more
than once, e.g., at regular intervals over a period of time. In
particular embodiments, the antibody is administered over a period
of at least a month or more, e.g., for one, two, or three months or
even indefinitely. For treating chronic conditions, long-term
treatment is generally most effective. However, for treating acute
conditions, administration for shorter periods, e.g. from one to
six weeks, may be sufficient. In general, the antibody is
administered until the patient manifests a medically relevant
degree of improvement over baseline for the chosen indicator or
indicators.
[0319] Particular embodiments of the present invention involve
administering an antibody at a dosage of from about 1 ng of
antibody per kg of subject's weight per day ("1 ng/kg/day") to
about 10 mg/kg/day, more preferably from about 500 ng/kg/day to
about 5 mg/kg/day, and most preferably from about 5 .mu.g/kg/day to
about 2 mg/kg/day, to a subject. In additional embodiments, an
antibody is administered to adults one time per week, two times per
week, or three or more times per week, to treat an IL-4 and/or
IL-13 mediated disease, condition or disorder, e.g., a medical
disorder disclosed herein. If injected, the effective amount of
antibody per adult dose may range from 1-20 mg/m.sup.2, and
preferably is about 5-12 mg/m.sup.2. Alternatively, a flat dose may
be administered; the amount may range from 5-100 mg/dose. One range
for a flat dose is about 20-30 mg per dose. In one embodiment of
the invention, a flat dose of 25 mg/dose is repeatedly administered
by injection. If a route of administration other than injection is
used, the dose is appropriately adjusted in accordance with
standard medical practices. One example of a therapeutic regimen
involves injecting a dose of about 20-30 mg of anti-IL-4R antibody
to one to three times per week over a period of at least three
weeks, though treatment for longer periods may be necessary to
induce the desired degree of improvement. For pediatric subjects
(age 4-17), one exemplary suitable regimen involves the
subcutaneous injection of 0.4 mg/kg, up to a maximum dose of 25 mg
of antibody administered two or three times per week.
[0320] Particular embodiments of the methods provided herein
involve subcutaneous injection of from 0.5 mg to 10 mg, preferably
from 3 to 5 mg, of an anti-IL-4R antibody, once or twice per week.
Another embodiment is directed to pulmonary administration (e.g.,
by nebulizer) of 3 or more mg of antibody once a week.
[0321] Examples of therapeutic regimens provided herein comprise
subcutaneous injection of an anti-IL-4R antibody once a week, at a
dose of 1.5 to 3 mg, to treat asthma. pulmonary sarcoidosis,
minimal change nephrosis, autoimmune uveitis, sickle cell crisis,
Churg-Strauss syndrome, Sjogren's syndrome, autoimmune
lymphoproliferative syndrome, pre-eclampsia, autoimmune hemolytic
anemia, Barrett's esophagus, Grave's Disease, Kawasaki Disease, and
cavitary tuberculosis. Weekly administration of anti-IL-4R antibody
is continued until a desired result is achieved, e.g., the
subject's symptoms subside. Treatment may resume as needed, or,
alternatively, maintenance doses may be administered.
[0322] In another embodiment, an antibody is administered to the
subject in an amount and for a time sufficient to induce an
improvement, preferably a sustained improvement, in at least one
indicator that reflects the severity of the disorder that is being
treated. Various indicators that reflect the extent of the
subject's illness, disease or condition may be assessed for
determining whether the amount and time of the treatment is
sufficient. Such indicators include, for example, clinically
recognized indicators of disease severity, symptoms, or
manifestations of the disorder in question. In most instances, an
improvement is considered to be sustained if the subject exhibits
the improvement on at least two occasions separated by two to four
weeks. The degree of improvement generally is determined by a
physician, who may make this determination based on signs or
symptoms, and who may also employ questionnaires that are
administered to the subject, such as quality-of-life questionnaires
developed for a given disease.
[0323] As one example, in treating benign prostate hyperplasia, an
anti-IL-4R antibody is administered to the subject in an amount and
for a time effective in scar regression or complete healing.
Maintenance doses may be given or treatment resumed as needed.
[0324] Elevated levels of IL-4 are associated with a number of
disorders, as discussed above. Subjects with a given disorder may
be screened, to identify those individuals who have elevated IL-4
levels, or to identify those with an elevated TH2-type immune
response, thereby identifying the subjects who may benefit most
from treatment with an anti-IL-4R antibody. Thus, treatment methods
provided herein optionally comprise a first step of measuring a
subject's IL-4 level. An anti-IL-4R antibody may be administered to
a subject in whom IL-4 levels are elevated above normal.
Alternatively or additionally, a subject may be pre-screened to
determine whether the subject has an elevated TH2-type immune
response, prior to administration of antibody(-ies) and/or
antagonist(s) against one or more TH2-type cytokines.
[0325] A subject's levels of IL-4 (and, optionally, of other
TH2-type cytokines) may be monitored during and/or after treatment
with an anti-IL-4R antibody, to detect reduction in the levels of
the cytokines. For some disorders, the incidence of elevated IL-4
levels, and the balance between TH1-type and TH2-type immune
responses, may vary according to such factors as the stage of the
disease or the particular form of the disease. Known techniques may
be employed for measuring IL-4 levels, e.g., in a subject's serum,
and for assessing TH2-type immune responses. Cytokine levels in
blood samples may be measured by ELISA, or by a LUMINEX.TM.
multi-plex cytokine assay (Luminex Corporation, Austin, Tex.) or
DELFIA.RTM. (PerkinElmer LifeSciences, Wallac Oy., Turku, Finland),
for example.
[0326] Particular embodiments of methods and compositions of the
invention involve the use of an anti-IL4R antibody and one or more
additional IL-4R antagonists, for example, two or more antibodies
or antibody derivatives of the invention, or an antibody or
antibody derivative of the invention and one or more other IL-4R
antagonists. In further embodiments, anti-IL-4R antibodies are
administered alone or in combination with other agents useful for
treating the condition with which the patient is afflicted.
Examples of such agents include both proteinaceous and
non-proteinaceous drugs. When multiple therapeutics are
co-administered, dosages may be adjusted accordingly, as is
recognized in the pertinent art. "Co-administration" and
combination therapy are not limited to simultaneous administration,
but include treatment regimens in which an IL-4R antibody is
administered at least once during a course of treatment that
involves administering at least one other therapeutic agent to the
patient.
[0327] Examples of other agents that may be co-administered with
IL-4R antibodies are other antibodies, cytokines, or cytokine
receptors, which are chosen according to the particular condition
to be treated. Alternatively, non-proteinaceous drugs that are
useful in treating one of the particular conditions discussed above
may be co-administered with an IL-4R antagonist.
[0328] For treating IgE-mediated conditions, an anti-IL-4R antibody
may be co-administered with an IgE antagonist. One example is an
anti-IgE antibody, e.g., XOLAIR.RTM. (Genentech, South San
Francisco, Calif.). Humanized anti-IgE monoclonal antibodies are
described in, for example, Presta et al., 1993, J. Immunol.
151:2623-32 and Adelroth et al., 2000, J. Allergy Clin. Immunol.
106:253-59.
[0329] Anti-IL-4R antibodies may be co-administered with an IL-5
antagonist, which may be a molecule that interferes with the
binding of IL-5 to an IL-5 receptor, such as an anti-IL-5R or
anti-IL-5 antibody (e.g., a human or humanized anti-IL-5 or
anti-IL-5R monoclonal antibody), or a receptor such as a soluble
human IL-5 receptor polypeptide. IL-5 has been implicated as
playing a role in mediating allergic responses. Thus,
administration of antagonist(s) of IL-4R and IL-5 is contemplated
for treatment of allergic reactions, including but not limited to
allergic asthma.
[0330] Further examples of agents that can be used in conjunction
with IL-4R antibodies include anti-IL-4 antibodies, IL-4 muteins,
IL-4 binding derivatives of IL-4R (as described in, e.g., U.S. Pat.
Nos. 5,840,869; 5,599,905, 5,856,296, 5,767,065, 5,717,072,
6,391,581, 6,548,655, 6,472,179, and 5,844,099), IL-13 binding
derivatives of IL-13, IL-4 and/or IL-13 binding chimeric
derivatives of IL-4R and IL-13R, IL-13 muteins, and antagonists of
CD23 (e.g., anti-CD23 antibodies such as IDEC-152.TM. (IDEC
Pharmaceuticals, San Diego, Calif.), Phosphodiesterase 4 (e.g.,
ROFLUMILAST.RTM., Byk Gulden Pharmaceuticals, Konstanz, Germany),
integrins (e.g., R411.TM., Roche, Nutley, N.J.), TIMs, Gob5, STAT6,
and leukotrienes.
[0331] For treating asthma, an IL-4R antibody may be
co-administered with other anti-asthma medications, such as inhaled
corticosteroids, beta agonists, leukotriene antagonists, xanthines,
fluticasone, salmeterol, albuterol, non-steroidal agents such as
cromolyn, and the like. IL-4R antibodies may be co-administered
with other anti-allergy medications to treat allergic
reactions.
[0332] One embodiment of the present invention is directed to
co-administration of an antibody or antibody derivative of the
invention and fluticasone and/or salmeterol to treat a disorder
such as asthma. Compositions comprising an antibody or antibody
derivative of the invention, fluticasone, and salmeterol are
provided herein. ADVAIR DISKUS.RTM. (GlaxoSmithKline, Research
Triangle Park, N.C.) comprises fluticasone propionate and
salmeterol xinafoate. ADVAIR DISKUS.RTM. and the antibody or
antibody derivative can be delivered by any route of administration
effective for treating or preventing a particular disease,
disorder, injury, or condition e.g., by inhalation for treating
asthma.
[0333] Another example of combination therapy comprises
co-administration of an antibody or antibody derivative of the
invention and an IL-9 antagonist to a patient who has asthma. Any
suitable IL-9 antagonist may be employed, such as an IL-9 receptor
(e.g., a soluble form thereof), an antibody that interferes with
binding of IL-9 to a cell surface receptor (e.g., an antibody that
binds to IL-9 or to an IL-9 receptor polypeptide), or another
compound that inhibits IL-9-induced biological activity. IL-9
receptors include those described in WO 93/18047 and U.S. Pat. Nos.
5,789,237 and 5,962,269, which are hereby incorporated by reference
herein.
[0334] In an additional embodiment of combination therapy, a method
for treating ulcerative colitis comprises co-administration of an
antibody or antibody derivative of the invention and at least one
IL-1 antagonist. Examples of IL-1 antagonists include type I IL-1
receptor, type II IL-1 receptor, IL-1 receptor antagonist (IL-1Ra),
antagonistic (blocking) antibodies directed against IL-1, and
antagonistic antibodies directed against an IL-1 receptor. Various
forms of the receptors may be employed, such as fragments, variants
and fusions, for example, a soluble form of type II IL-1 receptor,
e.g., as described in U.S. Pat. No. 5,350,683, hereby incorporated
by reference herein.
[0335] One method of the present invention comprises
co-administering an antibody or antibody derivative of the present
invention, alone or in combination with an IL-13 antagonist(s), to
a patient who has minimal change nephrosis, e.g., to reduce
severity of the disease.
[0336] Another method provided herein is a method for treating
various allergic inflammatory conditions, comprising
co-administering an antibody or antibody derivative of the
invention and IL-13 antagonist(s). Conditions such as asthma,
allergies, and chronic lung diseases such as cystic fibrosis and
chronic obstructive pulmonary disease are treated by such a
method.
[0337] Any suitable IL-13 antagonist may be employed, including but
not limited to IL-13 receptors (preferably soluble forms thereof),
IL-13 receptor antagonists, antibodies directed against IL-13 or an
IL-13R, other proteins that interfere with the binding of IL-13 to
an IL-13R, and compounds that inhibit IL-13-mediated signal
transduction. IL-13 receptors and heterodimers comprising IL-13R
polypeptides as components thereof are described above. Antibodies
that are raised against IL-4R may be screened for the ability to
also function as IL-13 antagonists, as discussed above.
[0338] A method for treating or preventing a condition
characterized by reduced epithelial barrier function comprises
co-administering an antibody or antibody derivative of the
invention and one or more IL-13 antagonists. Such conditions are
discussed above. In one embodiment, the condition is asthma.
Particular embodiments are directed to co-administering one or more
antibodies or antibody derivatives of the invention and one or more
IL-13 antagonists to a patient having a condition involving
reduction of lung epithelial barrier function or intestinal
epithelial barrier function, wherein both IL-4 and IL-13 play a
role in the reduced barrier function. The adverse effect of IL-13
on lung and intestinal epithelial barrier function can be confirmed
using assay techniques such as those described in Example 3. See
also Zund et al., 1996, J. Biol. Chem. 271:7460-64.
[0339] Another method provided herein comprises co-administering an
antibody or antibody derivative of the invention and
interferon-.gamma. (IFN-.gamma.) to a patient having a condition
involving reduction of lung epithelial barrier function.
Optionally, such a method further comprises co-administering one or
more IL-13 antagonists to the patient (i.e., co-administering an
antibody or antibody derivative of the invention, IFN-.gamma., and
an IL-13 antagonist). In one embodiment, the patient has asthma.
The antibody or antibody derivative of the invention, IFN-.gamma.,
and/or IL-13 antagonist can be administered via any method of
delivery effective for treating or preventing a particular disease,
disorder, condition, or injury, e.g., for treating asthma, via
inhalation or injection.
[0340] One method provided herein for treating asthma comprises
administering an antibody or antibody derivative of the invention
and interferon-.gamma. to a human who has asthma. Another method
for treating asthma comprises co-administering an antibody or
antibody derivative of the invention, IFN-.gamma., and an IL-13
antagonist to a human who has asthma. In one embodiment,
IFN-.gamma. is co-administered to an asthmatic, together with an
antibody that functions as an antagonist of both IL-4 and IL-13.
Examples of such antibodies are described elsewhere herein.
[0341] A single antibody or antibody derivative of the invention
may function as an IL-4 antagonist and an IL-13 antagonist, as
discussed above. As an example of such an agent, some antibodies
raised against IL-4R.alpha. may interfere with the binding of both
IL-4 and IL-13 receptor complexes, due to the shared IL-4R.alpha.
component in such multi-subunit receptor complexes (discussed
above). Thus, a single antibody or antibody derivative of the
invention may be employed in a method for inhibiting reduction of
barrier function.
[0342] An antibody or antibody derivative of the invention may be
co-administered with one or more leukotriene receptor antagonists
to treat disorders such as allergic inflammatory diseases, e.g.,
asthma and allergies. Examples of leukotriene receptor antagonists
include but are not limited to montelukast (e.g., SINGULAIR.RTM.,
Merck & Co., Whitehouse, N.J.), pranlukast (e.g., ONON.RTM.,
Ono Pharmaceuticals, Osaka, Japan), and zafirlukast (e.g.,
ACCOLATE.RTM., AstraZeneca, Wilmington, Del.). Drugs that function
as 5-lipoxygenase inhibitors may be co-administered with an IL-4R
antagonist to treat asthma.
[0343] Methods provided herein comprise administering an antibody
or antibody derivative of the invention and one or more of the
following to Churg-Strauss Syndrome patients: IL-4R antagonist(s),
IL-5 antagonist(s), IL-13 antagonist(s) and IgE antagonist(s). One
example of such a method involves co-administering an antibody or
antibody derivative of the invention and IL-5 antagonist(s) to a
Churg-Strauss Syndrome patient. In another embodiment, an antibody
or antibody derivative of the invention and IgE antagonist(s) are
co-administered to the patient. In yet another embodiment, an
antibody or antibody derivative of the invention and IL-13
antagonist(s) are co-administered to the patient.
[0344] The hormone relaxin may be co-administered with an antibody
or antibody derivative of the invention to treat scleroderma
(systemic sclerosis), idiopathic pulmonary fibrosis, or any other
disorder characterized by pulmonary fibrosis, such as the
conditions involving fibrosis of the lung that are discussed above.
Recombinant human relaxin is preferred for use in treating
humans.
[0345] A method for treating benign prostate hyperplasia comprises
co-administering an antibody or antibody derivative of the
invention and one or more additional anti-inflammatory agents.
Examples of agents that inhibit inflammation include tumor necrosis
factor (TNF) antagonists and IL-17 antagonists.
[0346] Any suitable IL-17 antagonist may be employed, including but
not limited to an IL-17 receptor (e.g., soluble forms thereof),
IL-17 receptor antagonists, antibodies directed against IL-17 or an
IL-17 receptor, other proteins that interfere with the binding of
IL-17 to an IL-17 receptor, and compounds that inhibit
IL-17-mediated signal transduction. An IL-17 receptor, including
soluble forms thereof and oligomers thereof, is described in WO
96/29408, hereby incorporated by reference. An alternative method
provided herein comprises administering an IL-17 antagonist to
treat a patient with benign prostate hyperplasia.
[0347] Likewise, any suitable TNF antagonist may be employed,
including but not limited to a TNF receptor (preferably soluble
forms thereof), fusion proteins comprising a TNF receptor (or
comprising the TNF-binding portion of a TNF receptor), TNF receptor
antagonists, antibodies directed against TNF or a TNF receptor,
other proteins that interfere with the binding of TNF to a TNF
receptor, and compounds that inhibit TNF-mediated signal
transduction. Further examples of TNF inhibitors are the drugs
thalidomide and pentoxyfylline. The TNF receptor protein known as
p75 or p80 TNF-R preferably is employed. A preferred TNF antagonist
is a soluble human TNF receptor (sTNF-R) in dimeric form, such as
dimers of sTNF-R/Fc fusion proteins. One such dimer is etanercept
(ENBREL.RTM., Immunex Corporation, Seattle, Wash.). p75/p80 TNF-R,
including soluble fragments and other forms thereof, is described
in WO 91/03553, hereby incorporated by reference herein.
[0348] Accordingly, in one embodiment of the present invention, an
antibody or antibody derivative of the invention is co-administered
with a TNF antagonist to treat any condition in which undesirable
IL-4R-mediated and TNF-induced immune responses play a role, such
as inflammation. One method provided herein comprises
co-administering an antibody or antibody derivative of the
invention and a TNF antagonist to a patient with inflammatory bowel
disease, Crohn's disease, or ulcerative colitis. Other embodiments
are directed to a method comprising co-administering an antibody or
antibody derivative of the invention and a TNF antagonist to a
patient who has Kawasaki Disease, autoimmune hemolytic anemia,
autoimmune uveoretinitis, autoimmune lymphoproliferative syndrome,
Sjogren's syndrome, chronic fatigue syndrome, or hepatotoxicity
induced by a drug such as diclofenac.
[0349] Another method provided herein comprises co-administering an
antibody or antibody derivative of the invention and a TNF
antagonist to a pregnant woman who has developed pre-eclampsia. In
one embodiment, the administration of the antibody or antibody
derivative of the invention TNF-antagonist continues for the
duration of the pregnancy.
[0350] Suitable dosages of etanercept will vary according to the
nature of the disease to be treated, disease severity, the size of
the patient (e.g., adult or child), and other factors, as is
recognized in the pertinent field. In one embodiment of the methods
provided herein, ENBREL.RTM. is administered twice a week by
subcutaneous injection at a dose of from 1 to 25 mg. One embodiment
of a pediatric dosage is 0.4 mg/kg. Particular methods provided
herein comprise co-administration of an antibody or antibody
derivative of the invention and ENBREL.RTM. to a patient has
autoimmune lymphoproliferative syndrome or Sjogren's syndrome,
wherein ENBREL.RTM. is given by subcutaneous injection at a dose of
from 1 to 25 mg.
[0351] For treating graft versus host disease ("GVHD"), an antibody
or antibody derivative of the invention is co-administered with at
least one of the following agents: a TNF antagonist, an IL-1
antagonist, steroids, or corticosteroids. In one embodiment, the
TNF inhibitor is ENBREL.RTM.. In another embodiment, the IL-1
antagonist is a soluble form of type II IL-1 receptor, e.g., as
described in U.S. Pat. No. 5,350,683. In another embodiment, the
GVHD is associated with (e.g., develops subsequent to) bone marrow
transplantation. An antibody or antibody derivative of the
invention may be employed in combination with at least one of the
above-listed agents, in methods for suppressing an immune response
directed against transplanted cells, tissue, and/or
alloantigen.
[0352] A number of cytokine antagonists and other agents/drugs are
disclosed herein as being useful for combination therapy (e.g.,
co-administration with an antibody or antibody derivative of the
invention) in treating particular diseases. It is to be understood
that such antagonists, agents, or drugs also find use as single
agents in treating those diseases. It also is to be understood that
disclosure of methods involving administration of an antagonist to
a particular cytokine, to treat a disease, encompasses
administration of one type of antagonist, and also encompasses
administration of two or more different antagonists for that
cytokine, unless specified otherwise.
Example 1
Preparation of Monoclonal Antibodies
[0353] This example demonstrates a method of preparing monoclonal
antibodies recognizing the human IL-4 receptor.
[0354] IL-4 receptor polypeptides may be employed as immunogens in
generating monoclonal antibodies by conventional techniques, e.g.,
techniques described in U.S. Pat. No. 5,599,905, hereby
incorporated by reference in its entirety. It is recognized that
polypeptides in various forms may be employed as immunogens, e.g.,
full length proteins, fragments thereof, fusion proteins thereof
such as Fc fusions, cells expressing the recombinant protein on the
cell surface, etc.
[0355] To summarize an example of such a procedure, an IL-4R
immunogen emulsified in complete Freund's adjuvant is injected
subcutaneously into Lewis rats, in amounts ranging from 10-100
.mu.l. Three weeks later, the immunized animals are boosted with
additional immunogen emulsified in incomplete Freund's adjuvant and
boosted every three weeks thereafter. Serum samples are
periodically taken by retro-orbital bleeding or tail-tip excision
for testing by dot-blot assay, ELISA (enzyme-linked immunosorbent
assay), or inhibition of binding of .sup.125I-IL-4 to extracts of
IL-4R-expressing cells. Following detection of an appropriate
antibody titer, positive animals are given a final intravenous
injection of antigen in saline. Three to four days later, the
animals are sacrificed, splenocytes harvested, and fused to the
murine myeloma cell line AG8653. The resulting hybridoma cell lines
are plated in multiple microtiter plates in a HAT selective medium
(hypoxanthine, aminopterin, and thymidine) to inhibit proliferation
of non-fused cells, myeloma hybrids, and spleen cell hybrids.
[0356] Hybridoma clones thus generated are screened for reactivity
with IL-4R. Initial screening of hybridoma supernatants utilizes an
antibody capture and binding of partially purified .sup.125I-IL-4
receptor. Hybridomas that are positive in this screening method are
tested by a modified antibody capture to detect hybridoma cells
lines that are producing blocking antibody. Hybridomas that secrete
a monoclonal antibody capable of inhibiting .sup.125I-IL-4 binding
to cells expressing IL-4R are thus detected. Such hydridomas then
are injected into the peritoneal cavities of nude mice to produce
ascites containing high concentrations (>1 mg/ml) of anti-IL-4R
monoclonal antibody. The resulting monoclonal antibodies may be
purified by ammonium sulfate precipitation followed by gel
exclusion chromatography, and/or affinity chromatography based on
binding of antibody to Protein G.
[0357] Methods for generating human antibodies in transgenic mice
have been described and are well known in the art. See, e.g., Chen
et al., 1993, Internat. Immunol. 5: 647-56; Chen et al., 1993, EMBO
J. 12: 821-30; Choi et al., 1993, Nature Genetics 4: 117-23;
Fishwild et al., 1996, Nature Biotech. 14: 845-51; Harding et al.,
1995, Annals New York Acad. Sci.; Lonberg et al., 1994, Nature 368:
856-59; Lonberg, 1994, Handbook Exper. I Pharmacol. 113: 49-101;
Lonberg et al., 1995, Internal Rev. Immunol. 13: 65-93; Morrison,
S, 1994, Nature 368: 812-13; Neuberger, 1996, Nature Biotech. 14:
826; Taylor et al., 1992, Nuc. Acids Res. 20: 6287-95; Taylor et
al., 1994, Internat. Immunol. 6: 579-91; Tomizuka et al., 1997,
Nature Genetics 16: 133-43; Tomizuka et al., 2000, Proc. Nat. Acad.
Sci. USA 97: 722-27; Tuaillon et al., 1993, Proc. Nat. Acad. Sci.
USA 90: 3720-24; Tuaillon et al., 1994, J. Immunol. 152: 2912-20;
Russel et al., 2000, Infection and Immunity April 2000: 1820-26;
Gallo et al., 2000, Eur. J. Immunol. 30: 534-40; Davis et al.,
1999, Cancer Metastasis Rev. 18:421-25; Green, 1999, J. Immunol.
Methods 231:11-23; Jakobovits, 1998, Advanced Drug Delivery Rev.
31:33-42; Green et al., 1998, J. Exp. Med. 188: 483-95; Jakobovits,
1998, Exp. Opin. Invest. Drugs 7: 607-14; Tsuda et al., 1997,
Genomics 42: 413-21; Mendez et al., 1997, Nature Genetics 15:
146-56; Jakobovits, 1996, Weir's Handbook of Experimental
Immunology, The Integrated Immune System Vol. IV, 194.1-194.7;
Mendez et al., 1995, Genomics 26: 294-307; Jakobovits, 1994,
Current Biol. 4: 761-63; Arbones, 1994, Immunity 1: 247-60; Green
et. al., 1994, Nature Genetics 7: 13-21; Jakobovits et al., 1993,
Nature 362: 255-58; Jakobovits et al., 1993, Proc. Nat. Acad. Sci.
USA 90: 2551-55.
Example 2
Assay for Assessing Blocking Activity
[0358] This example demonstrates an assay that can be used to
identify antibodies that reduce IL-4 and/or IL-13-dependent
expression of CD23. The assay is based on the ability of both IL-4
and IL-13 to enhance the expression of the activation-associated
surface antigen CD23 on human B cells.
[0359] Antibodies raised against human IL-4R (hulL-4R) are tested
either in the form of hybridoma supernatants or purified protein.
Prior to addition to cultures, the antibodies are buffer exchanged
against culture medium (RPMI 1640 plus 10% heat-inactivated fetal
bovine serum) by centrifugation, using Centricon filter devices
(Amicon) with a 10 kDa cutoff.
[0360] Human peripheral blood B cells are purified as described
previously (Morris et al., 1999, J. Biol. Chem. 274:418-23). The B
cells (3.times.10.sup.5/well) in culture medium are placed in
96-well round-bottomed microtiter plates and preincubated at room
temperature for 30 min with test antibodies at the final
concentrations indicated. Recombinant human IL-4 or IL-13 is then
added to the cultures at the concentrations indicated, and cells
are cultured for 20-24 hours at 37.degree. C. in a humidified
atmosphere of 5% CO.sub.2. At the end of the culture period, cells
are washed once in PBS+0.02% NaN.sub.3 in the 96-well culture plate
and are resuspended in blocking buffer (2% normal rabbit serum+1%
normal goat serum in PBS+NaN.sub.3). Phycoerythrin (PE)-conjugated
CD23 monoclonal antibody (mAb) or PE-conjugated isotype control mAb
(both from Pharmingen) are then added to cells at a final dilution
of 1:10. Cells are incubated for 30 minutes at 4.degree. C., washed
.times.3 in PBS+NaN.sub.3 and analyzed on a FacScan (Becton
Dickinson) for CD23 expression.
[0361] Cells cultured with hybridoma growth medium or
isotype-matched non-blocking human anti-hIL-4R antibody are
included as negative controls. An anti-hulL-4R murine mAb (MAB 230,
R&D Systems, Minneapolis, Minn.), previously shown to block the
binding and function of both hIL-4 and hIL-13, is used as a
positive control for neutralization of CD23 induction by IL-4 and
IL-13.
Example 3
Assays for Measuring Loss of Barrier Function
[0362] This example provides methods of assessing the ability of an
IL-4 antagonist to inhibit IL-4 induced damage to epithelial tissue
and loss of epithelial barrier function.
[0363] In one aspect, the present invention provides a method of
using an IL-4 antagonist to inhibit IL-4-induced damage to
epithelium, including but not limited to lung epithelium or
intestinal epithelium. Damage to epithelium can result in loss of
barrier function. The following are non-limiting examples of
techniques that may be employed in assessing the ability of an IL-4
antagonist to inhibit IL-4-induced damage to epithelium and loss of
epithelial barrier function.
[0364] Cells that may be employed in preparing in vitro models of
epithelium (epithelial barriers) are known. For example, Calu-3
human lung epithelial cells are suitable for use in barrier
function studies (Ahdieh et al., 2001, Am. J. Physiol. Cell
Physiol. 281:C2029-38). Another suitable cell line is the human
intestinal epithelial cell line designated T84. T84 cells are
cultured under conditions that result in formation of a monolayer
of epithelial cells on a permeable support, as described in Madara
et al., 1985, J. Cell Biol., 101:2124-33, Madara et al., 1989, J.
Clin. Invest. 83:724-27, and Youakim et al., 1999, Am. J. Physiol.
276 (Gastrointest. Liver Physiol. 39):G1279-88. The thus-generated
epithelial monolayer simulates the intestinal epithelial
barrier.
[0365] The cultured monolayers are tested for a property (e.g.,
resistance to passive transepithelial ion flow) that can
distinguish an intact epithelium from a damaged epithelium. One
such assay determines whether a particular radiolabeled compound is
able to cross an epithelial monolayer. Leakage of the radiolabeled
compound through the monolayer indicates that the barrier is
permeable rather than intact. For example, mannitol flux analysis
can be used to detect epithelial damage by assessing the movement
of radiolabeled mannitol (e.g., .sup.3H mannitol) across a
monolayer (see Madara and Stafford, supra).
[0366] Other examples of methods for assessing the condition of an
epithelial include imaging methods (e.g., those discussed in Madara
and Stafford, supra) and transepithelial electrical resistance
measurements (e.g., those discussed in Youakim and Ahdieh,
supra).
[0367] U.S. Pat. No. 6,033,688 ("the '688 patent"), incorporated
herein by reference in its entirety, also describes procedures that
may be employed in studies of barrier permeability; see, e.g.,
Examples 1 and 4 of the patent. Human tracheal epithelial cells are
cultured under conditions that yield a monolayer exhibiting
transepithelial electrical resistance. Transepithelial resistance
(indicating an intact barrier) is determined using a voltmeter. The
effect of a substance or treatment on the epithelial monolayer is
assessed by exposing the monolayer to the substance or treatment,
and then measuring ion transport activities in Ussing chambers
(column 8, lines 40-56). Similar procedures can be conducted using
monolayers that are generated from other types of cells, e.g.,
bronchial epithelial cells from a human cystic fibrosis patient
(see the '688 patent, example 4, column 11).
[0368] Thus, the ability of a substance's or treatment's ability to
inhibit IL-4-induced reduction in the barrier function of an
epithelial layer can be assessed by exposing the epithelial layer
to IL-4 and to the substance or treatment, assaying the condition
of the epithelial layer, and comparing the condition of the
epithelial layer to the condition of an epithelial layer that has
been exposed to IL-4 in the absence of the substance or condition.
An improvement in the condition of the epithelial layer exposed to
the substance or treatment relative to an epithelial layer not
exposed to the substance or treatment indicates that the substance
or treatment to inhibits IL-4 induced damage to epithelial tissue
and loss of epithelial barrier function.
[0369] In one such assay, a monolayer of T84 cells served as an in
vitro model of an intestinal epithelial barrier, as discussed
above. IL-4 added to the basolateral side of polarized epithelial
cells was found to reduce barrier function by 70% within 48-72
hours of treatment. When a soluble IL-4 receptor polypeptide
consisting of the extracellular domain was added at the same time
as IL-4, the reduction in barrier function was prevented, and the
barrier was maintained at the same level as untreated (control)
cells.
[0370] The assay procedure also was conducted on a monolayer
derived from lung epithelial cells, which served as an in vitro
model of a lung epithelial barrier. IL-4 added to the basolateral
side of polarized lung epithelial cells was found to reduce barrier
function by 50% within 48-72 hours of treatment. When the IL-4
receptor polypeptide was added at the same time as IL-4, the
reduction in barrier function was prevented, and the barrier was
maintained at the same level as untreated (control) cells.
Example 4
Assays for Measuring Binding Activity
[0371] This example provides methods of assessing the binding
activity of an anti-IL-4R antibody.
[0372] Anti-hulL-4R (or a variant, derivative, or fragment
thereof), is radiolabeled with .sup.125I using a solid phase
chloramine-T analogue (IODOGEN.RTM., Pierce, St. Louis, Mo.) or
other, suitable radiolabeling technique, to a specific activity of
approximately 3.times.10.sup.16 cpm/mmol. Loss of bioactivity is
assessed by comparing binding inhibition or other biological
inhibition assay with the corresponding unlabeled protein.
Alternatively, inhibition of radiolabeled IL-4 binding by
anti-hulL-4R (or a variant or fragment thereof) can be measured.
Equilibrium binding assays on cells expressing IL-4R are performed
in 96-well microtiter trays substantially as described in Idzerda,
et al., 1990, J. Exp. Med. 171:3 861-73. Briefly, serial dilutions
of radiolabeled protein in binding medium (RPMI 1640, 2.5% BSA, 20
mM HEPES, 0.02% sodium azide, pH 7.2), supplemented with 0.5 mg/ml
human IgG and 5% human serum), are incubated with cells
(2.5.times.106/well) for 2 hours at 4.degree. C. in a total volume
of 150 microliters. Free and bound radiolabeled probes are
separated by microfugation through a phthalate-oil separation
mixture and counted in a gamma counter. Inhibition assays use
radiolabeled protein at a constant concentration of 0.5 nM in the
presence or absence of potential inhibitors. Nonspecific binding is
determined in the presence of a 100-fold excess of unlabeled
protein. Theoretical curves based on single-site competitive
inhibition model are fitted to the data as described in Dower et
al., 1984, J. Immunol. 132:751. Percent inhibition is calculated
according to the equation I (%)=[100Ki(I)/[1+Ka(L)+Ki(I)], where I
is the molar concentration of inhibitor, L is the molar
concentration of radiolabeled protein, and Ki and Ka are the
affinity constants of inhibitor and protein, respectively.
[0373] Equilibrium binding and competitive inhibition isotherms may
also determined in 96-well microtiter plates coated with IL-4R/Fc
or a control Fc protein, captured through goat anti-human Fc
polyclonal antibody (or other suitable anti-human Fc antibody).
Briefly, plates are incubated with 5 micrograms/ml anti-human Fc in
PBS at 4.degree. C., washed twice with PBS, and then incubated with
IL-4R/Fc or a control Fc protein in PBS/0.01 Tween 20 for about 12
hours at 4.degree. C. and washed again twice with PBS. Equilibrium
binding isotherms use serial dilutions of .sup.125I-labeled binding
protein in binding medium, and inhibition assays use a constant of
0.5 nM .sup.125I-labeled anti-hulL-4R in the presence or absence of
unlabeled, potential competitive inhibitors, as described above.
After 2 hours at 4.degree. C., plates are washed twice in PBS, and
specifically bound protein is released with 50 mM citrate (pH 3.0),
or SDS treatment, and released .sup.125I-labeled anti-hulL-4R
measured on a gamma counter. Data are processed as described in
Dower et al., supra.
[0374] Binding activity may also be assessed by surface plasmon
resonance using a BIACORE.RTM. biosensor (BIAcore International AB,
Uppsala, Sweden). Briefly, goat-antihuman IgG, gamma chain-specific
(or other suitable gamma chain-specific antibody; GHFC) is
covalently coupled to biosensor chips using a standard amine
coupling procedure and reagents according to the manufacturer's
instructions. Anti-hulL-4R or a control antibody is injected over
the immobilized GHFC, and varying amounts of IL-4R are
independently passed over a GHFC coated chip (negative control) as
well as an anti-hulL-4R-coated chip. Regeneration of the chip is
accomplished with one 10-microliter pulse of 100 mM phosphoric acid
at 10 microliters/minute. All binding is performed in HBS (10 mM
HEPES, 0.15 M NaCl, 3.4 mM EDTA, 0.02% NaN3, 0.005% surfactant P20,
pH 7.4).
Example 5
IL-4 Receptor Binding Antibodies
[0375] This example provides the amino acid sequences, and the
nucleotide sequences encoding them, of the variable domains of the
heavy and light chains of antibodies and antibody derivatives that
bind to hulL-4R.
[0376] A fully human IgG4 antibody comprising the light chain
variable region of L1 and the heavy chain variable region of H1 was
isolated as described in Example 8 of WO 01/92340 (published Dec.
6, 2001), incorporated herein by reference in its entirety.
[0377] The variable region of heavy chain H1 was isolated by cDNA
cloning from the hybridoma cell line that produced antibody L1H1
via the polymerase chain reaction (PCR) using the following
oligonucleotides as primers:
TABLE-US-00001 (SEQ ID NO: 70)
GTCGACGCCGCCACCATGGA(A/G)TT(G/T)GGGCTGAGCTGG Sal I Degenerate;
complementary to VH3030 (SEQ ID NO: 71) CTTGACCAGGCAGCCCAGGGC
Complementary to huIgG, 3' of Apa I site
[0378] The amplification product was inserted as a Sal I/Apa I
fragment into pGem-T easy (Promega, Madison, Wis.). In order to
improve cleavage, the native H1 leader sequence was replaced with
the VH3-30 leader sequence (Matsuda et al., 1993, Nature Genetics
3:88-94).
[0379] Oligonucleotide-based mutagenesis of the heavy chain
variable domain of H1 was used to create the heavy chain variable
domain sequences H2-H14, shown in FIG. 3. Each of these heavy chain
variable domain sequences was shown to bind, in combination with
the light chain variable domain sequence of L1, to IL-4 receptor
alpha using an enzyme-linked immunosorbent assay (ELISA).
[0380] Naive human light chain variable genes were generated by PCR
from human B cells and used to construct a variable region cDNA
gene library. These were screened in combination with the heavy
chain variable region H1 for binding to human IL-4 receptor. Light
chain variable regions L2-L6 were identified using this method.
Their nucleotide and amino acid sequences are shown in FIGS. 2 and
3, respectively, wherein the CDR regions of each chain are
indicated in bold and underlined in L1. The framework (FR) regions
also are indicated.
[0381] To clone the human kappa constant region, RNA was isolated
from a murine hybridoma cell line expressing a human kappa light
chain using the RNeasy Mini Kit (Qiagen, Valencia, Calif.). The RNA
was reverse transcribed using a First-Strand cDNA Synthesis Kit
(Amersham Pharmacia Biotech, Piscataway, N.J.). The human kappa
light chain nucleic acid was amplified by PCR from the cDNA as a
Bsw I/Not I cassette using primers:
TABLE-US-00002 (SEQ ID NO: 72) ATCAAACGTACGGTGGCTGCACCATCTGTCTTCATC
BsiW I (SEQ ID NO: 73)
GTTTAAACGCGGCCGCGGATCCTAACACTCTCCCCTGTTGAAGCTCTTT Not I
[0382] The light chain variable regions L1 and L2 were
independently joined to the human kappa light chain constant region
as follows: a Nhe I/Bsi WI DNA fragment encoding the light-chain
variable region of L1 and the Bsi WI/Not I DNA fragment encoding
human kappa constant region DNA fragment were simultaneously
subcloned into a pDC409 mammalian expression vector (described in
Giri et al., 1994, EMBO J. 13:2822-30 and U.S. Pat. No. 6,642,358,
incorporated herein by reference in their entireties) using a VkIII
leader sequence. The VkIII leader sequence was constructed as a Sal
I/Nhe I cassette by PCR amplification of Kozak (Kozak, 1989, J.
Cell Biol. 108:229-41) and VkIII A27 (Straubinger et al., 1988, J
Mol. Biol. 199:23-34) leader sequences using the following
oligonucleotides as primers:
TABLE-US-00003 (SEQ ID NO: 74)
GTCGACGCCGCCACCATGGAAACCCCAGCGCAGCTTCTCTTCCTCCTG Sal I
CTACTCTGGCTCCCAGATACCGCTAGCGAAATTGTGTTGACGCAGTCT CCA (SEQ ID NO:
75) TGGAGACTGCGTCAACACAATTTCGCTAGCGGTATCTGGGAGCCAGAG
TAGCAGGAGGAAGAGAAGCTGCGCTGGGGTTTCCATGGTGGCGGC GTCGAC Sal I
[0383] The last six nucleotides in the natural VkIII A27 leader
were replaced with the nucleotides encoding an Nhe I site. This
resulted in amino acid changes from threonine to glycine and
alanine to serine, but did not affect the cleavage site.
[0384] Each heavy chain variable region H1, H4, and H14 was joined
to a human IgG4 constant region as follows: a Sal I/Apa I DNA
fragment encoding the heavy-chain variable region of H1 and an Apa
I/Not I DNA fragment encoding human IgG4 constant region (SEQ ID
NO:77) were simultaneously inserted into Sal I/Not I digested
mammalian expression vector pDC409 (described in Giri et al., 1994,
EMBO J. 13:2822-30) using a VH5a leader sequence that was modified
at its 3' end to encode an Nhe I site:
TABLE-US-00004 (SEQ ID NO: 76)
ATGGGGTCAACCGCCATCCTTGGCCTCCTCCTGGCTGTTCTCCAAGGA GTCGCTAGC Nhe
I
[0385] As a result of this change, the last two amino acids are
alanine and serine, whereas the last two amino acids of the wild
type VH5a are cysteine and alanine. Site-directed mutagenesis was
used on the H4-IgG4-encoding construct to make constructs
comprising the H12 and H13 heavy chain variable regions. The
nucleotide and amino acid sequences of H1-H14 are shown in FIGS. 2
and 3, respectively, wherein the CDR regions of each chain are
indicated in bold and underlined in H1. The framework (FR) regions
also are indicated.
[0386] Antibodies and/or antibody derivatives comprising the
variable domain combinations L1H1, L1H2, L1H3, L1H4, L1H5, L1H6,
L1H7, L1H8, L1H9, L1H10, L1H11, L2H1, L2H2, L2H3, L2H4, L2H5, L2H6,
L2H7, L2H8, L2H9, L2H10, L2H11, L2H12, L2H13, L2H14, L3H1, L4H1,
L5H1, and L6H1 were tested using a biochemical binding assay and/or
the method of Example 2 and found to bind to IL-4 receptor.
Example 6
Species and Sequence Specificity of Antibodies
[0387] This example provides a method for determining the species
and sequence specificity of an antibody that binds to the IL-4
receptor.
[0388] A fluorescence-activated cell sorter (FACS) binding assay
can be used to evaluate the species and/or sequence specificity of
an anti-IL-4 receptor antibody. The extracellular domain of IL-4
receptor comprises a cytokine receptor domain (domain I) and a
fibronectin type III domain (domain II) (Hage et al., 1999, Cell
97:271-81). Constructs comprising human IL-4 receptor domains I
and/or II, murine IL-4 receptor domains I and/or II, combinations
of human and murine IL-4 receptor domains I and II, or fragments of
human or murine IL-4 receptor domains I and/or II are expressed as
C-terminal, in-frame fusions with chicken avidin. (Murine IL-4
receptor sequences are provided in, for example, Schulte et al.,
1997, J. Exp. Med. 186:1419-29, Wrighton et al., 1992, Growth
Factors 6:103-18, Harada et al., 1990, Proc. Natl. Acad. Sci.
U.S.A. 87:857-61, Mosley et al., 1989, Cell 59:335-48.) The fusion
protein expression vectors are individually transiently transfected
into 293T cells. The conditioned media are used as the source of
fusion protein without purification. The avidin tag of the IL-4
receptor construct is captured from solution by a biotin-coated
bead. A FITC labeled anti-avidin antibody is used to detect the
avidin portion of the fusion construct. An anti-IL-4 receptor
antibody is incubated with the biotin-captured IL-4 receptor
construct. FITC labeled mouse F(ab').sub.2 anti-human IgG is used
as a secondary antibody for detection. The bead-antibody mixture is
subjected to FACS analysis on a Becton Dickinson Bioscience FACScan
(BD, Franklin Lakes, N.J.).
[0389] Using the above method, it was found that several anti-IL-4
receptor antibodies described herein bound well to a construct
comprising domains I and II of human IL-4 receptor but did not bind
to a construct comprising domains I and II of murine IL-4 receptor.
The antibodies bound weakly to a construct comprising domain I of
human IL-4 receptor (but not comprising domain II) and not at all
to a construct comprising human IL-4 receptor domain II (but not
comprising domain I). It was further found that the antibodies
bound well to a construct comprising domain I of human IL-4
receptor and domain II of murine IL-4 receptor.
[0390] The foregoing examples, both working and prophetic, are
non-limiting and are provided to illustrate particular embodiments
of the instant invention. All references cited herein are
incorporated by reference in their entireties.
Sequence CWU 1
1
7712475DNAHomo sapienCDS(1)..(2475) 1atg ggg tgg ctt tgc tct ggg
ctc ctg ttc cct gtg agc tgc ctg gtc 48Met Gly Trp Leu Cys Ser Gly
Leu Leu Phe Pro Val Ser Cys Leu Val1 5 10 15ctg ctg cag gtg gca agc
tct ggg aac atg aag gtc ttg cag gag ccc 96Leu Leu Gln Val Ala Ser
Ser Gly Asn Met Lys Val Leu Gln Glu Pro 20 25 30acc tgc gtc tcc gac
tac atg agc atc tct act tgc gag tgg aag atg 144Thr Cys Val Ser Asp
Tyr Met Ser Ile Ser Thr Cys Glu Trp Lys Met 35 40 45aat ggt ccc acc
aat tgc agc acc gag ctc cgc ctg ttg tac cag ctg 192Asn Gly Pro Thr
Asn Cys Ser Thr Glu Leu Arg Leu Leu Tyr Gln Leu 50 55 60gtt ttt ctg
ctc tcc gaa gcc cac acg tgt atc cct gag aac aac gga 240Val Phe Leu
Leu Ser Glu Ala His Thr Cys Ile Pro Glu Asn Asn Gly65 70 75 80ggc
gcg ggg tgc gtg tgc cac ctg ctc atg gat gac gtg gtc agt gcg 288Gly
Ala Gly Cys Val Cys His Leu Leu Met Asp Asp Val Val Ser Ala 85 90
95gat aac tat aca ctg gac ctg tgg gct ggg cag cag ctg ctg tgg aag
336Asp Asn Tyr Thr Leu Asp Leu Trp Ala Gly Gln Gln Leu Leu Trp Lys
100 105 110ggc tcc ttc aag ccc agc gag cat gtg aaa ccc agg gcc cca
gga aac 384Gly Ser Phe Lys Pro Ser Glu His Val Lys Pro Arg Ala Pro
Gly Asn 115 120 125ctg aca gtt cac acc aat gtc tcc gac act ctg ctg
ctg acc tgg agc 432Leu Thr Val His Thr Asn Val Ser Asp Thr Leu Leu
Leu Thr Trp Ser 130 135 140aac ccg tat ccc cct gac aat tac ctg tat
aat cat ctc acc tat gca 480Asn Pro Tyr Pro Pro Asp Asn Tyr Leu Tyr
Asn His Leu Thr Tyr Ala145 150 155 160gtc aac att tgg agt gaa aac
gac ccg gca gat ttc aga atc tat aac 528Val Asn Ile Trp Ser Glu Asn
Asp Pro Ala Asp Phe Arg Ile Tyr Asn 165 170 175gtg acc tac cta gaa
ccc tcc ctc cgc atc gca gcc agc acc ctg aag 576Val Thr Tyr Leu Glu
Pro Ser Leu Arg Ile Ala Ala Ser Thr Leu Lys 180 185 190tct ggg att
tcc tac agg gca cgg gtg agg gcc tgg gct cag tgc tat 624Ser Gly Ile
Ser Tyr Arg Ala Arg Val Arg Ala Trp Ala Gln Cys Tyr 195 200 205aac
acc acc tgg agt gag tgg agc ccc agc acc aag tgg cac aac tcc 672Asn
Thr Thr Trp Ser Glu Trp Ser Pro Ser Thr Lys Trp His Asn Ser 210 215
220tac agg gag ccc ttc gag cag cac ctc ctg ctg ggc gtc agc gtt tcc
720Tyr Arg Glu Pro Phe Glu Gln His Leu Leu Leu Gly Val Ser Val
Ser225 230 235 240tgc att gtc atc ctg gcc gtc tgc ctg ttg tgc tat
gtc agc atc acc 768Cys Ile Val Ile Leu Ala Val Cys Leu Leu Cys Tyr
Val Ser Ile Thr 245 250 255aag att aag aaa gaa tgg tgg gat cag att
ccc aac cca gcc cgc agc 816Lys Ile Lys Lys Glu Trp Trp Asp Gln Ile
Pro Asn Pro Ala Arg Ser 260 265 270cgc ctc gtg gct ata ata atc cag
gat gct cag ggg tca cag tgg gag 864Arg Leu Val Ala Ile Ile Ile Gln
Asp Ala Gln Gly Ser Gln Trp Glu 275 280 285aag cgg tcc cga ggc cag
gaa cca gcc aag tgc cca cac tgg aag aat 912Lys Arg Ser Arg Gly Gln
Glu Pro Ala Lys Cys Pro His Trp Lys Asn 290 295 300tgt ctt acc aag
ctc ttg ccc tgt ttt ctg gag cac aac atg aaa agg 960Cys Leu Thr Lys
Leu Leu Pro Cys Phe Leu Glu His Asn Met Lys Arg305 310 315 320gat
gaa gat cct cac aag gct gcc aaa gag atg cct ttc cag ggc tct 1008Asp
Glu Asp Pro His Lys Ala Ala Lys Glu Met Pro Phe Gln Gly Ser 325 330
335gga aaa tca gca tgg tgc cca gtg gag atc agc aag aca gtc ctc tgg
1056Gly Lys Ser Ala Trp Cys Pro Val Glu Ile Ser Lys Thr Val Leu Trp
340 345 350cca gag agc atc agc gtg gtg cga tgt gtg gag ttg ttt gag
gcc ccg 1104Pro Glu Ser Ile Ser Val Val Arg Cys Val Glu Leu Phe Glu
Ala Pro 355 360 365gtg gag tgt gag gag gag gag gag gta gag gaa gaa
aaa ggg agc ttc 1152Val Glu Cys Glu Glu Glu Glu Glu Val Glu Glu Glu
Lys Gly Ser Phe 370 375 380tgt gca tcg cct gag agc agc agg gat gac
ttc cag gag gga agg gag 1200Cys Ala Ser Pro Glu Ser Ser Arg Asp Asp
Phe Gln Glu Gly Arg Glu385 390 395 400ggc att gtg gcc cgg cta aca
gag agc ctg ttc ctg gac ctg ctc gga 1248Gly Ile Val Ala Arg Leu Thr
Glu Ser Leu Phe Leu Asp Leu Leu Gly 405 410 415gag gag aat ggg ggc
ttt tgc cag cag gac atg ggg gag tca tgc ctt 1296Glu Glu Asn Gly Gly
Phe Cys Gln Gln Asp Met Gly Glu Ser Cys Leu 420 425 430ctt cca cct
tcg gga agt acg agt gct cac atg ccc tgg gat gag ttc 1344Leu Pro Pro
Ser Gly Ser Thr Ser Ala His Met Pro Trp Asp Glu Phe 435 440 445cca
agt gca ggg ccc aag gag gca cct ccc tgg ggc aag gag cag cct 1392Pro
Ser Ala Gly Pro Lys Glu Ala Pro Pro Trp Gly Lys Glu Gln Pro 450 455
460ctc cac ctg gag cca agt cct cct gcc agc ccg acc cag agt cca gac
1440Leu His Leu Glu Pro Ser Pro Pro Ala Ser Pro Thr Gln Ser Pro
Asp465 470 475 480aac ctg act tgc aca gag acg ccc ctc gtc atc gca
ggc aac cct gct 1488Asn Leu Thr Cys Thr Glu Thr Pro Leu Val Ile Ala
Gly Asn Pro Ala 485 490 495tac cgc agc ttc agc aac tcc ctg agc cag
tca ccg tgt ccc aga gag 1536Tyr Arg Ser Phe Ser Asn Ser Leu Ser Gln
Ser Pro Cys Pro Arg Glu 500 505 510ctg ggt cca gac cca ctg ctg gcc
aga cac ctg gag gaa gta gaa ccc 1584Leu Gly Pro Asp Pro Leu Leu Ala
Arg His Leu Glu Glu Val Glu Pro 515 520 525gag atg ccc tgt gtc ccc
cag ctc tct gag cca acc act gtg ccc caa 1632Glu Met Pro Cys Val Pro
Gln Leu Ser Glu Pro Thr Thr Val Pro Gln 530 535 540cct gag cca gaa
acc tgg gag cag atc ctc cgc cga aat gtc ctc cag 1680Pro Glu Pro Glu
Thr Trp Glu Gln Ile Leu Arg Arg Asn Val Leu Gln545 550 555 560cat
ggg gca gct gca gcc ccc gtc tcg gcc ccc acc agt ggc tat cag 1728His
Gly Ala Ala Ala Ala Pro Val Ser Ala Pro Thr Ser Gly Tyr Gln 565 570
575gag ttt gta cat gcg gtg gag cag ggt ggc acc cag gcc agt gcg gtg
1776Glu Phe Val His Ala Val Glu Gln Gly Gly Thr Gln Ala Ser Ala Val
580 585 590gtg ggc ttg ggt ccc cca gga gag gct ggt tac aag gcc ttc
tca agc 1824Val Gly Leu Gly Pro Pro Gly Glu Ala Gly Tyr Lys Ala Phe
Ser Ser 595 600 605ctg ctt gcc agc agt gct gtg tcc cca gag aaa tgt
ggg ttt ggg gct 1872Leu Leu Ala Ser Ser Ala Val Ser Pro Glu Lys Cys
Gly Phe Gly Ala 610 615 620agc agt ggg gaa gag ggg tat aag cct ttc
caa gac ctc att cct ggc 1920Ser Ser Gly Glu Glu Gly Tyr Lys Pro Phe
Gln Asp Leu Ile Pro Gly625 630 635 640tgc cct ggg gac cct gcc cca
gtc cct gtc ccc ttg ttc acc ttt gga 1968Cys Pro Gly Asp Pro Ala Pro
Val Pro Val Pro Leu Phe Thr Phe Gly 645 650 655ctg gac agg gag cca
cct cgc agt ccg cag agc tca cat ctc cca agc 2016Leu Asp Arg Glu Pro
Pro Arg Ser Pro Gln Ser Ser His Leu Pro Ser 660 665 670agc tcc cca
gag cac ctg ggt ctg gag ccg ggg gaa aag gta gag gac 2064Ser Ser Pro
Glu His Leu Gly Leu Glu Pro Gly Glu Lys Val Glu Asp 675 680 685atg
cca aag ccc cca ctt ccc cag gag cag gcc aca gac ccc ctt gtg 2112Met
Pro Lys Pro Pro Leu Pro Gln Glu Gln Ala Thr Asp Pro Leu Val 690 695
700gac agc ctg ggc agt ggc att gtc tac tca gcc ctt acc tgc cac ctg
2160Asp Ser Leu Gly Ser Gly Ile Val Tyr Ser Ala Leu Thr Cys His
Leu705 710 715 720tgc ggc cac ctg aaa cag tgt cat ggc cag gag gat
ggt ggc cag acc 2208Cys Gly His Leu Lys Gln Cys His Gly Gln Glu Asp
Gly Gly Gln Thr 725 730 735cct gtc atg gcc agt cct tgc tgt ggc tgc
tgc tgt gga gac agg tcc 2256Pro Val Met Ala Ser Pro Cys Cys Gly Cys
Cys Cys Gly Asp Arg Ser 740 745 750tcg ccc cct aca acc ccc ctg agg
gcc cca gac ccc tct cca ggt ggg 2304Ser Pro Pro Thr Thr Pro Leu Arg
Ala Pro Asp Pro Ser Pro Gly Gly 755 760 765gtt cca ctg gag gcc agt
ctg tgt ccg gcc tcc ctg gca ccc tcg ggc 2352Val Pro Leu Glu Ala Ser
Leu Cys Pro Ala Ser Leu Ala Pro Ser Gly 770 775 780atc tca gag aag
agt aaa tcc tca tca tcc ttc cat cct gcc cct ggc 2400Ile Ser Glu Lys
Ser Lys Ser Ser Ser Ser Phe His Pro Ala Pro Gly785 790 795 800aat
gct cag agc tca agc cag acc ccc aaa atc gtg aac ttt gtc tcc 2448Asn
Ala Gln Ser Ser Ser Gln Thr Pro Lys Ile Val Asn Phe Val Ser 805 810
815gtg gga ccc aca tac atg agg gtc tct 2475Val Gly Pro Thr Tyr Met
Arg Val Ser 820 8252825PRTHomo sapien 2Met Gly Trp Leu Cys Ser Gly
Leu Leu Phe Pro Val Ser Cys Leu Val1 5 10 15Leu Leu Gln Val Ala Ser
Ser Gly Asn Met Lys Val Leu Gln Glu Pro 20 25 30Thr Cys Val Ser Asp
Tyr Met Ser Ile Ser Thr Cys Glu Trp Lys Met 35 40 45Asn Gly Pro Thr
Asn Cys Ser Thr Glu Leu Arg Leu Leu Tyr Gln Leu 50 55 60Val Phe Leu
Leu Ser Glu Ala His Thr Cys Ile Pro Glu Asn Asn Gly65 70 75 80Gly
Ala Gly Cys Val Cys His Leu Leu Met Asp Asp Val Val Ser Ala 85 90
95Asp Asn Tyr Thr Leu Asp Leu Trp Ala Gly Gln Gln Leu Leu Trp Lys
100 105 110Gly Ser Phe Lys Pro Ser Glu His Val Lys Pro Arg Ala Pro
Gly Asn 115 120 125Leu Thr Val His Thr Asn Val Ser Asp Thr Leu Leu
Leu Thr Trp Ser 130 135 140Asn Pro Tyr Pro Pro Asp Asn Tyr Leu Tyr
Asn His Leu Thr Tyr Ala145 150 155 160Val Asn Ile Trp Ser Glu Asn
Asp Pro Ala Asp Phe Arg Ile Tyr Asn 165 170 175Val Thr Tyr Leu Glu
Pro Ser Leu Arg Ile Ala Ala Ser Thr Leu Lys 180 185 190Ser Gly Ile
Ser Tyr Arg Ala Arg Val Arg Ala Trp Ala Gln Cys Tyr 195 200 205Asn
Thr Thr Trp Ser Glu Trp Ser Pro Ser Thr Lys Trp His Asn Ser 210 215
220Tyr Arg Glu Pro Phe Glu Gln His Leu Leu Leu Gly Val Ser Val
Ser225 230 235 240Cys Ile Val Ile Leu Ala Val Cys Leu Leu Cys Tyr
Val Ser Ile Thr 245 250 255Lys Ile Lys Lys Glu Trp Trp Asp Gln Ile
Pro Asn Pro Ala Arg Ser 260 265 270Arg Leu Val Ala Ile Ile Ile Gln
Asp Ala Gln Gly Ser Gln Trp Glu 275 280 285Lys Arg Ser Arg Gly Gln
Glu Pro Ala Lys Cys Pro His Trp Lys Asn 290 295 300Cys Leu Thr Lys
Leu Leu Pro Cys Phe Leu Glu His Asn Met Lys Arg305 310 315 320Asp
Glu Asp Pro His Lys Ala Ala Lys Glu Met Pro Phe Gln Gly Ser 325 330
335Gly Lys Ser Ala Trp Cys Pro Val Glu Ile Ser Lys Thr Val Leu Trp
340 345 350Pro Glu Ser Ile Ser Val Val Arg Cys Val Glu Leu Phe Glu
Ala Pro 355 360 365Val Glu Cys Glu Glu Glu Glu Glu Val Glu Glu Glu
Lys Gly Ser Phe 370 375 380Cys Ala Ser Pro Glu Ser Ser Arg Asp Asp
Phe Gln Glu Gly Arg Glu385 390 395 400Gly Ile Val Ala Arg Leu Thr
Glu Ser Leu Phe Leu Asp Leu Leu Gly 405 410 415Glu Glu Asn Gly Gly
Phe Cys Gln Gln Asp Met Gly Glu Ser Cys Leu 420 425 430Leu Pro Pro
Ser Gly Ser Thr Ser Ala His Met Pro Trp Asp Glu Phe 435 440 445Pro
Ser Ala Gly Pro Lys Glu Ala Pro Pro Trp Gly Lys Glu Gln Pro 450 455
460Leu His Leu Glu Pro Ser Pro Pro Ala Ser Pro Thr Gln Ser Pro
Asp465 470 475 480Asn Leu Thr Cys Thr Glu Thr Pro Leu Val Ile Ala
Gly Asn Pro Ala 485 490 495Tyr Arg Ser Phe Ser Asn Ser Leu Ser Gln
Ser Pro Cys Pro Arg Glu 500 505 510Leu Gly Pro Asp Pro Leu Leu Ala
Arg His Leu Glu Glu Val Glu Pro 515 520 525Glu Met Pro Cys Val Pro
Gln Leu Ser Glu Pro Thr Thr Val Pro Gln 530 535 540Pro Glu Pro Glu
Thr Trp Glu Gln Ile Leu Arg Arg Asn Val Leu Gln545 550 555 560His
Gly Ala Ala Ala Ala Pro Val Ser Ala Pro Thr Ser Gly Tyr Gln 565 570
575Glu Phe Val His Ala Val Glu Gln Gly Gly Thr Gln Ala Ser Ala Val
580 585 590Val Gly Leu Gly Pro Pro Gly Glu Ala Gly Tyr Lys Ala Phe
Ser Ser 595 600 605Leu Leu Ala Ser Ser Ala Val Ser Pro Glu Lys Cys
Gly Phe Gly Ala 610 615 620Ser Ser Gly Glu Glu Gly Tyr Lys Pro Phe
Gln Asp Leu Ile Pro Gly625 630 635 640Cys Pro Gly Asp Pro Ala Pro
Val Pro Val Pro Leu Phe Thr Phe Gly 645 650 655Leu Asp Arg Glu Pro
Pro Arg Ser Pro Gln Ser Ser His Leu Pro Ser 660 665 670Ser Ser Pro
Glu His Leu Gly Leu Glu Pro Gly Glu Lys Val Glu Asp 675 680 685Met
Pro Lys Pro Pro Leu Pro Gln Glu Gln Ala Thr Asp Pro Leu Val 690 695
700Asp Ser Leu Gly Ser Gly Ile Val Tyr Ser Ala Leu Thr Cys His
Leu705 710 715 720Cys Gly His Leu Lys Gln Cys His Gly Gln Glu Asp
Gly Gly Gln Thr 725 730 735Pro Val Met Ala Ser Pro Cys Cys Gly Cys
Cys Cys Gly Asp Arg Ser 740 745 750Ser Pro Pro Thr Thr Pro Leu Arg
Ala Pro Asp Pro Ser Pro Gly Gly 755 760 765Val Pro Leu Glu Ala Ser
Leu Cys Pro Ala Ser Leu Ala Pro Ser Gly 770 775 780Ile Ser Glu Lys
Ser Lys Ser Ser Ser Ser Phe His Pro Ala Pro Gly785 790 795 800Asn
Ala Gln Ser Ser Ser Gln Thr Pro Lys Ile Val Asn Phe Val Ser 805 810
815Val Gly Pro Thr Tyr Met Arg Val Ser 820
8253327DNAArtificialLight chain variable sequence 3gaa att gtg ttg
acg cag tct cca ggc acc ctg tct ttg tct cca ggg 48Glu Ile Val Leu
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15gaa aga gcc
acc ctc tcc tgc agg gcc agt cag agt gtt agc agc agc 96Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30tac tta
gcc tgg tac cag cag aaa cct ggc cag gct ccc agg ctc ctc 144Tyr Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45atc
ttt ggt gca tcc agc agg gcc act ggc atc cca gac agg ttc agt 192Ile
Phe Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55
60ggc agt ggg tct ggg aca gac ttc act ctc acc atc agc aga ctg gag
240Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu
Glu65 70 75 80cct gaa gat ttt gca gtg tat tac tgt cag cag tat ggt
agc tca cct 288Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly
Ser Ser Pro 85 90 95ccg tgg acg ttc ggc caa ggg acc aag gtg gaa atc
aaa 327Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
1054109PRTArtificialSynthetic Construct 4Glu Ile Val Leu Thr Gln
Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Phe Gly
Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75
80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
1055327DNAArtificialLight chain variable sequence 5gaa att gtg ttg
acg cag tct cca ggc acc ctg tct ttg tct cca ggg
48Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1
5 10 15gaa aga gcc acc ctc tcc tgc agg gcc agt cag agt gtt agc aac
agc 96Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn
Ser 20 25 30tac tta gcc tgg tac cag cag aaa cct ggc cag gct ccc agg
ctc ctc 144Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg
Leu Leu 35 40 45atc tat ggt gca tcc agc agg gcc cct ggc atc cca gac
agg ttc agt 192Ile Tyr Gly Ala Ser Ser Arg Ala Pro Gly Ile Pro Asp
Arg Phe Ser 50 55 60ggc agt ggg tct ggg aca gac ttc act ctc acc atc
agc aga ctg gag 240Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Arg Leu Glu65 70 75 80cct gaa gat ttt gca gtg tat tac tgt cag
cag tat gat cac tca gca 288Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln
Gln Tyr Asp His Ser Ala 85 90 95ggg tgg acg ttc ggc caa ggg acc aag
gtg gag atc aaa 327Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
Lys 100 1056109PRTArtificialSynthetic Construct 6Glu Ile Val Leu
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Asn Ser 20 25 30Tyr Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile
Tyr Gly Ala Ser Ser Arg Ala Pro Gly Ile Pro Asp Arg Phe Ser 50 55
60Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65
70 75 80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp His Ser
Ala 85 90 95Gly Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
1057327DNAArtificialLight chain variable sequence 7gaa att gtg ttg
acg cag tct cca ggc acc ctg tct ttg tct ccg ggg 48Glu Ile Val Leu
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15gaa aga gcc
acc ctc tcc tgc agg gcc agt cag act gtt aac agc gac 96Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Thr Val Asn Ser Asp 20 25 30tac tta
gcc tgg tac cag cag aaa ccg ggc cag gct ccc agg ctc ctc 144Tyr Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45atc
tat ggt gca tcc agc agg gcc act ggc atc cca gac agg ttc agt 192Ile
Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55
60ggc agt ggg tct ggg aca gac ttc act ctc acc atc agc aga ctg gag
240Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu
Glu65 70 75 80cct gaa gat ttt gca gtc tat tac tgt cag cag tat ggt
agg tca cct 288Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly
Arg Ser Pro 85 90 95ccg tgg acg ttc ggc caa ggg acc aaa gtg gat atc
aaa 327Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100
1058109PRTArtificialSynthetic Construct 8Glu Ile Val Leu Thr Gln
Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Thr Val Asn Ser Asp 20 25 30Tyr Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly
Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75
80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Arg Ser Pro
85 90 95Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100
1059327DNAArtificialLight chain variable sequence 9gaa att gtg atg
acg cag tct cca ggc acc ctg tct ttg tct cca ggg 48Glu Ile Val Met
Thr Gln Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15gaa aga gcc
acc ctc tcc tgc agg gcc agt cag agt gtt agc agc gac 96Glu Arg Ala
Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asp 20 25 30tac tta
gcc tgg tac cag cag aaa cct ggc cag gct ccc agg ctc ctc 144Tyr Leu
Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45atc
tat ggt gca tct agc agg gcc tct ggc atc cca gac agg ttc agt 192Ile
Tyr Gly Ala Ser Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser 50 55
60ggc agt ggg ttt ggg aca gac ttc act ctc acc atc agc aga ctg gag
240Gly Ser Gly Phe Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu
Glu65 70 75 80cct gaa gat ttt gca ata tat tac tgt cag cag tat ggt
agc tca cct 288Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Tyr Gly
Ser Ser Pro 85 90 95ccg tgg acg ttc ggc caa ggg acc aag gtg gaa atc
aaa 327Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10510109PRTArtificialSynthetic Construct 10Glu Ile Val Met Thr Gln
Ser Pro Gly Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asp 20 25 30Tyr Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly
Ala Ser Ser Arg Ala Ser Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser
Gly Phe Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75
80Pro Glu Asp Phe Ala Ile Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95Pro Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10511327DNAArtificialLight chain variable sequence 11gat att gtg
ctg acc cag tct cca gcc acc ctg tct ttg tct cca ggg 48Asp Ile Val
Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15gaa aga
gcc acc ctc tcc tgc agg gcc agt cag agt gtt aac agc aac 96Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn 20 25 30tac
tta gcc tgg tac cag cag aaa cct ggc cag gct ccc agg ctc ctc 144Tyr
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40
45atc tat ggt aca tcc tac agg gcc act ggc atc cca gac agg ttc agt
192Ile Tyr Gly Thr Ser Tyr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60ggc agt ggg tct ggg aca gac ttc act ctc acc atc acc aga ctg
gag 240Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu
Glu65 70 75 80cct gaa gat ttt gca gtg tat tac tgt cag cag tat ggt
agc tca cca 288Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly
Ser Ser Pro 85 90 95ccg tgg acg ttc ggc caa ggg aca cga ctg gag att
aaa 327Pro Trp Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100
10512109PRTArtificialSynthetic Construct 12Asp Ile Val Leu Thr Gln
Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Asn Ser Asn 20 25 30Tyr Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly
Thr Ser Tyr Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Arg Leu Glu65 70 75
80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95Pro Trp Thr Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys 100
10513327DNAArtificialLight chain variable sequence 13gat att gtg
ctg acg cag act cca gcc acc ctg tct ttg tct cca ggg 48Asp Ile Val
Leu Thr Gln Thr Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15gaa aga
gcc acc ctc tcc tgc agg gcc agt cag agt gtt ggc agc agc 96Glu Arg
Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser 20 25 30tac
tta gcc tgg tac cag cag aga cct ggc cag gct ccc agg ctc ctc 144Tyr
Leu Ala Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu 35 40
45atc tat ggt gca tcc agc agg gcc act ggc atc ccg gac agg ttc agt
192Ile Tyr Gly Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser
50 55 60ggc agt ggg tct ggg aca gac ttc act ctc acg atc agc aga ctg
gag 240Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu
Glu65 70 75 80cct gaa gat ttt gca gtg tat tat tgt cag cag tat gga
agt tca cct 288Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly
Ser Ser Pro 85 90 95ccg tgg atg ttc ggc caa ggg acc aag gtg gag atc
aaa 327Pro Trp Met Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10514109PRTArtificialSynthetic Construct 14Asp Ile Val Leu Thr Gln
Thr Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Gly Ser Ser 20 25 30Tyr Leu Ala Trp
Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly
Ala Ser Ser Arg Ala Thr Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Arg Leu Glu65 70 75
80Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro
85 90 95Pro Trp Met Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10515345DNAArtificialHeavy chain variable sequence 15gag gtt cag
ctg gtg cag tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln
Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca aac tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac atg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tac ttt gac tac tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11516115PRTArtificialSynthetic Construct 16Glu Val Gln Leu Val Gln
Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser11517345DNAArtificialHeavy chain variable
sequence 17gag gtt cag ctg gtg cag tct ggg gga ggc ttg gta cat cct
ggg ggg 48Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro
Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca ggc tct gga ttc acc ttc
agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe
Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga aaa ggt
ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca agc tat
gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr
Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac aat gcc
aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg agt gcc gag
gac atg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Ser Ala Glu
Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tac ttc acc
cac tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Tyr Phe Thr
His Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca 345Val
Ser Ser 11518115PRTArtificialSynthetic Construct 18Glu Val Gln Leu
Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met
Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser
Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys 50 55
60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65
70 75 80Gln Met Asn Ser Leu Ser Ala Glu Asp Met Ala Val Tyr Tyr Cys
Ala 85 90 95Arg Gly Arg Tyr Tyr Phe Thr His Trp Gly Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser 11519345DNAArtificialHeavy chain
variable sequence 19gag gtt cag ctg gtg cag tct ggg gga ggc ttg gta
cat cct ggg ggg 48Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val
His Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca ggc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
agc tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Ser Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac atg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tgg
tac aac aac tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Trp
Tyr Asn Asn Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11520115PRTArtificialSynthetic Construct 20Glu Val
Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Trp Tyr Asn Asn Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11521345DNAArtificialHeavy chain variable sequence 21gag gtt cag
ttg gtg cag tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln
Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala
Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc
cag gct cca gga aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act
ggt ggt gcc aca aac tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr
Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc
atc tcc aga gac aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg
aac agc ctg aga gcc gag gac atg gct gtg tat tac tgt gca 288Gln Met
Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95aga
ggg agg tac tac ttc ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg
Gly Arg Tyr Tyr Phe Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105
110gtc tcc tca 345Val Ser Ser 11522115PRTArtificialSynthetic
Construct 22Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe
Ser Arg Asn 20 25 30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr
Ala Asp Ser Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
Lys Asn Ser Leu Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu
Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Tyr Phe Pro
Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11523345DNAArtificialHeavy chain variable sequence 23gag gtt cag
ctg gtg cag tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln
Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca aac tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac atg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tac ttc acg agg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Tyr Phe Thr Arg Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11524115PRTArtificialSynthetic Construct 24Glu Val Gln Leu Val Gln
Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Tyr Phe Thr Arg Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11525345DNAArtificialHeavy chain
variable sequence 25gag gtt cag ttg gtg cag tct ggg gga ggc ttg gta
cat cct ggg ggg 48Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val
His Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca ggc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
aac tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Asn Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac atg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tgg
tac ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Trp
Tyr Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11526115PRTArtificialSynthetic Construct 26Glu Val
Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11527345DNAArtificialHeavy chain variable sequence 27gag gtt cag
ctg gtg cag tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln
Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca agc tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac atg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg tac ccg tgg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11528115PRTArtificialSynthetic Construct 28Glu Val Gln Leu Val Gln
Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11529345DNAArtificialHeavy chain
variable sequence 29gag gtt cag ttg gtg cag tct ggg gga ggc ttg gta
cat cct ggg ggg 48Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val
His Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca ggc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
aac tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Asn Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac atg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tgg
ttc ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Trp
Phe Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11530115PRTArtificialSynthetic Construct 30Glu Val
Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Trp Phe Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11531345DNAArtificialHeavy chain variable sequence 31gag gtt cag
ctg gtg cag tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln
Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca agc tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac atg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg ttc ccg tgg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Trp Phe Pro Trp Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11532115PRTArtificialSynthetic Construct 32Glu Val Gln Leu Val Gln
Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Trp Phe Pro Trp Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11533345DNAArtificialHeavy chain
variable sequence 33gag gtt cag ttg gtg cag tct ggg gga ggc ttg gta
cat cct ggg ggg 48Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val
His Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca ggc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
aac tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Asn Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac atg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tgg
tac ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Trp
Tyr Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11534115PRTArtificialSynthetic Construct 34Glu Val
Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11535345DNAArtificialHeavy chain variable sequence 35gag gtt cag
ctg gtg cag tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln
Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca agc tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac atg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg tac ccg tgg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11536115PRTArtificialSynthetic Construct 36Glu Val Gln Leu Val Gln
Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys 50 55
60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65
70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val Tyr Tyr Cys
Ala 85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly Thr Leu
Val Thr 100 105 110Val Ser Ser 11537345DNAArtificialHeavy chain
variable sequence 37gag gtt cag ctg gtg cag tct ggg gga ggc ttg gta
cat cct ggg ggg 48Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val
His Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca ggc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
agc tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Ser Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac atg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tac
ttc ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Tyr
Phe Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11538115PRTArtificialSynthetic Construct 38Glu Val
Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Tyr Phe Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11539345DNAArtificialHeavy chain variable sequence 39gag gtt cag
ctg gtg cag tct ggg gga ggc ttg gta cat cct ggg ggg 48Glu Val Gln
Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca ggc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca agc tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg agt gcc gag gac atg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Ser Ala Glu Asp Met Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tac ttc ccg tgg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Tyr Phe Pro Trp Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11540115PRTArtificialSynthetic Construct 40Glu Val Gln Leu Val Gln
Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Gly Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Ser Ala Glu Asp Met Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Tyr Phe Pro Trp Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11541345DNAArtificialHeavy chain
variable sequence 41gag gtt cag ttg gtg gag tct ggg gga ggc ttg gta
cag cct ggg ggg 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca gcc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
agc tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Ser Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac acg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tac
ttc ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Tyr
Phe Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11542115PRTArtificialSynthetic Construct 42Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Tyr Phe Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11543345DNAArtificialHeavy chain variable sequence 43gag gtt cag
ttg gtg gag tct ggg gga ggc ttg gta cag cct ggg ggg 48Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca agc tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac acg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tac ttt gac tac tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11544115PRTArtificialSynthetic Construct 44Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11545345DNAArtificialHeavy chain
variable sequence 45gag gtt cag ttg gtg gag tct ggg gga ggc ttg gta
cag cct ggg ggg 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca gcc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
agc tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Ser Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac acg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tac
ttc acc cac tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Tyr
Phe Thr His Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11546115PRTArtificialSynthetic Construct 46Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Tyr Phe Thr His Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11547345DNAArtificialHeavy chain variable sequence 47gag gtt cag
ttg gtg gag tct ggg gga ggc ttg gta cag cct ggg ggg 48Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca agc tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac acg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg tac aac aac tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Trp Tyr Asn Asn Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11548115PRTArtificialSynthetic Construct 48Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Trp Tyr Asn Asn Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11549345DNAArtificialHeavy chain
variable sequence 49gag gtt cag ttg gtg gag tct ggg gga ggc ttg gta
cag cct ggg ggg 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca gcc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
agc tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Ser Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac acg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tac
ttc acg agg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Tyr
Phe Thr Arg Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11550115PRTArtificialSynthetic Construct 50Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Tyr Phe Thr Arg Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11551345DNAArtificialHeavy chain variable sequence 51gag gtt cag
ttg gtg gag tct ggg gga ggc ttg gta cag cct ggg ggg 48Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca agc tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac acg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg tac
ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Trp Tyr
Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11552115PRTArtificialSynthetic Construct 52Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11553345DNAArtificialHeavy chain variable sequence 53gag gtt cag
ttg gtg gag tct ggg gga ggc ttg gta cag cct ggg ggg 48Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca aac tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac acg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg tac ccg tgg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11554115PRTArtificialSynthetic Construct 54Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11555345DNAArtificialHeavy chain
variable sequence 55gag gtt cag ttg gtg gag tct ggg gga ggc ttg gta
cag cct ggg ggg 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca gcc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
agc tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Ser Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac acg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tgg
ttc ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Trp
Phe Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11556115PRTArtificialSynthetic Construct 56Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Trp Phe Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11557345DNAArtificialHeavy chain variable sequence 57gag gtt cag
ttg gtg gag tct ggg gga ggc ttg gta cag cct ggg ggg 48Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca aac tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac acg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg ttc ccg tgg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Trp Phe Pro Trp Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11558115PRTArtificialSynthetic Construct 58Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Trp Phe Pro Trp Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11559345DNAArtificialHeavy chain
variable sequence 59gag gtt cag ttg gtg gag tct ggg gga ggc ttg gta
cag cct ggg ggg 48Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val
Gln Pro Gly Gly1 5 10 15tcc ctg aga ctc tcc tgt gca gcc tct gga ttc
acc ttc agt aga aat 96Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe
Thr Phe Ser Arg Asn 20 25 30gct atg ttc tgg gtt cgc cag gct cca gga
aaa ggt ctg gag tgg gta 144Ala Met Phe Trp Val Arg Gln Ala Pro Gly
Lys Gly Leu Glu Trp Val 35 40 45tca ggt att ggt act ggt ggt gcc aca
agc tat gca gac tcc gtg aag 192Ser Gly Ile Gly Thr Gly Gly Ala Thr
Ser Tyr Ala Asp Ser Val Lys 50 55 60ggc cga ttc acc atc tcc aga gac
aat gcc aag aac tcc ttg tat ctt 240Gly Arg Phe Thr Ile Ser Arg Asp
Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75 80caa atg aac agc ctg aga
gcc gag gac acg gct gtg tat tac tgt gca 288Gln Met Asn Ser Leu Arg
Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95aga ggg agg tac tgg
tac ccg tgg tgg ggc cag gga acc ctg gtc acc 336Arg Gly Arg Tyr Trp
Tyr Pro Trp Trp Gly Gln Gly Thr Leu Val Thr 100 105 110gtc tcc tca
345Val Ser Ser 11560115PRTArtificialSynthetic Construct 60Glu Val
Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser
Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25
30Ala Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45Ser Gly Ile Gly Thr Gly Gly Ala Thr Ser Tyr Ala Asp Ser Val
Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu
Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys Ala 85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln
Gly Thr Leu Val Thr 100 105 110Val Ser Ser
11561345DNAArtificialHeavy chain variable sequence 61gag gtt cag
ttg gtg gag tct ggg gga ggc ttg gta cag cct ggg ggg 48Glu Val Gln
Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15tcc ctg
aga ctc tcc tgt gca gcc tct gga ttc acc ttc agt aga aat 96Ser Leu
Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30gct
atg ttc tgg gtt cgc cag gct cca gga aaa ggt ctg gag tgg gta 144Ala
Met Phe Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40
45tca ggt att ggt act ggt ggt gcc aca aac tat gca gac tcc gtg aag
192Ser Gly Ile Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys
50 55 60ggc cga ttc acc atc tcc aga gac aat gcc aag aac tcc ttg tat
ctt 240Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
Leu65 70 75 80caa atg aac agc ctg aga gcc gag gac acg gct gtg tat
tac tgt gca 288Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys Ala 85 90 95aga ggg agg tac tgg tac ccg tgg tgg ggc cag gga
acc ctg gtc acc 336Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly
Thr Leu Val Thr 100 105 110gtc tcc tca 345Val Ser Ser
11562115PRTArtificialSynthetic Construct 62Glu Val Gln Leu Val Glu
Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Asn 20 25 30Ala Met Phe Trp
Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ser Gly Ile
Gly Thr Gly Gly Ala Thr Asn Tyr Ala Asp Ser Val Lys 50 55 60Gly Arg
Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr Leu65 70 75
80Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala
85 90 95Arg Gly Arg Tyr Trp Tyr Pro Trp Trp Gly Gln Gly Thr Leu Val
Thr 100 105 110Val Ser Ser 11563109PRTArtificial27A1 light chain
variable region 63Glu Ile Val Leu Thr Gln Ser Pro Gly Thr Leu Ser
Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln
Ser Val Ser Ser Ser 20 25 30Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg Leu Leu 35 40 45Ile Tyr Gly Ala Ser Ser Arg Ala Thr
Gly Ile Pro Asp Arg Phe Ser 50 55 60Gly Ser Gly Ser Gly Thr Asp Phe
Thr Leu Thr Ile Ser Arg Leu Glu65 70 75 80Pro Glu Asp Phe Ala Val
Tyr Tyr Cys Gln Gln Tyr Gly Ser Ser Pro 85 90 95Pro Trp Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 10564116PRTArtificial27A1 heavy
chain variable region 64Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val
Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Ser Ala Ser Gly
Phe Thr Phe Ser Arg Tyr 20 25 30Gly Met His Trp Val Arg Gln Ala Pro
Gly Arg Gly Leu Glu Trp Val 35 40 45Ala Ile Ile Trp Phe Glu Gly Asn
Asn Gln Tyr Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Val Ser
Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Glu Met Asn Ser
Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Lys
Tyr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110Thr Val
Ser Ser 11565107PRTArtificial5A1 light chain variable region 65Glu
Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10
15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu
Ile 35 40 45Tyr His Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe
Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser
Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg
Ser Asn Trp Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
Lys 100 10566123PRTArtificial5A1 heavy chain variable region 66Glu
Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val His Pro Gly Gly1 5 10
15Ser Leu Arg Leu Thr Cys Ala Gly Ser Gly Phe Thr Phe Ser Asn Phe
20 25 30Val Met His Trp Val Arg Gln Thr Pro Gly Gln Gly Leu Glu Trp
Val 35 40 45Ser Ala Ile Gly Thr Gly Gly Gly Thr Tyr Tyr Ala Asp Ser
Val Lys 50 55 60Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Ser
Leu Tyr Leu65 70 75 80Gln Met Asn Ser Leu Arg Ala Glu Asp Met Ala
Val Tyr Tyr Cys Ala 85 90 95Arg Asp Arg Pro Met Val Arg Gly Val Ile
Ile Asp Tyr Phe Asp Tyr 100 105 110Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser 115 12067107PRTArtificial63 light chain variable region
67Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Thr
Trp 20 25 30Leu Ala Trp Tyr Gln His Lys Pro Gly Lys Ala Pro Lys Leu
Leu Ile 35 40 45Tyr Val Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
Ala Asn Ser Phe Pro Phe 85 90 95Thr Phe Gly Pro Gly Thr Lys Val Asp
Ile Lys 100 10568117PRTArtificial63 heavy chain variable region
68Glu Val Gln Val Leu Glu Ser Gly Gly Asn Leu Val Gln Pro Gly Gly1
5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
Tyr 20 25 30Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
Trp Val 35 40 45Ser Ser Ile Thr Gly Ser Gly Gly Ser Thr Tyr Tyr Ala
Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
Asn Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp
Thr Ala Ile Phe Tyr Cys 85 90 95Ala Lys Asp Asn Arg Gly Phe Phe His
Tyr Trp Gly Gln Gly Thr Leu 100
105 110Val Thr Val Ser Ser 11569107PRTArtificial1B7 light chain
variable region 69Glu Ile Val Leu Thr Gln Ser Pro Ser Ser Val Ser
Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln
Gly Ile Ser Asn Arg 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys
Ala Pro Lys Leu Leu Ile 35 40 45Tyr Ile Ala Ser Ile Leu Gln Arg Gly
Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr
Leu Thr Ile Thr Arg Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr
Tyr Cys Gln Gln Ala Asn Ser Phe Pro Phe 85 90 95Thr Phe Gly Pro Gly
Thr Lys Val Asp Ile Lys 100 1057036DNAArtificialPrimers
70gtcgacgccg ccaccatgga nttngggctg agctgg
367121DNAArtificialPrimers 71cttgaccagg cagcccaggg c
217236DNAArtificialPrimers 72atcaaacgta cggtggctgc accatctgtc
ttcatc 367349DNAArtificialPrimers 73gtttaaacgc ggccgcggat
cctaacactc tcccctgttg aagctcttt 497499DNAArtificialPrimers
74gtcgacgccg ccaccatgga aaccccagcg cagcttctct tcctcctgct actctggctc
60ccagataccg ctagcgaaat tgtgttgacg cagtctcca
997599DNAArtificialPrimers 75tggagactgc gtcaacacaa tttcgctagc
ggtatctggg agccagagta gcaggaggaa 60gagaagctgc gctggggttt ccatggtggc
ggcgtcgac 997657DNAArtificialPrimers 76atggggtcaa ccgccatcct
tggcctcctc ctggctgttc tccaaggagt cgctagc 5777327PRTHomo sapiens
77Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg1
5 10 15Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
Tyr 20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu
Thr Ser 35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
Leu Tyr Ser 50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
Gly Thr Lys Thr65 70 75 80Tyr Thr Cys Asn Val Asp His Lys Pro Ser
Asn Thr Lys Val Asp Lys 85 90 95Arg Val Glu Ser Lys Tyr Gly Pro Pro
Cys Pro Ser Cys Pro Ala Pro 100 105 110Glu Phe Leu Gly Gly Pro Ser
Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125Asp Thr Leu Met Ile
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140Asp Val Ser
Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp145 150 155
160Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe
165 170 175Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
Gln Asp 180 185 190Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser
Asn Lys Gly Leu 195 200 205Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys
Ala Lys Gly Gln Pro Arg 210 215 220Glu Pro Gln Val Tyr Thr Leu Pro
Pro Ser Gln Glu Glu Met Thr Lys225 230 235 240Asn Gln Val Ser Leu
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255Ile Ala Val
Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270Thr
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280
285Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser
290 295 300Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
Lys Ser305 310 315 320Leu Ser Leu Ser Leu Gly Lys 325
* * * * *